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Abstract 
Controlled by extracellular signals, tumour-induced angiogenesis is a crucial step in 
the development of tumours. Among the many cell signals already identified, the VEGF 
and Notch signalling pathways play a critical role in controlling endothelial cells (ECs) 
during angiogenesis. Although this regulatory mechanism has become a current research 
focus in biology, its computational modelling is still rare. We focus on developing a 
computational model to simulate the VEGF and Notch signalling regulatory mechanism to 
perceive the micro procedure of angiogenesis in silico and fill the gap between biology and 
computer engineering.    
We first developed a mathematical model with nonlinear partial differential equations 
(PDEs) to describe the migration of endothelial tip cells during tumour-induced 
angiogenesis. The simulation results show that both chemotaxis and haptotaxis have 
impacts on the migration of ECs in velocity and density, and the impacts depend on the 
gradient and direction of tumour angiogenenic factor (TAF), and fibronectin, implying a 
possible malignant mechanism for some subgroups of tumour. We then developed the 
model further to simulate the regression, recurrence or clearance of tumours due to tumour 
cytotoxic factors, including the immune system and drugs delivered through the vessels 
formed during angiogenesis, providing a broader understanding of tumours. Based on the 
PDE model which provided parameters of continuum mathematical model, we finally 
developed an enzymatic catalysed regulating model in the form of ordinary differential 
equations (ODEs) with agent-based modelling (ABM) using Java and MATLAB languages, 
to visually realise the sprouting regulated by VEGF and Notch signalling during 
iv 
angiogenesis. The simulation describes the process of how an endothelial stalk cell 
becomes an endothelial tip cell, and sprouts under the influence of VEGF and Notch 
signalling, revealing the relationship between sprouting and branching.  
As the simulation results are consistent with reported in vitro and in vivo assays, the 
study bridges angiogenesis research and computer modelling from the dynamic regulatory 
mechanism perspective, offering a huge leap over previous studies in computationally 
simulating tumour-induced angiogenesis. It is hoped that the results will assist researchers 
in both the experimental and theoretical angiogenesis communities to improve 
understanding of the complexity and identify the fundamental principles of angiogenesis, 
whilst also using modelling approaches that will enrich knowledge for computational 
scientists in this field.  
 
Key words: angiogenesis, mathematical model, agent-based model, endothelial cells, 
VEGF and Notch signalling, regulatory mechanism 
 
  
v 
Contents 
Contents 
Acknowledgements ................................................................................................................ i 
Declaration ............................................................................................................................ ii 
Abstract ................................................................................................................................ iii 
Contents ................................................................................................................................. v 
List of Figures ........................................................................................................................ x 
List of Abbreviations .......................................................................................................... xiv 
List of Publications ............................................................................................................ xvi 
Chapter 1. Introduction ....................................................................................................... 1 
1.1 Introduction ....................................................................................................... 2 
1.2 Motivation ......................................................................................................... 2 
1.3 Aim and Objectives ........................................................................................... 3 
1.4 Contributions ..................................................................................................... 5 
1.5 Thesis Outline ................................................................................................... 7 
1.6 Conclusion ........................................................................................................ 8 
Chapter 2. Biological Review ............................................................................................. 9 
2.1 Introduction ..................................................................................................... 10 
2.2 Biological background .................................................................................... 10 
2.2.1 The development of tumours ................................................................... 10 
2.2.2 Angiogenesis ............................................................................................ 12 
2.2.3 Cell signalling .......................................................................................... 13 
vi 
2.2.4 Cell communication in nascent sprouting ................................................... 15 
2.3 Tumour-induced angiogenesis ........................................................................ 16 
2.3.1 A complicated procedure involved in angiogenesis ................................. 16 
2.3.2 Endothelial cells (ECs) ............................................................................. 17 
2.3.3 Vascular endothelial growth factor (VEGF) ............................................ 20 
2.3.4 EC specification and blood vessel formation ........................................... 25 
2.3.5 Sprouting and branching .......................................................................... 33 
2.3.6 Fibronectin .................................................................................................. 37 
2.3.7 Retinal models ............................................................................................. 37 
2.4 Conclusion ...................................................................................................... 39 
Chapter 3. Modelling and Methods .................................................................................. 40 
3.1 Introduction ..................................................................................................... 41 
3.2 Mathematical Modelling Techniques .............................................................. 42 
3.2.1 ODE Models ............................................................................................ 42 
3.2.2 PDE Models ............................................................................................. 45 
3.3 Agent-Based Models ....................................................................................... 49 
3.4 Hybrid Models ................................................................................................ 51 
3.5 Modelling of tumour-induced angiogenesis .................................................... 54 
3.6 Conclusion ...................................................................................................... 56 
Chapter 4. Modelling of Tumour-Induced Angiogenesis by chemotaxis and haptotaxis . 58 
4.1 Introduction ..................................................................................................... 59 
4.2 Anderson and Chaplain's model ...................................................................... 61 
4.2.1 Model construction................................................................................... 61 
vii 
4.2.2 Initial conditions and parameter settings ................................................. 65 
4.3 Improved model in this work .......................................................................... 66 
4.3.1 Improved model with the new assumptions ............................................. 67 
4.3.2 Parameter settings and non-dimensionalisation ....................................... 69 
4.3.3 Boundary conditions ................................................................................ 73 
4.3.4 Initial condition ........................................................................................ 74 
4.4 Simulation ....................................................................................................... 76 
4.4.1 Comparison of the ECs migration between the two models without 
considering the effect of haptotaxis ..................................................................... 77 
4.4.2 Comparison of the ECs migration between the two models with 
considering the effect of haptotaxis ..................................................................... 79 
4.4.3 Effect of proliferation on ECs density ..................................................... 82 
4.4.4 Results of ECM ........................................................................................ 83 
4.4.5 Comparison of the evolution of capillary network between two models. 83 
4.5 Discussion ....................................................................................................... 86 
4.5.1 ECM degradation ..................................................................................... 86 
4.5.2 Haptotaxis influence................................................................................. 89 
4.6 Summary ......................................................................................................... 92 
4.7 Conclusion ...................................................................................................... 94 
Chapter 5. Modelling of Tumour-Induced Angiogenesis with Regression by Cell 
Cytotoxic Factor 96 
5.1 Introduction ..................................................................................................... 97 
5.2 Modelling of tumour-induced angiogenesis with regression by cell cytotoxic 
viii 
factor 99 
5.2.1 Establishing the mathematical model..................................................... 100 
5.3 Summary ....................................................................................................... 130 
5.4 Conclusion .................................................................................................... 132 
Chapter 6. Modelling of VEGF/Notch regulatory mechanism in angiogenesis ............. 133 
6.1 Introduction ................................................................................................... 134 
6.2 Establishing the VEGF signalling pathway regulatory model in angiogenesis134 
6.3 Establishing Notch signalling pathway regulatory model in angiogenesis ... 136 
6.4 Establishing the VEGF-Notch feedback regulatory mechanism in 
angiogenesis ............................................................................................................... 142 
6.4.1 Modelling the VEGF-Notch signalling feedback loop inside each cell . 142 
6.4.2 Regulation of specification of tip/stalk between adjacent ECs in 
angiogenesis ....................................................................................................... 143 
6.5 Establishing discrete model by Agent-based Modelling (ABM) .................. 148 
6.5.1 ABM ....................................................................................................... 148 
6.5.2 The ODEs regulatory mechanism .......................................................... 152 
6.5.3 Sprouting ................................................................................................ 157 
6.5.4 Branching ............................................................................................... 159 
6.6 Simulation and discussion ............................................................................. 160 
6.6.1 Solution of the ODEs using the Euler method and ABM ...................... 160 
6.6.2 Regulation of sprouting .......................................................................... 163 
6.6.3 Regulation of branching ......................................................................... 169 
6.6.4 Simulation of angiogenesis .................................................................... 171 
ix 
6.7 Conclusion .................................................................................................... 176 
Chapter 7. Conclusion .................................................................................................... 177 
7.1 Overview of the research .............................................................................. 178 
7.2 Contributions ................................................................................................. 180 
7.3 Reflections on the research ........................................................................... 183 
7.4 Future research .............................................................................................. 184 
References .......................................................................................................................... 187 
Appendix A - Solution of the nonlinear partial differential equations ................................... i 
 
  
x 
List of Figures  
FIGURE 2.1. A SCHEMATIC DIAGRAM OF A SIMPLIFIED TRANSDUCTION SIGNAL PATHWAY .................................. 14 
FIGURE 2.2 ILLUSTRATIONS OF ENDOTHELIAL CELLS. ....................................................................................... 18 
FIGURE 2.3 ILLUSTRATION OF THREE MAJOR VEGF-A ISOFORMS WHICH ARE DIFFERENT IN MOLECULAR 
WEIGHT AND IN BINDING ABILITY. ............................................................................................................ 22 
FIGURE 2.4 ILLUSTRATION OF VEGF-A SIGNALLING COMPONENTS. ................................................................. 27 
FIGURE 2.5 ILLUSTRATION OF VEGF-A, VEGF RECEPTORS, AND CO-RECEPTORS. ........................................... 29 
FIGURE 4.1. CONCENTRATIONS OF THE TAF AND FIBRONECTIN PRESENTED IN EQ. (4.11) AND EQ. (4.12) ........ 66 
FIGURE 4.2. CONCENTRATIONS OF THE TAF AND FIBRONECTIN FROM EQ. (4.19) AND EQ. (4.23) PROPOSED IN 
THE CURRENT STUDY ............................................................................................................................... 75 
FIGURE 4.3. THE SOLUTION OF EQ. (4.26) REPRESENTS THE INITIAL CONCENTRATION OF THE FOUR CLUSTERS 
OF ECS. ................................................................................................................................................... 76 
FIGURE 4.4. SPATIOTEMPORAL EVOLUTION OF THE ECS DENSITY IN ANDERSON AND CHAPLAIN’S MODEL ....... 77 
FIGURE 4.5. SPATIOTEMPORAL EVOLUTION OF THE ECS DENSITY IN THE NEW IMPROVED MODEL. .................... 78 
FIGURE 4.6. SPATIOTEMPORAL EVOLUTION OF THE ECS DENSITY IN ANDERSON AND CHAPLAIN’S MODEL [8] . 79 
FIGURE 4.7. SPATIOTEMPORAL EVOLUTION OF THE ECS DENSITY FROM THE IMPROVED MODEL ....................... 81 
FIGURE 4.8. ELUCIDATION OF EC DENSITY ....................................................................................................... 82 
FIGURE 4.9. SPATIOTEMPORAL EVOLUTION OF CAPILLARY NETWORK WITH ABMS TO DISCRETISE THE 
CONTINUUM MODEL WHERE THE ECM DEGRADATION IS NOT INVOLVED ................................................. 84 
FIGURE 4.10. SPATIOTEMPORAL EVOLUTION OF CAPILLARY NETWORK WITH ABM TO DISCRETIZE THE 
CONTINUUM MODEL................................................................................................................................. 85 
FIGURE 5.1. THE STEADY STATE TAF CONCENTRATION GRADIENT IS GENERATED BY A LINE TUMOUR. THIS 
xi 
FIGURE IS OBTAINED BY NUMERICALLY SIMULATING EQ. (4.19)............................................................. 108 
FIGURE 5.2. SPATIOTEMPORAL EVOLUTION OF EC DENSITY N ......................................................................... 108 
FIGURE 5.3. SPATIOTEMPORAL EVOLUTION OF AN IMMUNE FACTOR DENSITY I ................................................ 109 
FIGURE 5.4. SPATIOTEMPORAL EVOLUTION OF A VESSEL DENSITY B ................................................................ 110 
FIGURE 5.5. SPATIOTEMPORAL EVOLUTION OF A LINE TUMOUR T .................................................................... 111 
FIGURE 5.6. PROFILE OF THE LARGE TUMOUR LOAD CHANGING VIA TIME STEPS ............................................. 112 
FIGURE 5.7. ANIMATION PROFILE OF LARGE TUMOUR LOAD, TIP, VESSEL AND IMMUNE FACTOR PROFILE IN 
DIFFERENT TIME STEPS .......................................................................................................................... 114 
FIGURE 5.8. SPATIOTEMPORAL EVOLUTION OF A LINE TUMOUR T INFLUENCED BY IMMUNE FACTOR AND DRUG118 
FIGURE 5.9 SPATIOTEMPORAL EVOLUTION OF THE TUMOUR CYTOTOXIC DRUG D ............................................ 118 
FIGURE 5.10 ANIMATION PROFILE OF THE TUMOUR, TIP, VESSEL, IMMUNE FACTOR, AND DRUG PROFILE AT 
DIFFERENT TIME STEPS .......................................................................................................................... 120 
FIGURE 5.11 PROFILE OF THE LARGE TUMOUR LOAD CHANGE VIA TIME STEPS INFLUENCED BY IMMUNE FACTOR 
AND DRUG ............................................................................................................................................. 121 
FIGURE 5.12 THE STEADY STATE TAF CONCENTRATION GRADIENT GENERATED BY A SMALL TUMOUR. THIS 
FIGURE IS OBTAINED BY NUMERICALLY SIMULATING EQ. (4.19)............................................................. 122 
FIGURE 5.13 SPATIOTEMPORAL EVOLUTION OF ECS DENSITY N ...................................................................... 123 
FIGURE 5.14 SPATIOTEMPORAL EVOLUTION OF VESSEL DENSITY B. ................................................................. 125 
FIGURE 5.15 SPATIOTEMPORAL EVOLUTION OF AN IMMUNE FACTOR DENSITY I. .............................................. 126 
FIGURE 5.16 SPATIOTEMPORAL EVOLUTION OF A SMALL TUMOUR LOAD T CLEARED BY IMMUNE FACTOR ...... 126 
FIGURE 5.17 ANIMATION PROFILE OF A SMALL TUMOUR, TIP, VESSEL, IMMUNE FACTOR PROFILE AT DIFFERENT 
TIME STEPS ............................................................................................................................................ 127 
FIGURE 5.18 PROFILE OF THE TUMOUR LOAD CHANGE VIA TIME STEPS ........................................................... 128 
xii 
FIGURE 6.1. ELUCIDATION OF NOTCH SIGNALLING PATHWAY .......................................................................... 137 
FIGURE 6.2. TIP AND STALK CELL SPECIFICATION DURING SPROUTING ANGIOGENESIS UNDER THE 
VGEF/NOTCH REGULATORY MECHANISM [4] ........................................................................................ 144 
FIGURE 6.3 REGULATION PROCEDURE OF SPROUTING EQ. (6.13), EQ. (6.14), EQ. (6.15) AND EQ. (6.16) ........ 147 
FIGURE 6.4. ILLUSTRATION OF THE STRUCTURE OF SPROUTING [16] ............................................................... 153 
FIGURE 6.5 SCHEMATIC CELL BEHAVIOUR FLOWCHART OVERVIEW ................................................................. 155 
FIGURE 6.6 ILLUSTRATION OF CELL MOVEMENTS. ........................................................................................... 157 
FIGURE 6.7 THE SCHEMATIC DESIGN OF THE AGENT-BASED MODEL: SPROUTING AND BRANCHING .................. 159 
FIGURE 6.8 THE RESULTS OF THE SOLUTIONS TO EQ. (6.17) AND EQ. (6.18) .................................................... 162 
FIGURE 6.9 1REGULATION PROCEDURE OF SPROUTING ANALYSIS ................................................................... 165 
FIGURE 6.10 REGULATION PROCEDURE OF SPROUTING ANGIOGENESIS BASED ON THE VEGF SIGNALLING 
PATHWAY AND NOTCH SIGNALLING PATHWAY ........................................................................................ 167 
FIGURE 6.11 REGULATION PROCEDURE OF SPROUTING ANGIOGENESIS BASED ON THE VEGF SIGNALLING 
PATHWAY AND NOTCH SIGNALLING PATHWAY. ........................................................................................ 169 
FIGURE 6.12 REGULATION PROCEDURE OF SPROUTING ANGIOGENESIS BASED ON THE VEGF SIGNALLING 
PATHWAY AND NOTCH SIGNALLING PATHWAY ........................................................................................ 170 
FIGURE 6.13 SPATIOTEMPORAL EVOLUTION OF THE CAPILLARY NETWORK USING THE AGENT-BASED METHOD 
TO DISCRETIZE THE CONTINUUM MODEL UNDER THE REGULATION OF VEGF/NORTH SIGNALLING 
PATHWAYS .............................................................................................................................................. 172 
FIGURE 6.14 SPATIOTEMPORAL EVOLUTION OF CAPILLARY NETWORK WITH AGENT-BASED METHOD TO 
DISCRETIZE THE CONTINUUM MODEL UNDER THE REGULATION OF VEGF/NORTH SIGNALLING 
PATHWAYS .............................................................................................................................................. 173 
FIGURE 6.15 SPATIOTEMPORAL EVOLUTION OF CAPILLARY NETWORK WITH AGENT-BASED METHOD TO 
xiii 
DISCRETIZE THE CONTINUUM MODEL UNDER THE REGULATION OF VEGF/NORTH SIGNALLING 
PATHWAYS IN WHICH NOTCH SIGNALLING IS OVEREXPRESSED ............................................................... 175 
  
xiv 
List of Abbreviations 
ABM Agent-based modelling 
αFGF Acidic fibroblast growth factor 
bFGF Basic fibroblast growth factor 
CAF Cancer-associated fibroblasts  
CRC Colorectal cancer 
CIMP CpG island methylator phenotype 
Dll4 Delta-like ligand 4 
EC Endothelial cell 
ECM Extra cellular matrix 
EPC Endothelial progenitor cell 
GBC Gallbladder cancer  
MDE Matrix degradatory enzymes 
NICD Notch intracellular domain 
ODE Ordinary differential equation 
PDE Partial differential equation 
PDGF Platelet-derived growth factor 
SCLC Small Cell Lung Cancer 
TGF Transforming growth factor 
TAF Tumour angiogenic factor 
TNF Tumour necrosis factor 
VEGF Vascular endothelial growth factor 
xv 
VEGFR Vascular endothelial growth factor receptor 
Flt-1 Vascular endothelial growth factor receptor 1 
sFlt-1 soluble Flt-1 
 
  
xvi 
List of Publications  
Conference Paper  
Wei Chen, Alamgir Hossain, Li Zhang (2012) Review on Cellular Automaton Modelling 
Techniques in Cancer. Proceedings of the 6
th
 Conference on Software, Knowledge, 
Information Management and Applications, SKIMA 2012. 
Wei Chen, Li Zhang, Ling Shao, Rosemary Bass, Chenyu Liu, Alamgir Hossain (2015). 
Modelling of tumour-induced angiogenesis with regress by immune factor. 9
th
 
International Conference on Software, Knowledge, Information Management & 
Applications, SKIMA 2015. 
Journal Paper  
(Submitted) Wei Chen, Li Zhang, Chengyu Liu, Ling Shao, Rosemary Bass (2015) 
Modelling of tumour-induced angiogenesis influenced by haptotaxis. Journal of 
Biomedical Informatics.  
 
 
1 
Chapter 1. Introduction 
Computational models of complex biological phenomena, such as tumour development 
and tumour-induced angiogenesis, have become an important part of building our 
understanding of tumour biology and developing new methods of tumour therapy. In 
biology or biomedicine, biological experiments, such as in vivo and in vitro assays, are 
crucial in the exploration of the complex field of tumour biology. Computational models 
may be developed from the discoveries of biological experiments. When a computational 
model’s simulation results are consistent with the experiments, it will be a successful 
model in predicting experimental results and can be used to significantly improve 
biological and biomedical research throughput by allowing virtual in silico modelling. 
Therefore, we aimed to develop computational models to simulate the tumour-induced 
angiogenesis in the thesis. This chapter discusses the motivation for the research, 
proposes the research aim and objectives, points out the contributions of the research, 
outlines the organisation of the thesis, and finally provides a conclusion to the chapter.  
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1.1 Introduction  
This chapter provides an introduction to the thesis, outlining the focus and main areas of 
inquiry relevant to the research. It concludes with the structure of the thesis. 
 
1.2 Motivation  
Angiogenesis is the process of new blood vessel formation from pre-existing ones, which 
plays a key role in various physiological and pathological conditions [1]. Angiogenesis 
involves the vascular endothelial growth factor (VEGF) directory regulation which leads to 
the formation of vessels in an appropriate pattern, including the process of nascent 
sprouting and branching [2]. Tumour-induced angiogenesis is a crucial step in the 
development of tumours [3] and many researchers have investigated this area, leading to a 
large number of discoveries related to angiogenesis which includes the selection of tip and 
stalk phenotypes from endothelial cells (ECs) by VEGF-Notch regulation [4].  
Computational modelling simulation is another way to explore this field. Since the 
development and achievements in bioscience have provided many useful clues for 
explaining angiogenesis and a great number of hypotheses about mechanisms have 
appeared, modellers are directed to simulate and verify these hypotheses from the 
computational aspect. Through simulation in silico, researchers can invest these 
hypotheses.  
Many models have already been developed in the last few decades which simulate 
angiogenesis [5-15]. The majority of models merely simulate the morphology of 
3 
angiogenesis, and are rarely related to the simulation of dynamic regulation mechanisms 
during angiogenesis; this is, therefore, a current research focus in both the experimental 
and theoretical angiogenesis communities [4]. There is a wide gap between the in vitro, in 
vivo assay and in silico simulation of angiogenesis, and computational modelling has been 
left well behind in the present achievements in angiogenesis research.   
Based on the bio-discoveries in the last decade, especially in the area of regulatory 
mechanisms, many signalling pathways have been proposed in the regulation of 
angiogenesis. Among the most important ones are vascular endothelial growth factor 
(VEGF) and Notch signalling pathways, which determine the specification of tip and stalk 
phenotypes [4]. This will influence the behaviour of endothelial cells (ECs), such as 
migration, proliferation etc. [4, 16-23]. Hence, if we can develop a model to obtain 
simulation results consistent with the results from in vivo and in vitro assays, we will verify 
the hypotheses from bioscience to a certain extent. It will robustly promote the 
development of computational modelling, and in turn assist researchers in both the 
experimental and theoretical angiogenesis communities to understand better the 
complexity of the regulation mechanism in angiogenesis, and identify its fundamental 
principles. 
 
1.3 Aim and Objectives  
We aimed to develop a model including VEGF and Notch signalling pathways to regulate 
sprouting in tumour-induced angiogenesis. We established an enzymatic catalysed 
autonomous regulatory model to simulate tumour-induced angiogenesis with the help of 
4 
Agent-Based Modelling (ABM) and advanced mathematical tools, including Partial 
Differential Equations (PDEs) and Ordinary Differential Equations (ODEs). The 
simulation was to elucidate EC differentiation, migration, proliferation, tip/stalk 
specification, sprouting, and branching behaviours. In this way, we aimed to decipher the 
secrets of angiogenesis based on the VEGF/Notch regulatory mechanism, which is an 
advance on simulating morphology visually as seen in previous studies. This involved:  
(1) Developing a mathematical model using PDEs to simulate the continuum field of 
biological phenomena which change in space and time. These biological phenomena 
included the VEGF gradient, matrix degradatory enzymes (MDE), extracellular 
matrix (ECM), and EC migration, proliferation, and branching, both spatially and 
temporally. The simulation result was used as local parameters for ABM.  
(2) Developing an enzymatic catalysed competitive kinetic reaction model to simulate the 
VEGF and Notch signalling regulatory mechanism governing the specification of tip 
and stalk from ECs, the proliferation of ECs, and their sprouting and branching. This 
model is in ODEs. 
(3) Developing an ABM model using Java language to accelerate the calculation speed, by 
combining Matlab language with Java language to realise clear results to solve the 
ODEs, and to iteratively integrate with the Euler Method to realise the VEGF and 
Notch signalling feedback loop competitive regulatory control of cell differentiation 
and activation, etc.  
5 
(4) Simulating sprouting and branching through using ABM method. Representing ECs, 
agents are endowed with the functions of calculation, memory, comparison, judgment, 
taking information, sending signals, and reacting.  
 
1.4 Contributions 
This work makes original contributions in the following ways:  
 The innovative model we developed was based on VEGF and Notch signalling 
regulation, which depends on an enzymatic catalysed competitive reaction. This 
reaction generates VEGF and Notch regulatory signals in the form of ODEs. The 
simulation results revealed the pivotal role of VEGF and Notch signalling in the 
specification of tip and stalk which is a vital activity in sprouting. Our results are 
similar to published biological reports. Thus, to a certain extent, our simulation results 
support the VEGF and Notch signalling theory [4, 22-31] from the computational 
point of view (see Chapter 6). 
 We have integrated the ABM method with the Euler method to solve the ODEs, and 
realised the simulation of regulated angiogenesis. The agents are dynamically 
endowed with more functions compared with cellular automate (CA) in similar 
research. In our model, the VEGF and Notch signalling regulatory mechanism is at the 
core. The successful simulation shows that our model enriches the methods in the 
computational modelling of angiogenesis. Hence, we recommend that the ABM 
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method is a desired approach in the modelling of cancer related to a regulatory 
mechanism (see Chapter 6).  
 We used the ABM technique by dynamically endowing the agents with different 
functions, including calculation, memory, comparison, judgment, and update, by 
taking data from outside and sending signals to the adjacent agents. In this way, we 
have successfully simulated the regulated ODEs, and thus the study provides a new 
perspective for computer scientists (see Chapter 6).  
 We improved Anderson and Chaplain’s [8] two-dimensional hybrid 
continuum-discrete model by introducing and simulating the degradation of ECM 
proteolysed by enzymes generated by ECs in tumour-induced angiogenesis. This is 
necessary for the development of the capillary network when ECs migrate and 
proliferate, approaching tumours. Our work extends previous studies in simulating 
angiogenesis, by helping to reveal the fundamental principles of angiogenesis. It 
enriches knowledge of modelling in this field and provides a good example of the use 
of Matlab, which is a more current software development tool for computational 
modellers (see Chapter 4). 
 We innovatively linked the relationship of tumour-invasion and tumour-induced 
angiogenesis through simulating the migration of ECs accelerated by enhanced 
haptotaxis. In our continuum model, the simulation results show that invasive tumours 
may enhance haptotaxis by producing fibronectin. According to the consensus theory, 
in which angiogenesis supplies nutrients and promotes tumour development, turning it 
from harmless to fatal, we propose a possible mechanism in which both 
7 
tumour-invasion and tumour-induced angiogenesis promote each other to make the 
tumour develop faster and become more harmful for some subgroups of tumours. The 
possible mechanism for this has not yet been noticed. Our proposal would point out a 
possible direction for researchers working in the field of cancer (see Chapter 4).  
 
1.5 Thesis Outline  
The remainder of the thesis is organised as follows: 
Chapter 2 gives a critical literature review of the key research published from a biological 
background and from the perspective of computational modelling of tumour-induced 
angiogenesis. Particular attention is paid to work concerned with regulatory mechanisms.  
Chapter 3 presents the methods involved in the thesis. These methods include 
mathematical tools such as PDEs and ODEs, and discrete methods such as CA and ABM.  
Chapter 4 introduces Anderson and his colleague’s continuum model in PDEs which    
describes the ECs migration during angiogenesis. Based on the PDE model, we develop 
our PDE model which simulates EC migration influenced by both chemotaxis and 
haptotaxis at different conditions, and simulates how ECM is degraded by enzymes which 
are secreted by the ECs in a two-dimensional domain between a tumour and a parent vessel. 
In the model, the variables include TAF, fibronectin, ECs, enzymes, and ECM. Finally 
through simulation results, we proposed a possible mechanism that invasive tumour and 
angiogenesis promote each other in this chapter. 
Chapter 5 describes in details how the PDEs model simulates tumour-induced 
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angiogenesis with regress by cell cytotoxic factor in a two-dimensional domain, in the 
model the variables include ECs, TAF, tumour load, blood vessel density, immune factor 
and drug. 
In Chapter 6, we develop an innovative model. The model described the VEGF and Notch 
signalling regulatory mechanism during tumour-induced angiogenesis which is based on 
an enzymatic catalysed competitive kinetic reaction. The kinetic reaction rate is presented 
in ODEs hybrid with ABM. The model governs the specification of tip and stalk, and 
sprouting and branching. The mechanism of VEGF and Notch signalling feedback loop is 
simulated in this chapter.    
Chapter 7 is a summary of the relevant conclusions and possible extensions that can be 
drawn from the work presented in this thesis. 
 
1.6 Conclusion  
This chapter presents the research objectives and the rationale for the research. In the 
following chapter, Chapter Two, the literature review presents the biological background 
relevant to the research undertaken for this thesis. 
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Chapter 2. Biological Review  
Tumour-induced angiogenesis is a very complex biological and pathological phenomenon. 
The achievements of research in biology and discoveries in cancer field in recent decades 
are very important and crucial for computational modelling. Therefore, we should have 
possession of the cancer related knowledge, especially the tumour-induced angiogenesis 
and the fundamental biological theory about it. This chapter provides biological 
background and reviews relevant concepts and theories of tumour-induced angiogenesis 
related to the research, placing VEGF and Notch signalling pathways as a key strand in 
the regulation of angiogenesis. Finally, a conclusion to the review is provided. 
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2.1 Introduction  
Angiogenesis is the process of forming new blood vessels from existing parent vessels, 
and is a crucial requirement for the growth, progression and metastatic spread of a 
tumour [32-34]. Tumour-induced angiogenesis is the phenomenon that in a hypoxia or 
low oxygen microenvironment the tumour secretes vascular endothelial growth factor 
(VEGF) and triggers angiogenetic processes [4]. In this study, the research aims to 
develop models of tumour-induced angiogenesis based on VEGF and Notch signalling 
regulatory mechanisms, and to reveal the implications for research on angiogenesis. The 
purpose of this chapter is to outline the main areas of biological research which have 
informed, and are relevant to, the present study.  
 
2.2 Biological background  
2.2.1 The development of tumours 
Cancer is a collection of different diseases. It is “a neoplasm resulting from a continuous 
proliferation of abnormal cells that have the ability to invade and destroy other tissues” 
[35]. Another term for cancer is “tumour,” which is a swelling, neoplasm, or mass. 
Tumours do not have a blood supply and their size is limited. Several years may have 
passed before a tumour grows to about 2mm in diameter [8]. Within the mass of the tumour, 
cell replication is balanced by programmed cell death, which is the avascular period for the 
tumour, during which it has a sufficient supply of oxygen and nutrients [36].  
However, a tumour does not tend to stay in this state forever, as it begins to progress to the 
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surrounding tissues in a feature of acceleration. With the development of the tumour, the 
tumour runs out of oxygen and nutrients. Inside the tumour towards the centre, cells are 
deprived of an adequate supply of oxygen, situation known as hypoxia. The hypoxic cells 
activate the hypoxia stress response. These changes in the cells lead to the release of 
soluble proteins, which are called tumour angiogenic factors (TAF), from the tumour or its 
immediate vicinity [6, 8]. These TAFs diffuse and spread into the surrounding tissues, 
binding to receptors on the surface of the endothelial cells (EC) of nearby blood vessels [8]. 
The combination triggers a series of complicated reactions, initiating a cascade of 
processes leading to the formation of blood vessel sprouts which develop towards the 
tumour, and which consequently promote the development of the tumour [8].  
Early in 1975, Folkman and Klagsbrun [37] first reported the event of tumour-induced 
angiogenesis by a solid tumour secreting a number of chemicals, collectively called 
tumour angiogenic factors (TAF). These chemical factors diffuse through the tissue 
creating a chemical concentration gradient between the tumour and existing vessels. 
Since then, the term TAF is generally used in modelling tumour induced angiogenesis. 
TAF represents several angiogenic factors, for example, vascular endothelial growth factor 
(VEGF), acidic and basic fibroblast growth factor (αFGF, bFGF), angiogenin, and others 
[37]. In this thesis, we have used the term TAF to establish the tumour-induced 
angiogenesis, where TAF mainly refers to VEGF ligands which are secreted by the 
tumour cells in hypoxia and diffuse from the tumour into the adjacent microenvironment.     
VEGF binds to its receptors on the surface of ECs in the interior of blood vessels. VEGF 
causes ECs to break through existing blood vessels and migrate towards the signal, thus 
causing the growth and replication of new blood vessels. Through angiogenesis, tumours 
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induce the host’s blood vessel system to supply them with the nutrients the tumour needs to 
grow and develop, in a process known as tumour-induced angiogenesis.  
 
2.2.2 Angiogenesis  
Angiogenesis is the procedure of creating new blood vessels from the parent vasculature 
[38]. It has become the focus of a great number of experimental and theoretical studies on 
tumours, in that it is a pivotal requirement for the growth, progression, and metastatic 
spread of a tumour [32-34]. Hence, it is vital to model computationally the micro 
procedure of angiogenesis for research purposes. Among the many models in the literature 
attempting to address different features of the angiogenic process, the beginning of 
tumour-induced angiogenesis marks the new phase of tumours which turn from harmless to 
fatal for the patient [6, 8]. The concept that tumour growth is dependent on tumour-induced 
angiogenesis was firstly proposed by Judah Folkman in 1971 [39]. Since then, a huge 
amount of research in the field related to tumour-induced angiogenesis has been 
developed.  
After several decades, significant progress has been made. The phenomena of angiogenesis 
occurs in many situations, such as the growth of the embryo and the process of wound 
healing [36]. The tumour releases proteins which stimulate cellular growth, proliferation, 
and differentiation, and these are classified as growth factors, such as VEGF, bFGF, 
transforming growth factors (TGF- and platelet-derived growth factor (PDGF), 
interleukin-8 (Il-8), and tumour necrosis factor alpha (TNF-alpha) [40]. Section 2.3.3 will 
discuss the growth factors related to the present study in detail.  
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2.2.3 Cell signalling  
Cell signalling is an important concept in biology which is discussed here to provide a 
general understanding of tumour-induced angiogenesis. Organisms have the ability to 
constantly adjust and dynamically coordinate their own activities with environmental 
changes. An essential requirement for this process is a communication function between 
cells and their environment inside organisms. The function of communicating with the 
environment, between cells and within a cell, is called signal transduction. The signal 
transduction is realised through a series of pathways by which signals are received and 
processed, amplified, and/or terminated [41]. Signal transduction occurs when an 
extracellular signalling molecule, the ligand called primary messenger, binds to the 
receptor on the cell surface. The receptor activates and generates a cascade of signals 
through the cell embrane. This receptor triggers intracellular molecules creating a 
response, called second messagers, inside the cell, through the nuclear membrane into the 
nucleus, enabling gene transcription and protein synthesis. The second messengers can 
influence gene expression after they diffuse to the nucleus, and can also be amplified 
significantly. Thus, a low concentration of signalling molecule in the environment can 
yield a large intracellular signal and response [42]. The signalling transduction 
mechanism can be simply illustrated with the following schematic diagram.  
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Figure 2.1. A schematic diagram of a simplified transduction signal pathway 
Cells communicate with each other in order to combine into networks that achieve higher 
levels of organisation, such as tissues and organs. The cell-cell communication in all 
organisms is mediated through complicated networks. The networks integrate 
intracellular processes and extracellular signals to generate cellular responses [43].  
Signal transduction occurs when an extracellular signalling molecule binds to the cell 
surface, where receptors activate as a sequence of the passive diffusion of the ligand 
through the plasma membrane [42]. In turn, these receptors trigger intracellular 
molecules, creating a response inside the cell when the ligands pass through the nuclear 
membrane into the nucleus, enabling gene transcription and protein synthesis [42]. 
Intracellular signals are mainly caused by protein kinases and phosphatases in the cellular 
structure. Cytokines and tyrosine kinases surrounding the nucleus are phosphorylated and 
translocate from the cytoplasm to the nucleus to act as transcription activators [42].  
Extracellular signals are caused by many different chemical signals from their 
surroundings. The basic cell-cell communication depends on cell membrane receptors 
and is triggered by the extracellular signals generated by cells [44]. During the process of 
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signal transduction, information is transmitted from extracellular signals to intracellular 
signals. An external signal stimulates a receptor at the cell membrane and the stimulus 
can be altered between physical forms through intracellular biochemical reactions [45, 
46]. In this way, the relay of information can be promoted. The receptors are usually 
transmembrane proteins on the target cell surface. When they bind with specific 
signalling molecules (ligands), they become activated and produce the signal through a 
series of intracellular reactions that culminate in changes to the rate of gene expression or 
enzyme activity [47]. Through ligand binding, signalling often modifies intracellular 
enzymes or activation factor activity.  
In addition, a signalling feedback loop plays an important role in the biological process. 
The phenomenon of signalling regulation between cells has been reported [4, 48, 49]. For 
example, Freeman [50] observed that up- and down-regulatory feedback loops are 
important in dynamic regulation in the intercellular communication. He analysed the 
temporal and spatial control of signalling by feedback and pointed out that while 
up-regulatory feedback generates distinct signals, down- regulatory feedback can restrict 
the ligand range to contribute to stability [50]. Signalling regulation occurs in angiogenesis, 
and thus should be considered in research on tumour-induced angiogenesis. In section 
2.3.4, particular signalling pathways related to our study will be discussed in detail.  
 
2.2.4 Cell communication in nascent sprouting 
Every cell must have the ability to sense their surroundings for changes in conditions (for 
example, through the detection of extracellular molecules), and must be able to generate a 
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range of responses to these changes [51]. The situation is the same during angiogenesis. 
The ECs in the tip phenotype sense the soluble protein molecule VEGF-A by developing 
filopodia to probe into the ECM. A range of responses is generated, such as to migrate, bind 
the ligand with receptors, and trigger a cascade of reactions inside, leading to generate 
VEGF signals [4]. These sense and response systems need to be tightly regulated and there 
are a number of signalling pathways that cells may signal to each other, which mainly 
depend on the concentration of the interactions involved [52]. If cells are adjacent, they 
may signal through surface ligands and membrane receptors, or through the 
membrane-bound ligands of one cell identified and combined by a membrane receptor on a 
neighbouring cell [51]. If the cells are further apart, they may communicate through the 
release of signalling molecules, such as hormones, cytokines and growth factors [53]. In 
angiogenesis, these may include soluble VEGFR-1 (sFlt-1), tumour necrosis factors (TNF), 
and the members of VEGF family. Examples of growth factors include platelet derived 
growth factor (PDGF), epidermal growth factor, and fibroblast growth factor. 
 
2.3 Tumour-induced angiogenesis  
2.3.1 A complicated procedure involved in angiogenesis 
Tumour-induced angiogenesis is a complicated procedure, including the activation and 
migration of ECs, the specification of tip and stalk phenotypes of ECs, and the proliferation 
and formation of a pathogenic capillary network [4]. The formation of the network is 
mainly carried out by spearhead sprouting capillary vessels and emerging new branches [4]. 
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These vessels and branches are connected and subsequently remodelled into a functional 
capillary network [34]. 
Angiogenesis initiates from the sprouting of tips from existing parent vessels. In 
tumour-induced angiogenesis, the produced vessels appear tortuous, are uniquely formed, 
and are also notoriously leaky and mosaic in their cellular composition [54, 55]. The 
structure of the abnormal vessels affects the delivery of drugs in chemotherapy, and also 
affects the opportunity for tumour cells to spread along the vessels to distant parts of the 
body to form new metastases [35]. Thus, there are many reviews on the interaction 
between tumour and vessels, and between vessels and extracellular matrix (ECM), and the 
different phenomena and functions between normal vasculature and that produced by 
tumour-induced angiogenesis [56].  
A huge and complicated variety of cells, bio-chemicals and processes have been found to 
be involved in tumour-induced angiogenesis, including both proangiogenic and 
antiangiogenic factors, the specification of cell phenotypes, the signalling pathways and 
their regulation. The discussion here is not meant to be exhaustive, but rather to cover a 
selection of the fundamental topics in the biology of tumour-induced angiogenesis which 
have informed and are relevant to the present study. Thus, focus in this thesis is given to 
ECs, VEGF, the relationship between EC specification and blood vessel formation, and 
sprouting and branching, in which VEGF and Notch signalling pathways are highlighted.  
 
2.3.2 Endothelial cells (ECs)  
ECs are the most important cells involved in the process of angiogenesis, and sprouting is 
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the fundamental process of angiogenesis [4]. Those ECs that form the vessel at a nascent 
sprouting differentiate into tip and stalk phenotypes. The choice of tip and stalk depends on 
the position of the ECs and the VEGF condition. This is because during sprouting ECs in 
the nascent sprout are specified into two distinct cellular phenotypes, tip cells and stalk 
cells, both of which are endowed with specialized functions [4]. 
 
(a)                              (b) 
Figure 2.2 Illustrations of endothelial cells.  
(a) A limited number of endothelial cells which correspond to either tip cells (T) or stalk 
cells (S) and macrophage (M); (b) The tip and stalk cell specification under the influence of 
VEGF and Notch signalling, forming a consistent pattern of pairing tip and stalk cells [31].  
 
The cells which guide new vessels at nascent sprouts are specialised as endothelial tip cells 
[4]. The function of tip cells is to lead the movement of nascent blood vessels into an 
avascular tissue [7]. The tip cell at the spearhead of the vasculature consists of a single EC 
which extends multiple, long filopodia which probe into the ECM [16, 27, 57]. It 
determines the route of sprouting to form an organized vessel network [16], and is capable 
of migrating and invading but is unable to proliferate [16]. It also does not take part in the 
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generation of the lumen of a vasculature [58].  
Following tip cells are stalk cells. These ECs are referred to as endothelial stalk cells with 
different characteristics from tip cells. They are also the ECs that produce fewer filopodia 
but are proliferative [16, 30, 57]. Stalk cells proliferate more frequently, and are linked to 
each other to maintain the stability of the vessels and keep the vessels growing in length 
and diameter [4]. In addition, stalk cells undergo positional rearrangements within a vessel 
to form the lumen [4] and to make the vessels bigger in diameter. Endothelial tip and stalk 
cells are also different in their gene expression profile.  
The phenotype selection of ECs is determined by VEGF and Notch signalling, because the 
VEGF and Notch signalling regulatory mechanism engage in a complicated crosstalk to 
balance tip and stalk cell differentiation and to regulate directed tip cell migration and stalk 
cell proliferation [4, 31]. In this way, sprouting occurs and finally makes angiogenesis 
develop. The VEGF and Notch signalling regulatory mechanism is crucial in angiogenesis 
[4]. 
EC migration is also influenced by VEGF and other factors. Recently, a number of studies 
have shown that sequestering the VEGF-A by the injection of antibodies leads to the 
inhibition of EC migration and delays the plexus formation [59]. The result is the same as 
that of the removal of the VEGF gradient in the retina by increased expression of VEGF-A 
in transgenic mouse models [16, 60]. This proves that the VEGF gradient plays an essential 
and sufficient role in the formation of the vasculature. During angiogenesis, the migration 
of ECs in the ECM is very important. The interactions between the ECs and the ECM are 
mainly influenced by fibronectin, which has been shown to enhance cell adhesion to the 
matrix. Fibronectin, a matrix macromolecule, is a major component and an insoluble 
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constituent of the ECM and basement membranes of cells [61]. The insolubility of the 
cell adhesion function is known as haptotactic influence. Haptotactic influence in the 
migration of ECs is well known, and is mainly expressed by the existence of fibronectin 
gradient [7]. ECs use fibronectin for attachment in the matrix through integrins, a family 
of cell-surface receptors [62], and migrate up a concentration gradient of fibronectin [63]. 
The migration of ECs is promoted by fibronectin. The response of the ECs to a gradient 
of adhesiveness of bound fibronectin is termed haptotaxis [64, 65]. In addition to 
chemotaxis by VEGF, there is a complementary haptotactic response of endothelial tip 
cells to the fibronectin present within the extracellular matrix [66]. Astrocytes, a type of 
cell which can express VEGF-A in central nervous system angiogenesis, is another 
haptotactic factor which prevents the migration ability of ECs by the inhibition of ECs 
binding to fibronectin [59]. Tip cells may use its filopodia to attach to the astrocytes to 
migrate. The astrocyte-derived matrix may involve transient fibronectin deposition on 
astrocytes, which have been observed together with fibronectin-type integrin receptors 
localized at the tips of the endothelial filopodia [16]. Both chemotaxis and haptotaxis 
play an important role in ECs migration during angiogenesis; thus, in Chapter 4 we will 
demonstrate the modelling of the influence of VEGF and fibronetin. The function of 
VEGF will be discussed in detail in section 2.3.3.  
 
2.3.3 Vascular endothelial growth factor (VEGF) 
VEGF is a kind of glycoprotein found in the form of homodimers, with a mass in the range 
of 34-45 kDa. It is able to stimulate the generation of new blood vessels [67]. VEGF-A is 
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one of the important members in the VEGF family which induces angiogenesis; other 
members are VEGF-B, VEGF-C, VEGF-D and placental growth factor (PLGF) [68]. 
VEGF-A has multiple isoforms. At least seven different VEGF-A isoforms are found in 
humans, including VEGF-A121, -A145, -A148, -A165, -A183, -A189 and -A206 [67], and among 
them, three major secreted forms of isoforms are VEGF-A121, VEGF-A165, and VEGF-A189 
[69]. The number in these names refers to the number of amino acids in the mature protein. 
The most frequently secreted isoform is VEGF-A165 [70]. In mice, VEGF isoforms all 
have fewer amino acids, and so the corresponding major isoforms are VEGF-A120 , 
VEGF-A164 and VEGF-A188 [67]. 
Isoforms of VEGF-A are the same in the receptor binding region and the carboxyl terminal 
section [2, 4]. There are two regions of the protein, which appear different in different 
isoforms. In an area known as the heparin binding domain, sequences may be coded by 
both exon 6 and exon 7 of the gene such as in VEGF-A189, or be coded just by exon 7 such 
as in VEGF-A165, or there are no sequences such as in VEGF-A121[71, 72]. The sequences 
encoded by exon 6 and exon 7 are for binding to the cell surface and ECM, especially for 
binding heparin and heparin-sulphate proteoglycans (HSPGs), which are abundant in both 
the cell surface and ECM [73]. The VEGF-A189 with both exon 6 and exon 7 binds 
strongly to the ECM and cell surface, VEGF-A165 with exon 7 binds moderately, and 
VEGF-A121 without exon is known to diffuse freely [74]. The sequences encoded by exon 
7 enable it to bind to neuropilin, so VEGF-A189 and VEGF-A165, both with exon 7, can 
bind to neuropilins, the cell-surface glycoproteins, which were discovered as other 
co-receptors. The neuropilin1 (Nrp1) and neuropilin-2 (Nrp2) enhance the binding activity 
of VEGF to VEGFR1 and VEGFR2 and the effectiveness of the VEGF stimulation of their 
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receptors [48, 70, 75].  
Although a number of different variants of VEGF-A have been identified in recent research, 
VEGF-A165 and VEGF-A164 are the most widely expressed variants of human and murine 
homologue splice variants, respectively [76]. Both of the variants can bind to ECM and 
diffuse in the extracellular microenvironment. VEGF-A164 is the major isoform for the 
formation of the vasculature in retinas of mice [16, 76]. It is assumed that the isoforms have 
different angiogenic effects as a result of the differences in binding ability. 
 
Figure 2.3 Illustration of three major VEGF-A isoforms which are different in molecular 
weight and in binding ability. 
Three major VEGF-A isoforms (ignore minor isoforms) VEGF-A121, VEGF-A165 and 
VEGF-A189 (in mice, VEGF-A120, VEGF-A164 and VEGF-A188) Exons 6 and 7 have 
heparin-binding domains, and each major isoform has a different capacity for matrix 
interactions [2]. 
 
Actions of VEGF-A include at least two aspects: 
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1. VEGF-A gradient is necessary for the migration of ECs. It can be secreted by tumours 
or by astrocytes, a kind of cell which can generate VEGF in hypoxia. Astrocytes 
contact the filopodia of the tip cells and can guide the direction of sprouting. In the 
development of the retina, astrocytes are found as a source of VEGF-A secreted in 
hypoxic regions [16]. Once the tissue is in hypoxia, VEGF-A is generated by 
astrocytes. The highest VEGF-A concentration is found in the avascular region of a 
retina, and the lowest is found in the vascularised centre [16]. Disturbed VEGF-A 
gradient inhibits endothelial tip cell migration and results in defective tip cell filopodia 
formation [16]. Endothelial tip cells respond to a VEGF-A gradient but not to the local 
concentration of VEGF-A, whereas endothelial stalk cells do not respond to a 
VEGF-A gradient but to the local concentration of VEGF-A [16]. Since the local 
concentration of VEGF-A affecting the stalk cell proliferation leads to the increase of 
ECs per vessel length, the diameter of vessels is increased. Thus, the balance of guided 
tip cell migration and stalk cell proliferation determines the vessel patterns [16].  
2. VEGF-A is the factor which increases the permeability of vessels, and the action is 
very effective. The effect of VEGF-A is 50,000 times more than that of histamine [77], 
with an effective concentration of below 1nmol/L [77]. VEGF-A is also known as 
vascular permeability factor due to its effect on increasing the permeability of blood 
vessels. In experiments where VEGF-A was injected in vivo, the promoted 
permeability was within one minute [77]. When the vessels become more permeable, 
blood plasma leaks out and the clotting system is activated; this will finally result in 
deposition of fibrin [77].  
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Here in the thesis, the model established focuses on the first action of VEGF-A, whereas 
the second action of VEGF-A used as the factor to increase vessel permeability will not be 
discussed. The reason for this is that our focus is to establish the model to describe the 
development of the vascular network and the regulatory mechanism of VEGF and Notch 
signalling pathways, and if too many variables and parameters are involved in a model it 
becomes too complex and the results will be confused. Thus, keeping the model free of 
excessive elements is a trend known as simple focus but extendable modelling [78].  
The expression and functions of VEGF-A are crucially important for angiogenesis. 
VEGF-A is required for chemotaxis of ECs migration, differentiation and vascular 
remodelling [4]. The presence of VEGF-A promotes the migration and differentiation of 
ECs. In vascular development, VEGF-A increases the differentiation of ECs and the 
expression of genes related to these processes, such as matrix metalloproteases (MMP) 
activation and specification of tip and stalk from ECs [4]. It may also promote the 
expression of receptors, such as VEGFR1 and VEGFR2. VEGF-A also acts on some other 
cell types, for example it has been found accumulated in EC membrane (see, for instance, 
[79]).  
VEGF-A is described as a survival factor for ECs [80-82], particularly for the cells of 
immature vessels or those vessels that have not acquired mural cell coverage. For instance, 
inactivation of VEGF-A allele in mice can cause deficient development of ECs and the 
inhibition of vessel development, and thereby results in early embryonic fatality [83, 84]. 
More recent research [85, 86] has found that interactions between VEGF-A, VEGFR2 and 
TGF-1 can lead to uncontrolled apoptosis in ECs, pointing to a more complex role of 
VEGF-A in EC survival. 
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The functions of VEGF are determined by the specificity of their receptors. There are two 
VEGF receptors (VEGFR), VEGFR-Flt-1 (VEGFR-1) and VEGFR-Flk-1/KDR 
(VEGFR-2), which are members of the tyrosine-kinase family and conserved in ECs. 
These VEGF receptors are located in ECs and tumour cells, among others [87, 88]. The 
expression of these receptors is up-regulated during the development of those pathological 
states when angiogenesis occurs [89].  
 
2.3.4 EC specification and blood vessel formation  
Normal blood vessels are tubular shaped [90, 91]. Blood flows through the cavity of the 
tube which is called a lumen [90, 91]. The coverage on the tube is the vascular basement 
membrane which acts to maintain the vessel’s stability [90, 91]. In the microvasculature, 
pericytes sparsely distributed on the exterior of the vascular basement membrane are 
known as the mural cells, but in larger vessels more layers and cell types may be presented 
[90, 91].  
After the contact with angiogenic growth factors such as VEGF-A in particular, the 
existing parent vessels begin to swell and become more permeable. The ECs begin to 
secrete enzymes, the proteases, especially matrix metalloproteases (MMPs),  which 
perform a number of functions, including facilitating the ability of ECs to remove the 
physical barrier in ECM in order to form pathways for the growth of new vessels [92, 93]. 
When VEGF-A presents, ECs begin to migrate up the gradient of the VEGF toward the 
tumour. The influence of VEGF leading to ECs migrating up the gradient is called 
chemotaxis [92, 93]. The proliferation of ECs also takes place simultaneously.  
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Since signalling pathways always branch and a signalling network may be comprised of 
multiple pathways, researchers often simply describe signalling pathways 
diagrammatically as linear sequences of events [94]. There are two possible ways to 
mediate the branching and generation of networks. One is to combine different signals 
into a pathway through activating a given signalling component which can receive a signal 
from different upstream components; the other is to branch into more than one 
downstream pathway through forming different signals by a given signalling component 
[94]. Cells receive signals associated with multiple signalling pathways, so their 
integration of these multiple stimuli can be promoted through a combination of multiple 
upstream and downstream pathways [47]. Hence, the term crosstalk is used to describe 
the interdependence of signalling, such that the activity of components in one pathway 
may impact on signalling in other pathways; crosstalk also enables cells to coordinate 
multiple inputs at the level of signal transduction [47]. 
 
Tumour-induced angiogenesis is a system involving many types of elements, such as ECs, 
fibronectin, fibroblast and many soluble proteins like VEGF-A, -B, -C, etc. The regulatory 
signalling system is also very complex, in which the elements can be divided into at least 
three groups: soluble molecules that transmit signals between cells (e.g. VEGF-A); 
receptors (e.g. VEGFR1, VEGFR2, sFlt-1); and intracellular signalling components (e.g. 
Notch receptor) that transmit the stimulation of cell surface receptors through one cell to 
activate another cell response [4]. The activity of cells is regulated by a series of signalling 
pathways, with many regulatory molecules, soluble and insoluble molecules to be 
distributed across the various cell types [4]. Hence, exploring signalling pathways is a 
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way to understand tumour-induced angiogenesis. 
 
Figure 2.4 Illustration of VEGF-A signalling components.  
VEGF-A is secreted and released from a tumour source (top of figure), and forms a 
gradient from the source to the target vessel. Some endothelial cells respond to this 
signal. These cells represent the characteristics of tip cell (grey). Its adjacent lateral base 
cells (red) up-regulate Flt-1 (VEGFR-1) and secrete sFlt-1, which inactivates VEGF-A in 
the lateral areas, providing a corridor of ligand for effective outward migration of the 
sprout [2]. 
 
2.3.4.1 VEGF signalling pathway 
VEGF is known as a key factor of angiogenesis, as mentioned above in section 2.3.3. 
Mostly, receptors on the target cell surface are activated following the binding of specific 
ligands. Receptors which are on the surface of cells or the transmembrane are specialised 
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proteins, and they are utilised for the sensing of signals from the exterior. The signal is 
sensed externally through binding and activating the cell membrane receptor, or it crosses 
the cell membrane and activates a receptor. The proangiogenic VEGF signal reaches and 
reactivates the quiescent ECs to initiate angiogenesis [16].  
VEGFR-1 is a member of the VEGFR family, and binds VEGF-A. The binding-affinity 
of VEGFR-1 for VEGF-A is of a magnitude 10-fold higher than that of VEGFR-2, 
whereas the kinase activity of VEGFR-1 is only about one tenth that of VEGFR-2 [88]. 
VEGFR-1 expresses two types of mRNA: one for a full-length receptor known as (Flt-1) 
and another for a soluble short protein known as soluble VEGFR-1 (sFlt-1). Therefore, 
VEGFR-1 plays a negative role in angiogenesis because of its high affinity with VEGF-A, 
but cannot strengthen tyrosine kinase activity, which is vital in VEGFR-2 and crucial in 
the expression of the VEGF signalling pathway [95]. VEGFR-1 suppresses angiogenesis 
by trapping VEGF-A and suppressing the local concentration of VEGF-A near VEGFR-2 
on the surface of ECs [95]. Thus, VEGFR-1 can act as a competitive inhibitor in the 
expression of VEGF signalling. 
Flt-1 isoforms bind VEGF-A with high affinity and function as competitive inhibitors of 
the VEGF pathway by ligand binding. Through negatively regulating VEGF expression, 
the Flt-1 isoforms potentially dominate the mechanism of developmental angiogenesis. 
Flt-1 isoforms affect vessel proliferation versus sprouting. Secreted from ECs, it 
potentially inactivates VEGF at a distance from producing ECs. Flt-1 can form a gradient 
into the matrix from its source. The expression of sFlt-1 by ECs adjacent to an emerging 
sprout is proposed to inactivate local VEGF [2].  
The family of VEGF ligands reacts with tyrosine kinase receptors (VEGF receptor) at the 
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corridor of tyrosine kinase to form an active complex [4]. In the VEGF signalling pathway, 
VEGF-A reacts with the tyrosine kinase receptor to form the dimerization of the VEGF 
receptor (VEGF-VEGFR complex), then releases the VEGF signal. This is VEGF 
signalling pathway expression. The signal stimulates the ECs to become tip cells. At the 
same time, during the tip cell formation, the VEGF signalling stimulates Delta-like4 (Dll4) 
expression which is up-regulated in the tip cells. The mechanism of the VEGF signalling 
pathway formation is much more complex, but to model the VEGF signalling pathway a 
simple schematic is used as shown in Figure 2.5.  
 
Figure 2.5 Illustration of VEGF-A, VEGF receptors, and co-receptors. 
VEGF-A binds the tyrosine kinase receptors, VEGFR2, VEGFR1 and Nrp1; VEGFRs 
interact with the co-receptors Nrp1; VEGFR2 is the principal mediator of VEGF-A 
signalling; VEGFR2 regulates angiogenesis during sprouting angiogenesis; VEGFR1 or 
soluble VEGFR1 (sVEGFR1) acting as a decoy receptor and limits the VEGF activity [4]. 
Activation of VEGFR1 and VEGFR2 regulates vasculogenesis and angiogenesis.  
Once activated, the receptors propagate the signals by triggering a cascade of intracellular 
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biochemical reactions that change the rate of gene expression or enzyme activity [47]. This 
situation occurs at the process of the nascent sprouting of angiogenesis: the VEGF-A is the 
ligand binding with the receptor VEGFR2 on the surface of target ECs, and the receptor 
propagates the VEGF signals and triggers a cascade of biochemical reactions inside ECs, 
which consequently generates the ligand Dll4 on its surface [31]. In most cases the 
consequence of signalling generation through the receptor binding ligand is a modification 
of the activity of intracellular enzymes [24, 30, 31, 47], such as tyrosine kinase and 
phosphatase. 
 
2.3.4.2 Notch signalling pathway 
Among all the signalling pathways involved in tumour angiogenesis, the Notch signalling 
pathway is the most crucial, as it regulates the angiogenesis by forming a pattern of 
pairing tip and stalk cells [31]. It is an intercellular contact-dependent signalling 
mechanism involved in multiple cell fate decisions and patterning processes during 
angiogenesis [18, 31, 96]. The core components of the Notch pathway are constituted by 
Notch receptors and Notch transmembrane ligands, including Delta-like ligands, Jaggeds, 
among which Dll4 and Jagged1 are the most important [31].  
Dll4 acts as a negative regulator of angiogenesis and is up-regulated in tumour vasculature 
by VEGF signalling [31, 97-100]. After binding with Dll4, the transmembrane Notch 
receptor is cleaved sequentially, first by an extracellular matrix metalloprotease and then 
by secretase which releases the Notch intracellular domain (NICD) [31]. After being 
liberated, NICD translocates to the nucleus where it interacts with the DNA-binding 
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protein CSL [31]. The Notch signalling pathway is critical in regulating the formation of an 
appropriate ratio of tip and stalk cells by suppressing tip cell formation in adjacent cells 
[31]. The molecular mechanism is responsible for the fact that not all ECs stimulated by 
VEGF become tip cells due to the activity of Dll4-Notch signalling [31]. Thus, the 
activation of Notch signalling cooperates to promote a suitable pattern of tip cell 
formation. 
Since overexpression of Notch signalling inhibits the tip cell characteristic, the activation 
level of Notch signalling expression quantitatively determines the ability of individual EC 
differentiation to the tip or stalk cell during the sprouting [16, 27, 30, 57]. The activation of 
Notch signalling using a synthetic Jagged1 ligand peptide to reduces the formation of 
filopodia [22]. The reduction of filopodia means the tip characteristic is weakened, and 
accordingly the emergence of branching is inhibited [22]. This phenomenon suggests a 
decrease in the number of ECs acquiring tip cell behaviour [22]. Notch signalling in ECs is 
more active in the absence of Jagged1, and thereby Jagged1 negatively regulates Notch 
activity.  
Jagged1 enhances differential Notch activity by competitively interfering with the ability 
of Dll4 [16]. The different ability of Jagged1 and Dll4 ligands to activate Notch is 
dependent on the glycosyltransferase Fringe, which is strongly activated by Dll4 but 
inhibited by Jagged1 [16]. The Notch signalling pathway, which appears to function as a 
central regulator of vascular branching, can be modulated not only by the quantity of 
individual ligands, but also by their activity profile when Dll4 or Jagged1 interacts with the 
Notch receptor [4]. 
Notch signalling, acting as a negative regulator of VEGF-induced angiogenesis, is 
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essential for proper vascular morphogenesis [18, 24, 30, 31]. The blocking of Notch 
signalling significantly increases vessel branching and density of the tumour vasculature 
[18, 24, 30, 31], while over-activation of Notch signalling leads to an unbranched and less 
dense tumour vasculature devoid of sprouts and filopodia [17, 101]. In the absence of 
functional Notch signalling, tumour-induced angiogenesis is reduced, despite there being 
extensively abundant and dense vessel networks [17, 97, 102, 103].  
 
2.3.4.3 Summary  
VEGF-A and Notch signalling pathways are key players governing tip and stalk cell 
behaviour. VEGF-A is crucial in inducing endothelial tip cells, and its role in the procedure 
is both necessary and sufficient [4]. If tip cells are formed, they are not formed by adjacent 
ECs but at characteristic intervals to enable adequately spaced branching and sprouting. 
When VEGF-A is blocked, the tip cell filopodia is completely retracted in the sprouting 
retinal front [57]. As a result, the blocking of VEGF-A prevents tip cell migration and 
progression of vascular sprouting [16].  
Accordingly, endothelial Notch activation regulates the expression of the different 
VEGFRs (VEGFR1, VEGFR2 and VEGFR3) as well as their co-receptor Nrp1. Soker et al. 
[104] reported that the activation of Notch leads to VEGFR1 mRNA induction. In contrast, 
the reduction of Notch activation in human umbilical vein endothelial cells (HUVECs) 
marks an increase in VEGFR2 and Nrp1 mRNA, indicating that Notch signalling is able to 
regulate the ECs responding to VEGF signalling. In fact, it has been suggested that the 
reduction of VEGFR2 and Nrp1 expression may be responsible for the low proliferative 
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and migratory response observed in Dll4 overexpressing ECs [21, 26, 104, 105].  
VEGF and Notch signalling pathways have, in addition to their role in the development of 
physiological angiogenesis, also been implied in tip and stalk specification during 
pathological angiogenesis, such as cancer [17, 23]. We believe that modelling of 
tumour-induced angiogenesis based on VEGF and Notch signalling pathways is an 
innovative and promising direction.  
 
2.3.5 Sprouting and branching 
Sprouting in tumour-induced angiogenesis is a dynamic procedure, including EC 
migration, establishing connections with vessels encountered, shaping lumen, and finally 
forming a hierarchically branched and functionally perfused vascular net [4]. In the 
nascent sprout, ECs are specified into two distinct cellular phenotypes, tip and stalk cells, 
which are endowed with specialized functions and gene expression patterns [4]. The 
specification is due to VEGF and Notch signalling as discussed above in section 2.3.4. 
VEGF-VGEFR-2 and Dll4-Notch signalling engage in an intricate collaboration to balance 
tip and stalk cell selection and to regulate tip cell migration and stalk cell proliferation 
during angiogenesis, in which the sprouts and branches emerge and finally create the 
capillary network [4]. It is thought that during sprouting, specialized with distinct 
phenotypes and functions, individual ECs cooperate with each other in behaviour which 
might be described as teamwork [106].  
The ECs at the spearheading positions of the vascular sprouts are known as the endothelial 
tip cell, which has its own characteristic, such as being migratory with long and dynamic 
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filopodia [16]. Through filopodia, the tip cells sense the directional cues presented by the 
environment, and thereby define the route in which the new sprout grows [16]. Gerhardt 
[16] concluded that the extension and maintenance of tip cell filopodia depends on an 
appropriate VEGF-A concentration distribution, such as its concentration gradient is 
necessary for the correct guidance of tip cell filopodia. The tip cells create new 
connections between different sprouts to form an interconnected and circulated functional 
vascular network [107]. Behind the tip are the cells in stalk phenotype. Producing less 
filopodia, the stalk cells are highly proliferative [108, 109]. They establish adherent and 
tight junctions for the new sprout, and form the nascent vascular lumen [108, 109]. 
As angiogenesis with regard to the formation of a capillary network is too complex to be 
described clearly, we concentrated on two phenomena, sprouting and branching. To 
determine angiogenesis, sprouting predominates as the major function and process during 
the formation of capillary networks, while branching is a special state of sprouting. Thus, 
we focussed our attention on the mechanism of sprouting, regrade branching as a special 
type of sprouting. 
 
2.3.5.1 VEGF-Notch signalling pathway crosstalk 
First, we must consider how ECs become either tip or stalk cell phenotypes. Previous 
research shows that the VEGF and Notch signalling pathways are fundamental in the 
process of ECs becoming either tip or stalk during the angiogenesis sprouting process in 
tumour angiogenesis [16, 17, 22, 57].  
It is necessary for the cells to communicate during angiogenesis. Communication in all 
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organisms is mediated through complex networks that integrate extracellular signals and 
intracellular processes for the generation of appropriate cellular responses [43]. The 
process of angiogenesis is the same, in that the signalling pathway is generated inside and 
between cells [43]. The fundamental elements for this intercellular communication are the 
receptors in the cell membrane or on the surface of cells, and the extracellular signals 
released by adjacent cells [45, 46]. After the receptors sense the extracellular signalling, 
the transmission of signals to genes and the gene-regulatory mechanism occur through a 
cascade of reactions known as signal transduction [45, 46]. Here, the stimulus from 
external signals is received by the receptors on the surface of the cell or at the cell 
membrane, and are transmitted using intracellular biochemical reactions. This promotes 
the relay of information [45, 46]. 
The cells in different phenotypes show their distinct gene expression profiles, including 
cell surface receptors such as VEGFR1, VEGFR2, VEGFR3, Dll4, and Nidogen-2 [110]. 
The different expression behaviours and the mechanism of tip and stalk cells in the nascent 
sprout are still not clear, so recent efforts have been aimed at deciphering the functional 
relevance of sprouting [4]. 
The VEGF and Notch signal pathways are both key regulators of the angiogenic process 
involved in the specification of the tip and stalk cell phenotype. These two pathways work 
together to achieve functional patterning during sprouting angiogenesis. Several lines of 
evidence indicate that VEGF signalling acts upstream of the Notch signalling pathway 
during physiological and pathological angiogenesis, controlling the expression of different 
Notch components [21, 23, 98].  
The cell immediately adjacent to the vascular and hypoxic retina expresses high levels of 
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VEGF-A, in which high Dll4 expression is found at the vascular sprouting front [23, 57]. 
An intravitreal injection of VEGF-A increases Dll4 expression, showing that VEGF-A 
signalling in ECs in vitro and in vivo quantitatively regulates Dll4 expression [23, 57]. 
In addition to VEGF-A acting upstream of Dll4, it has become clear that Notch, in turn, 
controls VEGF signalling. In general, all observations support the concept that Notch 
signalling via Dll4 principally acts as a negative feedback regulator to control 
VEGF-induced angiogenesis [4].  
Signalling pathways are often branches, and indeed multiple pathways may be integrated 
into a signalling network, much like the metabolic pathways network noted by Nicholson 
[94]. The signalling in one pathway may influence the activity of the components of other 
signalling pathways. This interdependence of signalling is termed crosstalk [47], and 
enables the cell to coordinate multiple inputs at the level of signal transduction. For 
example, the VEGF signalling pathway has crosstalk with the Notch signalling pathway in 
regulating the specification of tip and stalk phenotype from ECs during sprouting. Both the 
VEGF signalling pathway and the Notch signalling pathway are interdependent. The 
crosstalk occurs between two adjacent cell membrane receptors. 
As described above, we can see the important role of VEGF-VEGFR and Dll4-Notch 
signalling pathways in angiogenesis. Many studies have investigated the regulatory 
mechanism involved in vivo and in vitro. Even if there are many models in tumour-induced 
angiogenesis in silico, it is rare in the modelling of the VEGF-VEGFR and Dll4-Notch 
signal pathway regulation in angiogenesis. Modelling the regulatory mechanism is a very 
challenging task, and our goal is to explore the field innovatively by establishing a model 
based on enzymatic catalysed kinetics. 
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2.3.6 Fibronectin  
Fibronectin is a major component of the ECM. The ECM macromolecule occurs in two 
distinctly different forms. One is soluble a glycoprotein molecular form found in various 
body fluids (including blood) known as plasma fibronectin, and the other is on insoluble 
constituent of the ECM and basement membranes of cells, known as cellular fibronectin 
[111]. Fibronectin plays a very important role in the migration of ECs during angiogenesis. 
The interactions between fibronectin and ECs directly affect cell migration. These specific 
interactions between ECs and fibronectin have been verified in Boyden-chamber assays by 
Greenberg at al. The verification showed that fibronectin stimulates ECs and a number of 
other cell types’ migration directionally [112-114]. Fibronectin has been shown to enhance 
cell adhesion to the matrix [7, 8]. For both cellular fibronectin and plasma fibronectin, ECs 
use fibronectin as a major ligand for attachment to the ECM through integrins, a family of 
cell-surface receptors [51, 62]. The ECs directional migration stimulated by fibronectin have 
demonstrated that fibronectin promotes cells to migrate up its concentration gradient [63, 115, 
116]. The response of ECs to a concentration gradient of fibronectin via adhesiveness of 
bound was termed haptotaxis [64, 65]. Therefore, in addition to the chemotactic response of 
ECs to the TAF known as chemotaxis, there is a complementary haptotactic response to the 
fibronectin presented within ECM known as haptotaxis [66]. 
 
2.3.7 Retinal models 
Mouse retinas are the biological materials mostly used to establish angiogenesis models in 
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vitro and in vivo experiments, because retinas are of an ideal structure to visualize the 
development of angiogenesis and make it observable during vasculature, including 
sprouting, branching fusion and network formation [16]. Researchers set or disrupt 
VEGF-A concentration gradient on retinas to study different aspects of vessel formation, 
including the proliferation, survival and migration of endothelial cells. Retinal models are 
also used to investigate functions of VEGF-A, the crucial regulator, which regulates the 
differentiation of tip and stalk phenotypes during blood vessel formation. In retinal models, 
it can be observed that VEGF-A controls angiogenic sprouting by guiding filopodia 
extension from specialized endothelial cells situated at the tips of the vascular sprouts. It 
also can be observed that the tip cells respond to VEGF-A only by guided migration; the 
stalk cells respond to VEGF-A, occurring in the proliferation. Both of the two cellular 
responses are triggered by the mediation of VEGF-A on VEGF receptor2 on the surface of 
ECs. In retinal models, experiment results show that tip cell migration depends on a 
gradient of VEGF-A, while stalk cell proliferation is regulated by VEGF-A concentration. 
Thus, in retinal models, it is demonstrated that vessel patterning depends on the balance 
between two different qualities of the extracellular VEGF-A distribution, which regulates 
distinct cellular responses during angiogenesis [16]. Dll4 and Notch receptor also play an 
important role in regulating pattern of vessels [31]. Therefore, the experiment results and 
conclusions mentioned above come out from retinal models, and are vital and fundamental 
for researchers in the modelling of angiogenesis. In our thesis, we use the conclusions of 
retinal models in vivo and in vitro to establish the models of tumour-induced angiogenesis 
in silico, such as modelling the VEGF-Notch regulatory mechanism of angiogenesis in 
Chapter 6. 
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2.4 Conclusion  
The chapter has reviewed the biological literature which is relevant to the research focus 
for this thesis. The chapter has performed a comprehensive analysis of research on 
tumour-induced angiogenesis from the biological perspective, which identified that 
tumour-induced angiogenesis is a central step in the development of the tumour and 
regulatory mechanism of VEGF and Notch signalling pathways, which play a crucial role 
in the selection of tip and stalk during the angiogenesis process. Although a vast amount 
of biological research has been completed in the field, computational research attached to 
this aspect is still rare, especially the modelling of angiogenesis based on the 
VEGF-Notch feedback theories; thus there is a gap between biology and computer 
engineering. Our focus on the signalling by feedback control mechanism makes an 
original contribution to the modelling of tumour-induced angiogenesis, and the VEGF 
and Notch signalling regulatory mechanism is the most important point for us to begin 
with. The next chapter, Chapter Three, discusses the computational models and modelling 
methods which helped us to determine the selected technique routes. 
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Chapter 3. Modelling and Methods 
Modelling of tumour-induced angiogenesis needs advanced mathematical methods, 
including ordinary differential equations (ODEs), partial differential equations (PDEs) 
and computer engineering methods such as cellular autometa (CA) and agent-based 
modelling (ABM). On the other hand, the model to be developed should be in front of the 
field, so it is necessary to review the models of tumour-induced angiogenesis developed 
in the past decades to provide an overview of the field. In this chapter we present a 
review of the modelling of angiogenesis and the methodologies developed so far, 
providing the basis for the choise of technique approach for the research aim. 
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3.1 Introduction   
The development of tumour research has led to a massive and rapidly evolving area 
covering biological, physiological, chemical, and physical processes to medical 
investigation. Later on, computational simulation is also involved. Computational 
modelling is a promising strategy to reveal the mechanism of tumour-induced angiogenesis 
and provides clues to develop therapy for patients suffering from a tumour. The use of 
computational modelling and simulation has been adopted by a growing number of 
researchers [117]. For instance, models based on mathematical equations and based agents 
have been used to generate hypotheses and decipher secretes of tumour [117]. 
To model tumour-induced angiogenesis, it is necessary to apply advanced mathematical 
tools. We used ordinary differential equations (ODEs), one useful advanced mathematical 
tool, to solve the regulation control problems for tumour-induced angiogenesis, involving 
the VEGF/Notch signalling feedback loop. We also used partial differential equations 
(PDEs), another advanced mathematical tool, to establish a two-dimensional continuum 
model to simulate the continuum of the biological phenomena, such as VEGF gradient, 
ECM, enzymes secreted by ECs and EC migration. These different substances as variables 
are in continuum distribution, and we used discrete agent-based modelling (ABM) to 
realise the simulation of angiogenesis. Hence, in this chapter we will discuss modelling 
methods which could give us insights into the modelling field related to our research. 
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3.2 Mathematical Modelling Techniques  
3.2.1 ODE Models  
ODEs are an advanced mathematical tool used to solve problems including reaction rate 
kinetics, enzymatic catalysed reactions, and feedback control systems [9, 118]. It has been 
used to model cancer for many years. The early work was described by Greenspan in 
modelling solid tumour growth [9, 118]. ODE models are generally simpler to analyse and 
can provide early, useful results, where spatial considerations can be ignored. ODE models 
can obtain and send control parameters dynamically [118]. By establishing an enzymatic 
catalytic reaction kinetic model which represents the VEGF and Notch signalling feedback 
loop, we can use ODEs to generate control signals to control the sprouting which is key to 
tumour-induced angiogenesis (Chapter Two).   
Perhaps Goodwin [119] may have been the first to model intracellular regulatory 
mechanisms. He studied the essential control features of enzymatic regulatory processes, 
through which he proposed a regulatory model. The model considered the intracellular 
interactions between enzymes and their mRNA in a negative feedback loop which lead to a 
set of ODEs describing the dynamics of this system. This showed oscillatory behaviour in 
relation to the organization of cellular processes in time [119]. Goodwin [119] reported that 
the majority of enzymes were synthesised in a cell and their activities were regulated by 
negative feedback control processes. 
Many aspects of signalling pathways have been modelled, and the models are mainly based 
on ODEs. Some of the models have involved very complex equations, with many variables, 
coefficients, and a series of complicated reactions. For example, a representative model in 
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ODEs in describing NF-κB signalling pathway is the model of Hoffmann et al. [120]. They 
developed an ODE-based computational model using Gepasi software. This mathematical 
model is comprised of 24 ODEs describing kinetic reactions and the change of variables’ 
concentrations. In these equations, they were particularly interested in the temporal control 
of NF-κB activation by the coordinated degradation and synthesis of IκB proteins. This 
kind of model succeeds in modelling the signalling pathway, but is too complex to be 
verified in wet-lab because too many coefficients should be determined and explained, 
which limits its usefulness. 
The models mentioned may represent the major components of the NF-κB signalling 
pathway, both mathematically and computationally. Although these models are successful 
in describing a series of complicated reactions, they are still questionable because the 
complex nature of these models makes them computationally expensive to run, and also 
complicated analysis techniques are required to make inferences from simulation results. 
As such, the term minimal models have been proposed and developed as simply as possible, 
by establishing a minimum number of equations of models to replicate the majority of the 
more complex computational models [121]. These reductionist models can also be 
investigated in vitro. 
After Carlotti and colleagues’ work, Krishna et al. [122] developed the first minimal model 
in NF-κB signalling pathway [123] and focused on a small core network of the pathway 
that drove oscillatory behaviour. By reducing the model of Hoffmann et al. to a core 
feedback loop of three coupled ODEs, they were able to ascertain the minimal model 
which was required to generate oscillations in modelling the signalling pathway. They 
focused on describing the crucial reaction generating oscillation behaviour, and set an 
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upper limit within the system for the degradation rate; they then conjectured that this 
effectively introduced a time delay into the negative feedback loop, which is known to 
generate oscillations. Thus, minimal models represent another trend of modelling in 
signalling pathways. 
Based on the recent experimental evidence, Stamper et al. [9] developed a model 
considering both angiogenesis and vasculogenesis, both of which contribute to vessel 
formation, by using a nonlinear ODEs-based continuum approach. This model is 
composed of seven variables, such as the vessel within the tumour, activation of ECs by 
TAF (e.g. VEGF), and levels of endothelial progenitor cells (EPCs) which contribute to the 
construction of new blood vessels by vasculogenesis [9]. In their model, angiogenesis was 
referred to as the migration and proliferation of ECs from pre-existing vessels, while 
vasculogenesis referred to the mobilisation of bone marrow-derived EPCs. The EPCs 
homed in on the tumour, where subsequently they might differentiate into ECs and form 
vascular structures. In this model, vessels were created by angiogenesis and vasculogenesis, 
and tumours were shown to exhibit similar growth dynamics. The model reveals three 
possible results: the tumour had unlimited vascular growth; the tumour evolved to a 
vascular equilibrium; or the tumour remained in an avascular steady state [9]. Neither the 
immune system response to the tumour nor chemotherapeutic drugs were involved in the 
model. The aim of the modelling was to reduce vasculogenesis and inhibit tumour growth, 
but a detailed discussion was given on using the model dependent parameter values to 
predict the effects of these treatments.   
In our study, the use of ODEs was to describe reaction kinetic-based interactions between 
different variables, and to present the rate of change in system variables over time. 
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Applying the mathematical tool ODEs in our model, we established a VEGF and Notch 
signalling regulation minimal model based on enzymatic catalysed kinetic reactions. 
 
3.2.2 PDE Models  
ODE models are very useful in the field of signalling feedback control, but their limitations 
are very clear. They are not able to describe reactions in which reactions occur spatially and 
temporally. Particularly, they ignore the spatial aspects of biological phenomena that are of 
critical importance, such as tumours’ inhomogeneous nutrient delivery, heterogeneous 
tissue structure, and angiogenesis [117].  
In the modelling of tumour-induced angiogenesis, there are many different types of 
reactions, such as EC migration and proliferation, enzymes secreted by ECs, degradation 
of ECM through secretion of MMPs, and the diffusion of VEGF from the tumour to its 
environment. The simulation to describe those reactions that occur at different locations 
and times depends on Fick’s diffusion law [117].  
These are all implemented at space and time dimensions. Hence, all these biological 
phenomena should be solved by the use of PDEs allowing for additional independent 
variables, such as space and time [117]. For example, a PDE model can spatially 
represent the change in concentration of ECs in time and space to represent their 
movement. 
Early in 1985, Balding and McElwain [124] established a one-dimensional, mathematical 
model to describe published angiogenesis experiment results. In these experiments, TAF 
was placed in the avascular cornea of a host animal [124]. TAF diffuses and forms 
46 
concentration gradient chemotactically. This triggered angiogenesis, which caused 
sprouting and growth from nearby pre-existing vessels. The sprouts or tips move toward 
the source of TAF, form loops by anastomosis and leave new capillary vessels in their trails 
[8]. Disruption of the concentration gradient of TAF results in a gradual regress of the new 
vessel [124]. To model these experiment results, Balding and McElwain [124] developed 
conservation equations for the TAF or angiogenic factor (c) and for the blood vessels. In 
their model, the new vessel was composed of two variables, motile tips (n) and capillary 
vessel lengths (ρ). This concept elegantly distinguished the different behaviours and spatial 
distribution in angiogenesis.  
One of the most influential mathematical models of tumour-induced angiogenesis using 
PDEs is the work of Anderson and Chaplain et al. [6-8, 36]. In their models, the variables 
are ECs, fibronectin, VEGF, ECM, and enzymes secreted by ECs. The application of PDEs 
to simulate angiogenesis exhibits the migration of ECs from the side of an existing vessel 
towards the side of tumour, during which the concentration of ECs changes at different 
locations and time. During angiogenesis, ECs move by random motion, chemotaxis 
generated by the VEGF gradient, or haptotaxis. But their model does not contain any 
consideration of EC proliferation, even though the equations reveal angiogenesis dynamics, 
such as diffusion of TAF, fibronectin, and angiostatin [125].  
 
In fact, during angiogenesis when the capillary network approaches the tumour, the density 
of the capillary network also increases, which means the density of the ECs should increase 
first [125]. To supply enough cells to form the capillary network, proliferation is essential 
for the formation of the capillary network [126-128]. During the procedure, ECM is 
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degraded to make way for the development of the capillary network. As a result, the 
degradation dynamics of the ECM is catalysed by protease enzymes.  
Mantzaris, Webb and Othmer [125] point out that EC proliferation influences the protease 
enzyme dynamics in the tissue. Hence, the protease enzyme concentration should be above 
a certain threshold value so that cells can proliferate. Moreover, high values of the protease 
enzyme also stimulate migration through the degradation of fibronectin [125]. Thus, 
Mantzaris, Webb and Othmer [125] argue that the tight relationship between proliferation 
and migration in this model contradicts some experimental observations; they point out 
that localisation of proliferation behind the leading tip of the vasculature is multiplying the 
proliferation term with an arbitrary function depending on tip curvature. Since ECs have a 
long half-life [129], Mantzaris, Webb and Othmer [125] further propose that Anderson and 
Chaplain’s continuous model does not include EC proliferation. We agree with Mantzaris’s 
opinion and so we improved in this aspect by involving the EC proliferation in our model.  
Anderson and Chaplain assumed the highest concentration of fibronectin is at the side of 
the parent vessel and the lowest concentration is at the side of the tumour line source, 
which is opposite to that of TAF in the concentration gradient. Based on this assumption, 
they established a model and simulated the migration of ECs influenced by the 
concentration gradient of fibronectin. The simulation results show that the velocity of ECs 
migration is slowed by the concentration gradient of fibronectin [7, 8]. However, we 
noticed that in recent studies, some bio-clues imply that for some subgroups of tumours, 
the highest concentration of fibronectin may be at the side of the tumour line source and the 
lowest concentration at the side of the parent vessel. For this reason, we may improve their 
work by establishing a model to simulate tumour-induced angiogenesis influenced by 
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haptotaxis. The bio-clues are dip50, scussed as follows.   
The fibroblasts have high expression of fibronectin at the tumour side according to 
Lundberg [130]. Their results indicate that fibroblasts induce the CpG island methylator 
phenotype (CIMP)-negative tumour cells to produce more fibronectin. Because cancer is 
always associated with fibroblasts, the term CAF is known as cancer associated fibroblasts. 
It implies that for some cancers the fibronectin density in the ECM near the tumour may be 
higher than that in the ECM far away from the tumour. The tumour stroma is enriched in 
fibrillar proteins, including collagen I and fibronectin [130]. According to Kumar, Das and 
Sen [131], “Cancer progression is marked by increased deposition and cross linking of 
fibrillar ECM proteins, including collagen and fibronectin, which lead to an increase in 
ECM density and enhance the progression.” This means that the invasive tumour increases 
the density of fibronectin by deposition at the ECM near the tumour. In turn, this implies 
that the concentration of fibronectin may be higher near the tumour. For example, in breast 
cancer, there is a nearly 10-20 fold increase in bulk stiffness in the tumour 
microenvironment [131].  
According to a recent study, fibronectin also plays a critical role in the invasion of cancer 
progression. Cao et al. [132] report that fibronectin protein expression in human 
gallbladder cancer (GBC) tissue samples is primarily overexpressed. The overexpression 
of fibronectin promoted cancer progression and was associated with a worse prognosis in 
GBC patients. Their experimental results indicate that exogenous fibronectin significantly 
enhances and promotes the proliferation and metastasis of GBC cells not only in vitro but 
also in vivo. The overexpression of fibronectin near tumours has also been reported [130]. 
From these clues, we assume that it may be possible that in some subgroups of tumours, 
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especially the invasive tumour, the density of fibronectin is higher near the tumour than far 
away from the tumour. For other types of tumour, including Small Cell Lung Cancer 
(SCLC), an aggressive form of lung cancer, the ECM surrounding SCLC cells contains a 
great amount of fibronectin [130, 133-141].  
In some cases, fibronectin density is increased near tumours which would enhance the 
haptotactic influence. The increased fibronectin density might enhance the haptotactic 
influence by increasing the cells express receptors to bind to the matrix. We aimed to 
improve the continuous model of Anderson and Chaplain’s work [6-8] from perspectives 
considering EC proliferation, enzyme catalyzed ECM degradation, and the impact of 
fibronectin on EC migration. As there are many biological phenomena which occur in 
space and time during angiogenesis, by establishing a two dimensional model in PDEs 
and simulating the model, we can obtain a better insight into tumour-induced 
angiogenesis and achieve parameters of PDEs for the agent-based model which is used to 
simulate angiogenesis regulated by a VEGF/Notch signalling pathway. 
 
3.3 Agent-Based Models  
For the modelling of complicated biological systems, the advanced mathematical tools 
were traditionally used to approach the dynamics of the systems. Through establishing and 
solving ODEs, the modeller can obtain time-series dynamics at the system level; through 
establishing and solving PDEs, the modeller can obtain dynamic spatial and temporal 
information of biological phenomena in the domain simulated. Both of the two advanced 
mathematical tools are unsuitable for describing individual behaviour. Recently, a number 
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of computational approaches taken from the field of computer engineering have been used 
to model individual components. For example, agent-based modelling (ABM) is the one 
emerging in the computer field.  
ABM is an innovative computational methodology using computational objects that focus 
on the rules and interactions between the individual agents of system [142]. ABM is based 
on rule setting, agent discrete, and time discrete methods [142-144]. The goal of ABM 
simulation is to generate the populations of the system agents, to simulate the interactions 
in a ‘virtual world’, and to create an experimental model in silico [142]. ABM starts with 
mechanisms or rules for behaviour, and seeks to reconstruct through the computational 
instantiation of those mechanisms [142]. Thus, ABM can be extremely useful if the goal is 
to test the veracity of a set of identified or presumed mechanisms in a system.   
ABM has been widely applied in the modelling of geographical system and financial 
marketing research. It rarely enters into the area of biological field. A large amount of 
significant in vitro and in vivo data already exists, but it is still difficult to develop a 
complex modelling technique based on these data. One initial study in using ABM of 
filopodia is provided by Bentley et al. [30]. They developed an agent-based model to 
analyse the role of Notch-mediated selection of cells in the early stage of angiogenesis. 
This model only involves the VEGF-A gradients and simulates filopodia extension during 
the stalk cell activation procedure, but does not actually refer to the VEGF-Notch 
regulatory mechanism.  
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3.4 Hybrid Models  
De Pillis et al. [145] developed a mathematical model of tumour-immune system/cell 
interactions, which discussed tumour-immune system/cell dynamics. The model focused 
on the role of natural killer (NK) and CD8+ T cells. The tumour-immune cell interactions 
described in the model were in the form of ordinary differential equations (ODEs), 
including several variables such as the (CD8+ T)-tumour kill term, the immune recruitment 
term, and the cell-cell kill term. They considered that in previous work tumour cells were 
assumed to grow logistically in the absence of an immune response, but in fact both CD8+ 
T cells and NK cells could kill tumour cells. In the presence of tumour cells, the CD8+ T 
cells were recruited as part of specific immunity. They developed the model associated 
with variables including tumour immune growth, interaction rates and immune response. 
The solution of the model was realised by using a numerical differential equations solver 
and a least-squares method. The simulation results showed that in the immune system the 
dynamics of CD8+ T cells were different from that of NK cells. Simulations of tumour 
growth in the developed model can give predictive data by using different levels of 
immune ligands, effector cells, and tumour resistance. 
A number of recent papers used a hybrid continuum mathematical/cellular automata 
approach to model the interactions between tumours and the immune system. For example, 
Mallet and de Pillis [146] used a hybrid approach to model the interactions between tumour 
and immune system on a two-dimensional domain, but angiogenesis was not involved in 
this model. Byrne et al. [147] developed a hybrid continuous mathematical model, which 
focused on the response of a vascularised tumour to chemotherapeutic drugs which 
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targeted proliferating cells. The proliferation and death of tumour cells can be influenced 
by nutrient diffusion. Tumour cells and the surrounding stromal cells were modelled using 
a cellular automata approach, while a number of variables such as oxygen and an 
angiogenic factor were modelled using a continuum approach. The chemoattractant is 
generated by the tumour cells under hypoxic conditions. The blood vessels in this model 
were represented by a hexagonal network superimposed on the cellular automata grid. The 
tumour volume was a mixture composed of macrophages, tumour cells, and extracellular 
material. The volume of tumour spheroid was assumed to be constant. Simulation results 
show that changes induced in the vasculature by TAF can lead to oscillations in a tumour’s 
composition. Macrophages infiltrate solid tumours, in which macrophages cause fatal 
damage to the proliferating tumour cells. This occurs either by delivering cytotoxic factors 
directly or by releasing enzymes that activate an external pro-drug, thus making the tumour 
more sensitive to chemotherapeutic drugs that target proliferating cells [148]. 
Eikenberry et al. [149] presented a model of melanoma invasion into healthy tissue with an 
immune response. They established a two-dimensional mathematical model, with seven 
variables such as the growth and metastasis of malignant melanomas. These variables 
include ECs and angiogenic factors. In this model, the immune system was introduced to 
simulate its effect on tumour suppression. The immune system includes two variables, 
cytotoxic cells of the immune system and their attractant. The authors thought that small 
metastatic satellite lesions could be held to a minimal size through the immune system’s 
interaction with the larger primary tumour, because the existing tumour can trigger and 
maintain the host’s immune activity. So metastatic satellite lesions were optimally 
suppressed by immune activation when the primary tumour was moderately rather than 
53 
minimally or surgically removed. The model illustrates that disruption of the host’s 
immune response after surgical incision of a tumour could lead to increased metastasis 
which encourages the total cancer mass to increase more quickly. These simulation results 
are consistent with many clinical case investigations involving surgical resection of a 
primary melanoma followed by recurrence in local metastases. ECs did not undergo 
chemotaxis in this model, though TAF affects the rate of EC mitosis and apoptosis. As the 
immune system cells are assumed to undergo both diffusion and chemotaxis, from the 
model of Eikenberry et al. we might think that the tumour-immune system dynamics is 
critically important in determining the likelihood and the extent of tumour regrowth 
following surgical resection. Thus, their work implies that in the modelling of 
tumour-induced angiogenesis it would better to include the immune system. 
Rejniak and McCawley [150] provided an excellent mini review on approaches to the 
computational modelling of a variety of interactions between a tumour and its surrounding 
microenvironment. These computational models mathematically include continuum, 
cellular automata, particle based, IB cell, and cellular Potts methods. The 
microenvironment of tumour is very complex, including tumour stromal cells, the dense 
network of various ECM fibres, and the immune cells (e.g. cytotoxic T-lymphocytes). A 
tumour was modelled at different scales of complexity, such as chemical interactions, 
biochemical pathways, cellular functions, and tumour-induced angiogenesis. In the article, 
the advantages and disadvantages of modelling approaches in the area have been analysed. 
The authors assume that computational models of cancer are invaluable for researchers by 
providing them with powerful tools to integrate the complexity into organising principles 
as well as suggesting testable hypotheses in the future. 
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3.5 Modelling of tumour-induced angiogenesis 
For the modelling of tumour-induced angiogenesis, the most representative ones are from 
the work of Anderson et al. between the 1990s to 2010s. Byrne and Chaplain [148, 151] 
proposed a snail-trail model for the scenario in which the formation of the vascular 
network was stimulated by the production of VEGF by a tumour. Anderson et al. [6-8, 152] 
proposed two dimensional models by using nonlinear partial differential equations (PDEs) 
to describe the migration of ECs, which are considered as tips from a parent vessel moving 
towards a solid tumour [7, 11, 153]. In the models, fibronectin and TAF are characterised 
by the presence of haptotaxis and chemotaxis terms, respectively. Chemotaxis is 
influenced by the soluble angiogenic isoforms gradient in concentration, which is secreted 
and diffused from tumours such as TAF. Haptotaxis is formed by insoluble ECM molecules 
such as fibronectin gradient density. The continuum models successfully simulate the 
migration distances, moving the velocity and local density of ECs.  
As the continuum models could not retain the exact features of capillary networks, since 
1998 they have integrated the continuum models with a discrete method to model the 
spatial and temporal progression of tip cells and capillary network formation [6, 154]. This 
involves the influence of perfused blood in the development of vessels induced by the 
tumour [15, 155, 156]. The inclusion of blood perfusion in growing capillary networks 
implies that the modelling of angiogenesis is going to involve more factors which can 
influence the forming of vessels [5-7, 157, 158]. With the discrete method, ECs follow a 
random path in a square lattice towards the tumour. The stochastic version of continuum 
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models captures the cell-scale structures, which could be called a hybrid 
discrete-continuum model. The macroscopic clusters of cells in the continuum are 
described into microscopic as entities in discrete forms, according to laws obtained by a 
discretization of suitable continuum models, moving towards the tumour under the 
influence of PDEs and substrata [10]. In this way, Anderson and Chaplain have developed 
the hybrid discrete-continuum models, and their achievement represents a breakthrough in 
modelling realistic vascular structures [6-8, 152]. 
Their idea is to use the coefficients from the five-point stencil of the standard central 
finite-difference scheme to generate the probabilities of movement for an individual cell, 
which is influenced by TAF and fibronectin gradients, to superimpose to an isotropic 
random walk. Branching might take place when sprouts are older than a threshold 
branching age, and branching occurs stochastically, which means the possibility of 
branching is based on the concentration of TAF. This is under the assumption that new 
sprouts must be mature enough before being able to branch [10]. Branching might take 
place when sprouts are older than a threshold branching age; branching occurs 
stochastically, and the possibility of branching is based on the concentration of VEGF [10]. 
The two-dimensional hybrid partial differential equation-discrete model was further 
developed by Watson and McDougall [36]. The model was derived to track the migration 
of endothelial tip cells and individual astrocyte in response to the appropriate biochemical 
cues, such as chemotactic gradient of PDGF-A, including blood perfusion in retinal 
vascular plexus (RVP), which successfully simulates a wild-type in silico RVP structures 
[36]. They thought that the implementation of the retinal vascular process is an excellent 
tactic for mathematical modelling, by which modellers can compare the results of retinal 
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vascular experiments with the results of simulation by computer. This gives a rigorous test 
for studies in silico, especially for the mathematical modelling of tumour-induced 
angiogenesis, which often results in highly heterogeneous capillary networks which are 
more straightforward to reproduce numerically by simulation [36]. In their models, the 
biological regulatory mechanism is still not included.  
Many models have appeared in the last decades but few have described the fascinating 
developmental process of the differentiation of cells during vessel formation. Regulated by 
VEGF and Notch, the differentiation of cells mainly includes tip and stalk phenotypes 
specified from ECs. Maggelakis et al. have developed a model approaching to study the 
interaction between VEGF, oxygen and capillary density in angiogenesis by employing 
continuum PDEs [12, 159], whereas Liu et al. [13] used a small digitised network taken 
from the human retina to predict distributions of flow and oxygen partial pressure. Briefly, 
the exploration of VEGF and Notch signalling regulatory mechanism in the 
tumour-induced angiogenesis is crucial.  
 
3.6 Conclusion 
The computational modelling in the field of tumour-induced angiogenesis has developed 
rapidly in the last few decades. For instance, tip cell density, vessel density, vessel pattern, 
vessel morphology, developing velocity, etc. have been simulated. Moreover, a variety of 
methodologies have been developed, including mathematical methods such as PDEs and 
ODEs, the stochastics method, and the CA and ABM discrete method. Even though effort 
has been made in the field, the progress of computational modelling is still far behind 
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compared with the progress in biology, which has recently achieved significant discoveries. 
Most models focus on simulating the blood vessel morphology, but rarely explore the 
angiogenesis regulatory mechanism.  
This chapter has performed a comprehensive analysis of research on tumour-induced 
angiogenesis from the computational modelling perspective. The PDEs, ODEs are the 
powerful mathematical tools which are used to deal with continuum models. ABM and CA 
are the appropriate methodologies which are used to deal with discrete models. With the 
help of these methodologies and by integrating these tools, we may model the very 
complicated tumour-induced angiogenesis in which both the continuum and discrete 
models are involved. Based on the review in this chapter which has helped to determine 
our technique routes towards our goal, we decided to model the tumour-induced 
angiogenesis by using ODEs to model the regulatory signalling kinetically, by using PDEs 
to model the variables such as ECs, blood vessels, and VEGF etc. spatially and temporally. 
In this way, we aimed to model the VEGF and Notch signalling regulatory mechanism in 
the process of angiogenesis to decipher its secret. In the next chapter, Chapter Four, we 
present and discuss our mathematical models of tumour-induced angiogenesis by 
chemotaxis, haptotaxis, aiming to provide parameters of PDEs and a broader 
understanding of the tumour.   
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Chapter 4. Modelling of Tumour-Induced 
Angiogenesis by chemotaxis and 
haptotaxis 
Mathematical modelling of tumour-induced angiogenesis has itself been developed and 
expanded over years. In general, the angiogenesis occurs temporally and spatially. To 
incorporate the temporal and spatial scales, PDE is a powerful mathematical method to be 
used to describe the migration of ECs. The main aim of this chapter is to understand the 
influence of chemotaxis and haptotaxis in tumour-induced angiogenesis using two 
mathematical approaches: a continuum approach and an individual cell-based approach. 
For the continuum approach, first we started from a model of tumour-induced angiogenesis 
developed by Anderson and Chaplain [2], where the locomotion of ECs is governed by 
random motility, directional migration towards gradients of soluble chemoattractant TAF 
or chemotaxis, and directional movement up gradients of insoluble ECM components 
fibronectin or haptotaxis. We used this model as a basic model for tumour-induced 
angiogenesis, extended the model by incorporating cell proliferation and proposed a 
possible mechanism in which invasive tumours enhance haptotaxis and promote 
angiogenesis. In this chapter we present the continuum approach and discretised approach 
respectively.  
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4.1 Introduction  
This chapter presents and discusses the proposed mathematical models of angiogenesis 
by tumour-induced chemotaxis and haptotaxis, providing parameters of PDEs and a 
broader understanding of tumour-induced angiogenesis.   
Angiogenesis is the process of forming new blood vessels from the existing ones, and is a 
crucial requirement for the growth, progression and metastasis of a tumour [32-34]. 
Tumour-induced angiogenesis is the phenomenon that in hypoxic microenvironment, the 
tumour triggers angiogenesic processes by secreting the tumour angiogenic factor (TAF), 
such as vascular endothelial growth factor (VEGF) [4]. The concept that tumour growth is 
dependent on the tumour-induced angiogenesis was first proposed by Judah Folkman in 
1971 [39]. Since then, lots of studies on the tumour-induced angiogenesis have been 
developed. 
Endothelial cells (ECs) are the most important cells involved in the angiogenesis process. 
Endothelial tip cells are some ECs spearheading at the nascent sprouts and guiding the 
newly formed vessel there (see section 2.3.2). The procedure of angiogenesis is the 
migration of the endothelial tip cells and the proliferation of the stalk cells following the 
endothelial tip cells. Modelling of the migration of the endothelial tip cells is a pivotal 
aspect for studying the angiogenesis process.  
Previously, the most commonly used models of tumour-induced angiogenesis were mainly 
based on the partial differential equations (PDEs). One of the most influential PDEs model 
in two dimensions was firstly proposed by Anderson and Chaplain [5-8, 152]. The 
variables of ECs, fibronectin, TAF and the matrix degrading enzyme (MDE) secreted by 
60 
ECs were included in this model. The migration process of ECs from vessel side towards 
tumour side could be observed from the PDEs, giving the details about ECs concentrations 
at different locations and times. During angiogenesis, concentrations of TAF (or VEGF) 
and fibronectin varied over time, inducing the changes of concentration gradients of TAF 
(or VEGF) and fibronectin. These changes were related to two important features in 
angiogenesis process, named as chemotaxis and haptotaxis respectively. According to the 
previous works [160-162], Anderson and Chaplain assumed that the largest concentration 
for fibronectin locates at the parent vessel side, while the lowest concentration locates at 
the side of tumour line source. However, other different points of view appeared in some 
recent studies. Cao et al [132] reported that fibronectin protein from the human gallbladder 
cancer (GBC) tissue samples is primarily overexpressed. The overexpression of 
fibronectin protein will accelerate the cancer progress and is associated with a worse 
prognosis in GBC patients. The overexpression of fibronectin at the tumour side has also 
been reported by Cervantes-Arias et al [130, 131, 137, 163, 164]. Thus, we argue that, at 
least in some cases, fibronectin plays a critical role in the invasion of cancer progression 
and the fibronectin density is higher at the side of the tumour, which would enhance the 
influence of haptotaxis.  
In addition, the most important aspects for modelling the migration of endothelial tip cells 
are density and velocity. There are two factors influencing the migration of endothelial tip 
cells: chemotactic and haptotactic factors. The chemotactic factor is the soluble 
bio-compound which is secreted by a tumour, such as VEGF, and is diffused to the 
surrounding microenvironment, forming a concentration gradient. The soluble 
bio-compound is generally called TAF in the computational modelling field. The 
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phenomenon of the tip cell migration by introducing TAF concentration gradient and 
moving up the gradient towards the tumour is called chemotaxis. The haptotactic factor is 
the insoluble bio-molecular compound concentration gradient in an extra cellular matrix 
(ECM) such as fibronectin. The phenomenon of the tip cells migrating by introducing 
insoluble bio-molecular compound concentration gradient and moving up the gradient is 
called haptotaxis. Therefore, chemotaxis and haptotaxis have vital influences on the 
migration of endothelial tip cells, and can play important roles in the development of 
angiogenesis.  
Therefore, we aimed to model the relationship between tumour-invasion and 
tumour-induced angiogenesis, which until now has rarely been considered. In this study, 
we proposed an improved tumour-induced angiogenesis model based on Anderson and 
Chaplain’s work and the improvements included three new characteristics: 1) Involving 
endothelial tip cell proliferation the angiogenesis process; 2) Modelling the degradation of 
ECM by enzymes secreted by endothelial tip cells; 3) Modelling the different influences of 
haptotaxis according to the fibronectin concentration gradient direction. For simplicity, the 
endothelial tip cells are called ECs in this chapter. 
 
4.2 Anderson and Chaplain's model 
4.2.1 Model construction  
We started from Anderson and Chaplain’s mathematical model [5-8, 152]. In this model, 
the EC density (at or near a capillary sprout tip) per unit area is denoted by n, which is 
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influenced by random motility, chemotaxis, and haptotaxis. The TAF concentration and the 
fibronectin concentration are represented by 𝑐  and 𝑓 , accordingly. Chemotaxis is in 
response to TAF gradients and haptotaxis is in response to fibronectin gradients [115, 116, 
165]. To derive the nonlinear partial differential equation (PDE) governing the ECs motion, 
the total cell flux balance was considered as follows. The conservation equation for cell 
density was used. The three contributions to the ECs flux  𝐽𝑛, are given by, 
 
𝐽𝑛 = 𝐽𝑟𝑎𝑛𝑑𝑜𝑚 + 𝐽𝑐ℎ𝑒𝑚𝑜 + 𝐽ℎ𝑎𝑝𝑡𝑜 (4.1) 
where 𝐽𝑟𝑎𝑛𝑑𝑜𝑚 represents the ECs flux generated by random motility, 𝐽𝑐ℎ𝑒𝑚𝑜 indicates 
the ECs flux by chemotaxis, and 𝐽ℎ𝑎𝑝𝑡𝑜  refers to the ECs flux by haptotaxis respectively. 
To describe the random motility of the ECs at or near the sprout tips, the flux of the ECs is 
assumed to be proportional to the concentration gradient of ECs ∇n. Thus, the first term of 
Eq. (4.1), 𝐽𝑟𝑎𝑛𝑑𝑜𝑚 = −𝐷𝑛𝛻𝑛  , where 𝐷𝑛  is the cell diffusion coefficient, a positive 
constant, and the minus represents that the diffusion direction is opposite to the 
concentration of the ECs. 
 
The flux of tip migration is assumed as being proportional to the gradient of TAF. 
Considering the second term of Eq. (4.1),  𝐽𝑐ℎ𝑒𝑚𝑜 , the chemotactic flux is assumed 
proportional to the concentration of ECs n and to the concentration gradient of TAF ∇c; the 
chemotactic flux can be described as 𝐽𝑐ℎ𝑒𝑚𝑜 = 𝜒(𝑐)𝑛𝛻𝑐, where the chemotactic migration 
is characterized by the function 𝜒 (𝑐) =
𝜒
1+𝛿𝑐
, which reflects the decrease in chemotactic 
sensitivity with increased TAF concentration, where  𝜒 , the chemotactic coefficient, and 
𝛿 are positive constants. 
 
The symbol 
𝜕𝑛
𝜕𝑡
 represents the change rate of ECs. The migration of tips, n, can also be 
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influenced by haptotactic factor. For the third term of Eq. (4.1), 𝐽ℎ𝑎𝑝𝑡𝑜, the haptotactic flux 
is assumed proportional to the concentration of ECs 𝑛 and to the concentration gradient of 
fibronectin 𝛻𝑓, so the influence of fibronectin on the ECs is modelled by the haptotactic 
flux, 𝐽ℎ𝑎𝑝𝑡𝑜 = 𝜌𝛻𝑓, where ρ is a positive constant which is the haptotactic coefficient. 
The conservation equation for the ECs density 𝑛 is given as: 
 𝜕𝑛
𝜕𝑡
+  𝛻 · 𝐽𝑛 = 0 (4.2) 
and hence the PDE governing ECs motion is, 
 𝜕𝑛
𝜕𝑡
= 𝐷𝑛𝛻
2𝑛 − 𝛻 ⋅ (𝜒(𝑐)𝑛𝛻𝑐) − 𝛻 ⋅ (𝜌𝑛𝛻𝑓) (4.3) 
where n denotes the ECs density (at or near a capillary sprout tip) per unit area, c denotes 
the TAF concentration, f denotes the fibronectin concentration. To derive the equation 
governing TAF, the procedure of tumour-induced angiogenesis should be considered. This 
procedure is starting from the secretion of TAF by the tumour cells. Then, TAF is diffused 
into the surrounding tissue and ECM. Thus, the concentration gradient between tumour 
and nearby vessels is set up and finally establishes a steady state. As the ECs migrate 
through the ECM in response to this steady state gradient, there is some uptake and binding 
of TAF by the cells [166, 167]. According to Ausprunk and Folkman’s report, when the 
ECs migrate in the microenvironment towards the tumour, there is some uptake and 
binding of TAF molecular by the ECs [168]. Anderson and Chaplain [2] proposed a simple 
TAF uptake function. The function describing the change rate of TAF concentration is as 
follows: 
 
𝜕𝑐
𝜕𝑡
 = −𝜂𝑛𝑐 (4.4) 
where 𝜂 is a positive constant coefficient, it represents the consumption rate of TAF, n is 
the density of ECs, and c is the concentration of TAF.  
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Fibronectin is a component of ECM, and can be produced and secreted by ECs [169-171]. 
Then, it becomes bound to the ECM and does not diffuse [169, 172]. The equation for 
fibronectin contains no diffusion term. The production rate of fibronectin by ECs is 
proportional to the density of ECs 𝑛 and the coefficient 𝛽 is a positive constant.  
The degradation of fibronectin 𝑓 is proportional to the matrix degrading enzyme (MDE) 
density m and to the density of fibronectin, the coefficient is a positive constant 𝛾. The 
MDE is produced by each individual EC 𝑛 at rate 𝛼. The MDE is induced by the growth 
factor from the tumour. These production and degradation processes are modelled by the 
following equation: 
 
𝜕𝑓
𝜕𝑡
= 𝛽𝑛 − 𝛾𝑚𝑓 (4.5) 
Where 𝛾 is a positive constant coefficient, it represents the degradation rate of fibronectin, 
m represents the matrix degradatory enzymes (MDE) activity, and 𝛽 is a positive constant 
coefficient, it represents the generation rate of fibronectin secrated by ECs. 
Once the MDE is produced, it diffuses locally with diffusion coefficient ε and is degraded 
at rate ν. These production, diffusion and degradation processes are modelled by the 
following equation: 
 
𝜕𝑚
𝜕𝑡
= 𝛼𝑛 + 𝜀𝛻2𝑚 − 𝜈𝑚 (4.6) 
Hence, by putting Eq. (4.3), Eq. (4.4), Eq. (4.5) and Eq. (4.6) together, the complete 
continuous model of Anderson and colleagues’ [6-8] is shown as follows, 
 
𝜕𝑛
𝜕𝑡
  =  𝐷𝑛𝛻
2𝑛 − 𝛻 · (𝜒(𝑐)𝑛𝛻𝑐) − 𝛻 · (𝜌𝑛𝛻𝑓) (4.7) 
 
𝜕𝑐
𝜕𝑡
= −𝜂𝑛𝑐 (4.8) 
 
  𝜕𝑓
𝜕𝑡
= 𝛽𝑛 − 𝛾𝑚𝑓 (4.9) 
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𝜕𝑚
𝜕𝑡
= 𝛼𝑛 + 𝜀𝛻2𝑚 − 𝜈𝑚 (4.10) 
 
4.2.2 Initial conditions and parameter settings 
1) TAF concentration distribution 
An assumption that a large initial concentration of TAF locates at the side of the tumour 
line source and a low concentration locates at the parent vessel was considered in the 
original Anderson and Chaplain’s model [8]. The initial conditions of TAF concentration 
in a two dimension domain Ω(𝑥, 𝑦) were described as follows: 
𝑐(𝑥, 𝑦, 0) = 𝑒
−
(1−x)2
𝜀2 ,    (𝑥, 𝑦) ∈ [0, 1] × [0, 1] (4.11) 
where 𝜀 are positive constants. 
2) Fibronectin concentration distribution  
To establish an equation describing the concentration of fibronectin, Anderson and 
Chaplain [8] considered the following points. First, the TAF activates ECs, which damage 
the parent vessel basement membrane, resulting in an increased vessel permeability [163]; 
second, the plasma fibronectin leaking from the parent vessel is diffused into the corneal 
tissue and becomes bound to the ECM of the corneal tissue [160-162]; third, a high initial 
concentration of fibronectin is formed in and around the parent vessel [161, 173-175]. 
According to Anderson and Chaplain’s consideration, they assume the highest 
concentration of fibronectin is at the side of parent vessel and the lowest concentration is at 
the side of the tumour line source. They set an exponential function to describe the initial 
condition of fibronectin concentration as: 
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𝑓(𝑥, 𝑦, 0) = 𝑘𝑒
−
𝑥2
𝜀2 ,                 (𝑥, 𝑦) ∈ [0, 1] × [0, 1] (4.12) 
where f represents the concentration of fibtronectin, Anderson took the parameters 𝜀2  
to be 0.45 and the coefficient 𝑘 to be 0.75 [8]. Eq. (4.12) describes the fibronectin 
concentration distribution where the concentration of fibronectin is lowest at the side of 
x=1 which represents the side of tumour. The highest concentration of fibronectin is at the 
side of x=0 which represents the parent vessel 
 
Figure 4.1. Concentrations of the TAF and fibronectin presented in Eq. (4.11) and Eq. 
(4.12) 
 
From Figure 4.1, we can observe that the gradient of TAF and the gradient of fibronectin is 
in opposite direction.  
 
4.3 Improved model in this work 
Based on the Anderson and Chaplain's model, we modified and improved their model in 
three aspects: i.e., involving ECs proliferation, ECM degradation and fibronectin 
concentration gradient. 
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4.3.1 Improved model with the new assumptions 
In Anderson and Chaplain's model, there are no birth and death terms, which means the 
total number of cells does not change. In fact, during the progress of angiogenesis, the 
density of the capillary network increases. This means that ECs density should increase in 
magnitude. So the proliferation of ECs occurs during the approach. In addition, the fact 
that ECM is degraded by enzymes should be also taken into account. 
We have created a proliferation term 𝜇𝑀𝑛 (1 −
𝑛
𝑛0
), which means that proliferation is 
proportional to the density of ECs, n, and is also limited by the density of itself 
autonomously, as described in (1 −
𝑛
𝑛0
). Here 𝑛0 should be at the same scale of the 
non-dimensionlized initial ECs concentration 𝑛 so we set 𝑛0 = 0.9. We assume that the 
proliferation rate is also proportional to ECM because the proliferation of cells requires 
growth factors which rely on ECM. The ECM is a vast source of potent growth factors 
which can promote EC proliferation and subsequent invasion through a degraded ECM 
[125]. 𝜇 is the constant proliferation coefficient. By including the proliferation term into 
Eq. (4.7) we obtained Eq. (4.13). 
𝜕𝑛
𝜕𝑡
   =  𝐷𝑛𝛻2𝑛 − 𝛻 · (𝜒(𝑐)𝑛𝛻𝑐) − 𝛻 · (𝜌𝑛𝛻𝑓) + 𝜇𝑀𝑛 (1 −
𝑛
𝑛0
) (4.13) 
1) TAF concentration distribution  
Under hypoxia condition, the tumour secretes TAF to induce angiogenesis. The TAF is 
produced by the tumour and diffuses into the two dimensions surrounding tissue and ECM 
toward the vessels based on Ficks’ diffusion law with diffusion constant 𝐷𝑐. At the same 
time, the decay of TAF occurs. Thus, the TAF concentration c satisfies Eq. (4.14). Once 
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TAF is secreted and diffused, a steady state concentration gradient between the tumour and 
vasculature can be set up. Therefore, the steady state concentration gradient of TAF 
concentration 𝑐 can be used as the initial condition for inducing angiogenesis: 
𝜕𝑐
𝜕𝑡
= 𝐷𝑐𝛻
2𝑐 – 𝜃𝑐𝑐 (4.14) 
where 𝐷𝑐  is the TAF diffusion coefficient and 𝜃𝑐  is the decay rate, both are positive 
constant. 
2) Degradation of ECM 
ECM degradation as Mantzaris et al point out [125], it is necessary to account for the fact 
that the ECM should be degraded during the approach. In order to make way for the 
capillary network process, we assume that the ECM degradation rate follows the first order 
dynamic reaction and is proportional to the MDE concentration. Thus, we modelled ECM 
degradation using Eqs. (4.15) - (4.17): 
𝜕𝑓
𝜕𝑡
= 𝛽𝑛 − 𝛾𝑚𝑓 (4.15) 
𝜕𝑚
𝜕𝑡
= 𝛼𝑛 + 𝜀𝛻2𝑚 − 𝜈𝑚 
(4.16) 
𝜕𝑀
𝜕𝑡
= −𝜔𝑀𝑚 (4.17) 
where M and m represent the concentration of ECM and MDE respectively, 𝜔 is a positive 
degradation constant, and the minus represents the opposite direction of the ECM 
concentration change [176]: 
Consequently, we obtained the mathematical model, including Eqs. (4.13) - (4.17) to 
describe the migration and proliferation of ECs, the concentration diffusion of TAF, the 
change of MDE and ECM. These equations combine together to form a mathematical 
model of tumour-induced angiogenesis. 
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4.3.2 Parameter settings and non-dimensionalisation  
To simplify the simulation, the first step was the non-dimensionalisation for the model and 
parameters. The procedure can be shown as follows. First, we should consider the length of 
the two dimensional domain at an appropriate range. From the experiments of Gimbrone, 
an average distance from a tumour implant to the parent vessels in the cornea is between 
1mm and 2mm [177, 178], and the distance between tumour and vessels upon implant is 
around 3mm [37]. Therefore, a length scale of  𝐿 = 2𝑚𝑚 was taken as the initial distance 
between the tumour and vessels from the experiments of Folkman et al. [37]. Folkman and 
Klagsbrun reported that angiogenesis was initiated when this distance was 2mm. Therefore, 
we took a length scale of 𝐿 = 2𝑚𝑚 for the domain to simulate the angiogenesis [37].  
Before non-dimensionalisation, it is useful to use a characteristic variable associated with 
time when choosing a scaling for time length. In other words, the initial distance between 
the tumour and the vessel is suitable for use as distance scaling L. The time scaling τ is 
defined as the time for TAF to diffuse across the domain. As one parameter should be taken 
as the standard parameter, Balding and McElwain [124] used 𝜏 =
𝐿2
4𝐷𝑐
, and Byrne and 
Chaplain [148] took the TAF diffusion coefficient 𝐷𝑐 as the standard parameter and used 
𝜏 =
𝐿2
𝐷𝑐
. The authors called their respective values of 𝜏 as ‘TAF transit time’ and defined it 
as 𝜏 =
𝐿2
𝐷𝑐
. Later on, the TAF transit time was taken by Anderson and Chaplain [8] as the 
time scaling or as the length of timescale by rescaling distance L between the parent vessel 
and tumour, so the length of timescale  was defined as 𝜏 =
𝐿2
𝐷𝑐
  (where 𝐷𝑐  is the TAF 
diffusion coefficient). We took the length of timescale  𝜏 =
𝐿2
𝐷𝑐
. 
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For the coefficient of ECs induced by the chemotaxis, Stokes et al. [179] measured the 
chemotactic coefficient of migrating ECs in gradients of αFGF. They measured the 
maximum chemotactic response in concentrations of αFGF around 10−10𝑀, and gave a 
chemotactic coefficient of 2,600 𝑐𝑚2𝑠−1𝑀−1 which is equal to 0.033𝑚𝑚2𝑑𝑎𝑦−1𝑀−1. 
Thereby, Anderson et al. [8] in their model took 𝜒∗ = 2,600 𝑐𝑚2𝑠−1𝑀−1, c∗ ≈ 10−10𝑀. 
In the absence of any available data for the haptotactic coefficient 𝜌∗, they assumed that 
this was of the same magnitude as 𝜒∗. As the ECs generally migrate towards the tumour, it 
is reasonable to assume that 𝜒∗ > 𝜌∗ . Hence, they thought the  𝜌∗ would be between 
0~0.03. Terranova et al. [165] identified a phenomenon of ECs responding to a haptotactic 
manner in the concentrations of fibronectin around 10−10𝑀. Anderson and Chaplain [8] 
took the concentrations of fibronectin as an estimation for the concentration of fibronetin 
𝑓∗. They took EC density as 𝑛∗ = 10−10𝑀, and TAF 𝑐∗ = 10−10𝑀 respectively (where 
𝑛∗, 𝑐∗, 𝑓∗ are appropriate reference variables).  
Balding and McElwain [124] estimated this diffusion coefficient at around 0.29 𝑚𝑚2 per 
day, based on their own simulation results. Byrne and Chaplain [148] estimated a value of 
10−8𝑐𝑚2/𝑑𝑎𝑦 (8.64𝑚𝑚2/𝑑𝑎𝑦), but if we estimate this diffusion coefficient using 𝜏 =
𝐿2
𝐷𝑐
 
with 𝜏 = 3.5 days and 𝐿 = 2𝑚𝑚, the diffusion coefficient will be 𝐷𝑐 = 2.57𝑚𝑚
2/𝑑𝑎𝑦. 
Sherratt et al. [180] and Bray [181] estimated the diffusion coefficient of TAF in the range 
of 5 × 10−7~ 5.9 × 10−6𝑐𝑚2/𝑠, so Anderson et al. [8] took 𝐷𝑐 = 2.9 × 10
−7𝑐𝑚2/𝑠, 
which is equal to 0.025 𝑐𝑚2/𝑑𝑎𝑦  or 2.5 𝑚𝑚2/𝑑𝑎𝑦 . Hence, we took the diffusion 
coefficient of TAF 𝐷𝑐 = 2.5 𝑚𝑚
2/𝑑𝑎𝑦. 
Stokes et al. [179] and Rupnick et al. [182] estimated EC random motility coefficients 𝐷𝑛 
in the range 2 × 10−9~10−8 𝑐𝑚2/𝑠 in their experiments. The estimation result was under 
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the assumption that the cells moved independently. However, when the movement of 
individual EC is constrained by surrounding cells, the random motility coefficient should 
be smaller than the coefficient that was estimated under independent movement. From in 
vivo experimental results, the random movement of ECs at the capillary sprout tips is very 
limited [129, 175]. Considering the factor that the capillary sprouts are associated with 
neighbouring cells due to the formation of vessel walls, the ECs are contiguous with one 
another. It is reasonable to expect a smaller random-motility coefficient than that observed 
by Rupnick et al. [182]. Anderson and Chaplain [8] took 𝐷𝑛 = 10
−10𝑐𝑚2/𝑠, which is 
equal to 8.64 × 10−5𝑐𝑚2/𝑑𝑎𝑦.  
For EC random motility, the coefficients are as seen in Eq. (4.7):  
?̃? =
𝐷𝑛
𝐷𝑐
=
1 × 10−10
2.9 × 10−7
= 0.00035 
?̃? =
𝜒∗𝑐∗
𝐷𝑐
= 2600 ×
10−10
2.9×10−7 
= 0.896,  
the ?̃? =
𝜌∗𝑓∗
𝐷𝑐
= 2600 ×
10−10
2.9×10−7
= 0.896. 
To simulate, the modeller may have a choice between 0.1~0.9 for both the 𝜒 and 𝜌. 
Anderson and Chaplain [8, 152] took ?̃? = 0.00035, 𝜒 = 0.38 and 𝜌 = 0.34, and we 
took the same magnitude of the parameters as theirs. 
When considering the time scale, Addison-Smith [117] chose the value  𝐷𝑐 =
0.864 𝑚𝑚2/𝑑𝑎𝑦. This gives a value of time length for 𝜏 as 4.6 days, (𝜏 =
𝐿2
𝐷𝑐
= 4.6) 
which is similar to Byrne and Chaplain’s value of 3.5 days. Folkman [37] reported that 
approximately four days after implanting the tumour in the rabbit cornea, the tumour grew 
to within 2mm of the limbus, and angiogenesis commenced. It seems reasonable to take τ 
as the TAF transit time. In Anderson and Chaplain’s model [8], they considered the 
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timescale 𝜏 =
𝐿2
𝐷𝑐 
 as 1.5 days. The difference produced is due to the difference of TAF 
diffusion coefficient, and it maybe that the approximately four days reported by Folkman 
from their experiments was too long, because the time from the implanting of tumour to the 
commencement of angiogenesis includes a lag phase in which no TAF may have yet been 
secreted. Anyway, both the time scales are at the same scale. We assumed 𝜏 =
𝐿2
𝐷𝑐 
=
2×2
2.5
=
1.6 day, so we took the timescale 𝜏 as 1.6 day.  
We have simulated this model at a domain 𝐿 = 2𝑚𝑚 which is related to a grid at size 
100×100. To simplify the analysis and simulations, the model was non-dimensionalised as 
follows: tilde notation is used for the non-dimensional variables, and scaling values for the 
concentration of these variables in the model are indicated with star  notation.  
𝜏 =
𝐿2
𝐷𝑐
∗, ?̃? =
𝑐
𝑐∗
 , 𝑓 =
𝑓
𝑓∗
 , ?̃? =
𝑛
𝑛∗
, ?̃? =
𝑡
𝜏
 , ?̃? =
𝐷𝑛
𝐷𝑐
∗ , ?̃? =
𝑥
𝐿
, ?̃? =
𝑦
𝐿
, ?̃? =
𝜒∗𝑐∗
𝐷𝑐
∗  and  ?̃? =
𝜌0
∗𝑓∗
𝐷𝑐
∗ ,  
𝛽 =
𝜔𝐿2𝑛∗
𝑓0𝐷𝑐
∗ 
, 𝛾 =
𝜃𝐿2𝑛∗
𝐷𝑐
∗ 
, 𝜂 =
𝜆𝐿2𝑛∗
𝐷𝑐
∗ , 𝜃 =
𝜃𝑐𝜏
𝐷𝑐
∗ 
, 𝐷𝑐 =
𝐷𝑐
∗
𝐷𝑐
∗ = 1. 
 
Dropping the tilde notation, we established the non-dimensional model in Eq. (4.13), Eq. 
(4.14), Eq. (4.15), Eq. (4.16) and Eq. (4.17) as follows: 
 
𝜕𝑛
𝜕𝑡
   =  𝐷𝛻2𝑛 − 𝛻 · (𝜒(𝑐)𝑛𝛻𝑐) − 𝛻 · (𝜌𝑛𝛻𝑓) + 𝜇𝑀𝑛 (1 −
𝑛
𝑛0
) (4.18) 
 
𝜕𝑐
𝜕𝑡
= 𝛻2𝑐 – 𝜃𝑐 (4.19) 
 
𝜕𝑓
𝜕𝑡
= 𝛽𝑛 − 𝛾𝑚𝑓 (4.20) 
 
𝜕𝑚
𝜕𝑡
= 𝛼𝑛 + 𝜀𝛻2𝑚 − 𝜈𝑚 (4.21) 
 
𝜕𝑀
𝜕𝑡
= −𝜔𝑀𝑚 (4.22) 
The parameters in the aforementioned Eqs were set as follows: 
𝐷 = 0.00035 , 𝜒 = 0.38 , 𝜌 = 0;  (or 𝜌 = 0.34  respectively), 𝜂 = 0.1  , 𝛽 = 0.05  , 
𝛾 = 0.1  and , 𝛿 = 0.6  [8], 𝛼 = 10−6 , 𝜀 = 0.01 , ν = 3  [6, 7];  𝑀0 = 0.9 , and 𝜃 =
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0.003 [176]. The doubling time of ECs was estimated at 18 hrs [8], so the proliferation 
coefficient of ECs can be estimated as 𝜇 =
18
24×1.6
= 0.47. Considering the death of ECs, 
the proliferation coefficient of ECs should be less than 0.47, so we estimate it to be 
𝜇 = 0.3.  Chaplain gave the MDE secrete rate coefficient as 𝛼 = 10−6 [152], and thus to 
make the simulation results of ECM visible and in an appropriate range, we estimate the 
ECM degradation coefficient to be 𝜔 = 2 × 106. The symbol 𝑛0 represents the initial 
ECs concentration, from the solution of Eq. (4.24), so we take 𝑛0 = 0.9 (see Figure 4.3). 
 
4.3.3 Boundary conditions  
Appropriate initial and boundary conditions are demanded by the model. For Eq. (4.19) the 
boundary conditions for the vessel and tumour side satisfy the Dirichlet condition 
c(0, y , t) = 0, c(1, y, t) = 1 and on the left and right side satisfy the Neumann condition 
∂c
∂y
= 0. For Eq. (4.18) the boundary conditions should convey the idea that the ECs are 
issued at 𝑥 = 0 moves from 𝑥 = 0 to 𝑥 = 1, and reach the tumour at the later boundary.  
The boundary condition of the domain subject to the non-flux conditions satisfies the 
Neumann condition and can be presented as follows: 
For Eq. (4.18), Eq. (4.20), Eq. (4.21) and Eq. (4.22): 
𝜕𝑐
𝜕𝑥
= 0, 
𝜕𝑐
𝜕𝑦
= 0, 
𝜕𝑛
𝜕𝑥
= 0, 
𝜕𝑛
𝜕𝑦
= 0,  
𝜕𝑚
𝜕𝑥
= 0, 
𝜕𝑚
𝜕𝑦
= 0  
𝜕𝑀
𝜕𝑥
= 0,
𝜕𝑀
𝜕𝑦
= 0  
and  
𝜕𝑓
𝜕𝑦
= 0 , 
𝜕𝑓
𝜕𝑥
= 0.  
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4.3.4 Initial condition  
For the solution of Eq. (4.18), the initial condition should be described. As we discussed 
above, the TAF is diffused from the edge of the tumour and reaches a steady state. Its initial 
condition of concentration can be determined by Eq. (4.19). 
 
Recent studies [130, 133-141] have implied that, for some invasive cancers, the fibronectin 
density around the stroma is higher than that of the ECM. Accordingly, cancer marks its 
progression through increasing the ECM density where the amount of fibrillar ECM 
proteins, including collagen and fibronectin, is enhanced [131]. Based on the above, we 
assume the highest concentration of fibronectin is at the side of the tumour line source and 
the lowest concentration at the side of the parent vessel. Thus, we established the equation 
describing fibronectin concentration as follows: 
𝑓(𝑥, 𝑦, 0) = 𝑘𝑒
−
(1−𝑥)2
𝜀2 , (𝑥, 𝑦) ∈ [0, 1] × [0, 1] (4.23) 
Eq. (4.23) represents the fibronectin concentration distribution and the gradient of 
fibronectin concentration is in opposite direction to that described in Eq. (4.12). In Eq. 
(4.23) we take the magnitude of parameters 𝜀2 and 𝑘 as same as that in Eq. (4.12). 
The concentration of fibronectin in Eq. (4.23) is lowest at the side of 𝑥 = 0 which 
represents the side of the parent vessel. The highest concentration of fibronectin is at the 
side of x=1 which represents the tumour 
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Figure 4.2. Concentrations of the TAF and fibronectin from Eq. (4.19) and Eq. (4.23) 
proposed in the current study 
 
From Figure 4.2, we can observe that the gradient of TAF and the gradient of fibronectin 
are in the same direction.  
We set four clusters of ECs at the side of the parent vessel, which has four discrete peaks of 
form, as the initial ECs condition. We establish a function to describe the four clusters of 
ECs. The function can be represented as: 
𝑛(𝑥, 𝑦, 0) = 𝑒
−
𝑥2
𝜖3(1 − 𝑠𝑖𝑛2(10𝜋𝑦)) (4.24) 
where n represents the concentration of ECs, 𝜀3 is a positive parameter 𝜀3 =0.001 [8]. 
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Figure 4.3. The solution of Eq. (4.26) represents the initial concentration of the four 
clusters of ECs.   
 
From Figure 4.3, we can observe four clusters of ECs at the side of the parent vessel where 
the highest concentration of ECs n is equal to one after non-dimensionallisation. 
MDE is stimulated by ECs. The initial value of MDE is equal to zero. We describe the 
initial MDE field as: 
𝑚(𝑥, 𝑦, 0) = 0 (4.25) 
We assume ECM is a homogenous density field with an initially uniform concentration of 
ECM components. Daub et al. [176] proposes that ECM concentration is 0.9 after 
non-dimensionalisation. This was taken and, therefore, the initial ECM field is presented 
as:  
𝑀(𝑥, 𝑦, 0) = 0.9 (4.26) 
 
4.4 Simulation  
All of the numerical solutions of the models presented in section 4.4 were obtained with 
finite difference methods. We compared the simulation results between Anderson and 
Chaplain’s model (refer to Eqs. (4.7) - (4.12) and (4.24) [8, 152, 157] and the improved 
model in this study (refer to Eqs. (4.18) - (4.22)) and summarised the results as follows. 
The boundary conditions are described in section 4.3.3 and the initial conditions are as in 
Eqs. (4.23) - (4.26).  
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4.4.1 Comparison of the ECs migration between the two 
models without considering the effect of haptotaxis 
To separately test the effects of the chemotaxis and haptotaxis factors on the model, firstly 
we did not include the haptotaxis factor in the models. So the migration of the ECs was 
mainly influenced by chemotaxis. Both Anderson and Chaplain’s model and our improved 
model were simulated at the conditions of 𝜌 = 0 (means no haptotaxis factor), and the 
results were shown in Figure 4.4 and Figure 4.5 respectively. From Figure 4.4 and Figure 
4.5, we can observe that the ECs move towards the tumour line source with the same 
migration velocities for both two models. The moved distances covered by the ECs were 
the same at 𝑡 = 1𝜏 (1.6 days), 𝑡 = 2𝜏 (3.2 days) and 𝑡 = 3𝜏 (4.8 days) for the two 
models. The difference between Figure 4.4 and Figure 4.5 is shown in the ECs density. 
The ECs density is larger in Figure 4.5 than that in Figure 4.4 due to the term of 
proliferation in Eq. (4.18). 
 
 
 
(t=1)                     (t=2)                     (t=3)     
Figure 4.4. Spatiotemporal evolution of the ECs density in Anderson and Chaplain’s model 
The figure shows that the ECs migrate from the parent vessel (𝑥 = 0) towards the tumour 
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line source (𝑥 = 1) with the influence of chemotaxis factor and without the influence of 
haptotaxis factor(𝜌 = 0). 
 
 
(a) t=1                     (b) t=2                   (c) t=3 
 
(d) t=1                      (e) t=2                     (f) t=3 
Figure 4.5. Spatiotemporal evolution of the ECs density in the new improved model.  
(a), (b) and (c) show that the ECs migrate from the parent vessel (𝑥 = 0) towards the 
tumour line source (𝑥 = 1) with the influence of chemotaxis factor and without the 
influence of haptotaxis factor 𝜌 = 0. (d), (e) and (f) show that the ECM is hydrolysed by 
the proteolytic enzyme secreted by the ECs. The four clusters of ECs move forward to the 
line of the tumour and correspondingly leave four ditches behind them. 
 
The same EC velocities in the two models are due to the same chemotactic attraction. Here, 
chemotaxis determines the velocity of tip cell migration. We can observe that at 𝑡 = 2𝜏 
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(3.2 days) the ECs have passed more than halfway through the domain, and at 𝑡 = 3𝜏 (4.8 
days) they have migrated across almost 80% of the domain. No significant lateral 
migration of the ECs is observed. The four clusters of ECs retain the shape of the initial 
distribution, while the density decreases to a certain extent. This is because the migration is 
mainly controlled by chemotaxis, and at the same time diffuses outwards, leading to a 
small amount of lateral movement due to random motility. 
 
4.4.2 Comparison of the ECs migration between the two 
models with considering the effect of haptotaxis 
Then we simulated the ECs migration with the influence of both chemotaxis and haptotaxis 
factors. If the fibronectin gradient is opposite to the TAF shown in Figure 4.1, the 
haptotaxis offsets the chemotaxis, and the influence on ECs velocity is negative. 
 
(a) t=1                     (b) t=2                      (c) t=3    
Figure 4.6. Spatiotemporal evolution of the ECs density in Anderson and Chaplain’s model 
[8]  
The initial four clusters of ECs density are moving towards the line tumour. Eq. (4.18) 
including the influence of haptotaxis at ρ = 0.34 . The fibronectin concentration 
distribution is based on Eq. (4.12). 
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In Figure 4.6 under the negative influence of haptotaxis the ECs move toward the tumour 
much more slowly than those as shown in Figure 4.4. The ECs only covered one third of 
the domain at 𝑡 = 3𝜏 (4.8 days). Significant overlaps of ECs can be observed in Figure 4.6 
(c). 
Compared with the results shown in Figure 4.4, without the influence of haptotaxis, the 
ECs move faster and take three time scaling (t=3𝜏) to cover 80% domain. However, in 
Figure 6, with the negative influence of haptotaxis, the ECs move much more slowly and 
take three time scaling (t=3𝜏) to cover only 30% domain. This is because TAF and 
fibronectin are opposite in their gradient direction and counteract the movement of the ECs. 
Therefore, the negative influence of haptotaxis could slow down the velocity of the ECs. 
On the other hand, if the fibronectin gradient is in the same direction as the TAF shown in 
Figure 4.2, the influence of haptotaxis on velocity is enhanced.  
 
(a) t=0.5                   (b) t=1                    (c) t=1.5 
 
(d) t=0.5                   (e) t=1                     (f) t=1.5 
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Figure 4.7. Spatiotemporal evolution of the ECs density from the improved model 
(a), (b) and (c) show that the ECs migration is influenced by chemotaxis and positive 
haptotaxis. (d), (e) and (f) show that the ECM is hydrolysed by the proteolytic enzyme 
secreted by EC migration. The ECs move forward to the tumour and correspondingly leave 
four ditches behind them. 
 
The simulation of the model Eq. (4.18) is under the enhanced influence of haptotaxis. The 
ECs move towards the tumour line source, as shown in Figure 4.7. The four separate peaks 
of cells covered 80% domain at 𝑡 = 1.5𝜏 (2.4 days), as shown in Figure 4.7 (c). The 
velocity of the ECs is fastest because both the TAF and fibronectin gradients are in the 
same direction. The superposition of both TAF and fibronectin accelerates the EC 
migration, and the ECM changes correspondingly.  
Therefore, through simulation, we obtained the important points as follows: 
1. Without haptotaxis, the clusters of endothelial-cell density migrate directly across 
the domain to the tumour. 
2. With negative haptotaxis in which the fibronectin gradient is opposite to the TAF 
gradient, the clusters of endothelial-cell density migrate more slowly, with lateral 
movement.  
3. With positive haptotaxis in which the fibronectin gradient is in same direction as 
the TAF gradient, the clusters of endothelial-cell density migrate fastest. This 
means angiogenesis is promoted by the superposition of both haptotaxis and 
chemotaxis.  
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4.4.3 Effect of proliferation on ECs density 
The change of total and average ECs density during angiogenesis can be shown in the 
following curves:  
 
(a)                                   (b)  
Figure 4.8. Elucidation of EC density 
(a) The dash curve shows the total EC density in Eq. (4.7) without proliferation and the 
solid curve shows the total EC density in Eq. (4.18) with proliferation. (b) The dash curve 
is the average density of ECs in Eq. (4.7) and the solid curve is the average EC density in 
Eq. (4.18). 
 
Figure 4.8 shows the change in EC density with and without proliferation. In Figure 4.8 (a), 
without proliferation, its total EC density is conserved kept at conservation with 
proliferation, and its total EC density is increasing towards the tumour. In Figure 4.8 (b), 
without proliferation, the trend of its average density for each cluster is declining in Eq. 
(4.7). This is due to the term of random motility which makes it diffuse, and its density per 
unit area is declining. In Eq. (4.18) with proliferation, the trend of its average density for 
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each cluster remains higher than that in Eq. (4.7) and tries to retain this density. 
 
4.4.4 Results of ECM 
The simulation results of ECM without the influence of haptotaxis are shown in Figure 4.5 
(d), (e) and (f). The simulation results of ECM with the positive influence of haptotaxis are 
shown in Figure 4.7 (d), (e) and (f) respectively. The ECM is proteolyzed by MDE secreted 
by ECs and degraded simultaneously when the ECs clusters move forward, forming a 
“ditch” in the ECM. This indicates that the density of the ECM decreases because of 
degradation. The front of the “ditches” is at the same distance from the parent vessel as that 
of ECs, which reveals that ECM approaches the tumour correspondingly with the ECs. It 
can be clearly seen that when the four clusters of ECs migrate forward, its enzymes, such as 
MMPs, degrade the ECM and leave the “ditch” behind them. Thus, we assume that the 
degradation can take place only at the front, and the four clusters of ECs are extremely 
actively, leaving the “ditches” behind it. It can also be clearly observed that in Figure 4.5 
(d), (e) and (f) the “ditches” are deeper and wider than those in Figure 4.7 (d), (e) and (f). 
This indicates that the faster the ECs migrate, the shallower the “ditches” will be. The more 
slowly the ECs migrate, the deeper and wider are the “ditches”. 
 
4.4.5 Comparison of the evolution of capillary network 
between two models  
Agent-based modelling (ABM) is a computational modelling approach providing a 
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systematic view of the simulation of action and interaction among autonomous individual 
entities [142]. Here, we use ABM to discretize the mathematical model described above, 
so that we can obtain the feature of the capillary sprouts and individual behaviour. The 
discrete capillary sprouts are shown as follows: 
 
(a)                           (b)                        (c) 
 
    (d)                       (e)                          (f) 
Figure 4.9. Spatiotemporal evolution of capillary network with ABMs to discretise the 
continuum model where the ECM degradation is not involved  
Figure 4.10 shows the ECs at the capillary sprout tips migrating from the parent vessel 
(𝑥 = 0) towards a tumour (𝑥 = 1). 
 
In Figure 4.9, we can observe that the four clusters of vessels develop from the parent 
vessel across the domain and finally reach the tumour. In front of the vessels are the 
sprout heads by the endothelial tip cells. In the simulation the ECM degradation is not 
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involved into the continuous model, so no background of degraded ECM can be observed 
and it seems that the capillary network formed mechanically. 
 
    (a)                    (b)                    (c) 
 
       (d)                     (e)                    (f) 
Figure 4.10. Spatiotemporal evolution of capillary network with ABM to discretize the 
continuum model.  
Figure 4.10  shows the ECs at the capillary sprout tips migrating from the parent vessel 
(x = 0) towards a tumour (x = 1). The background formed with contour lines and colours 
shows the ECM density degraded by the MDE secreted from ECs. 
 
In Figure 4.10, we can observe that the four clusters of vessels develop from the parent 
vessel across the domain and finally reach the tumour. In front of the vessels are the 
sprouts headed by endothelial tip cells. When the ECs approach, they secrete MDE and 
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proteolyse the ECM, making the density of ECM decline along in the way the ECs passed. 
In this way, the endothelial tip cells remove barriers and make their way for the vessels to 
develop. This can be observed from the background with different colours and contour 
lines. On the background the local density of the ECM adjacent to the vessels appears to 
change gradually from blue, green, yellow to red toward outside, which means the ECM 
density is the lowest at the vessels due to being proteolysed. At the same time, the 
directions of the nascent sprouts are mainly guided by the TAF gradient and also 
influenced by the density of local ECM, making the morphology of the vessels look 
tortuous. We can also observe that the density of vessels is increasing, forming a “brush 
border” approaching the tumour. This demonstrates the density of endothelial tip cells 
increasing due to the ECs proliferation.  
 
4.5 Discussion 
The simulation results show an accelerated endothelial tip cell migration towards the 
tumour when TAF and fibronectin concentration gradient are in the same direction, where 
the invasive tumours secrete TAF and generate fibronectin. The accelerated endothelial tip 
cell migration implies a possible mechanism that promotes angiogenesis in some 
subgroups of invasive tumours. 
 
4.5.1 ECM degradation 
The ECM is a major component of the microenvironment of cells. It takes part in most 
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basic cell behaviours, from cell proliferation, adhesion and migration, to cell 
differentiation [183]. The ECM is composed of a large collection of biochemically and 
structurally diverse components. These components include proteins, proteoglycans, and 
glycoproteins, such as collagen and fibronectin. They have various physical and 
biochemical properties. A large amount of evidence has demonstrated that ECM 
components greatly influence cell behaviour, such as regulating cell migration [183, 184]. 
The physical properties of the ECM are essential for its scaffolding role in supporting 
tissue structure and integrity, and for its role in migration and anchorage of the cell. In 
addition, ECM provides a critical framework for angiogenesis. During angiogenesis, the 
ECM forms the migration paths, and this releases force from the collagen assembly or 
cell-ECM interactions propelling cell movement [176].  
During tumour-induced angiogenesis, the ECM associated with angiogenesis is 
continuously remodelled to create a suitable microenvironment for the survival, adhesion 
and migration of the vascular progress of ECs [185]. The remodelling of ECM process 
includes the degradation of pre-existing ECM molecules by proteolytic enzymes, such as 
MMP and the neosynthesis of ECM secreted by tumour cells and/or stromal cells [132].  
Metalloproteinases, such as MMP families, are the most significant enzymes in ECM 
remodelling and they participate in cell migration [183]. EC migration depends on the 
expression of MMPs, which degrade the local ECM and generate a cell migration path, at 
the leading edge [183]. 
The ECs in front of the capillary network or at the top of the sprout are of the tip cell 
phenotype; the other ECs behind the tip cell are of the stalk cell phenotype when the 
angiogenesis occurs. We assume the ECs secrete the same amount of enzymes to 
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proteolyse the ECM, but the ECs as tip cells and as stalk cells generate different amounts of 
their innate inhibitor (which all proteases have to control their activity) so that the ECs in 
the stalk lack MDE activities to proteolyse the ECM. It is the tip cells which have 
characteristically high activity; the cells in the capillary vessels behind the tip cells, or in 
other words behind the four clusters of ECs, are stalk cells which lack activity. The 
secretion of enzyme proteolysis of ECM is based on the model described in Eq. (4.21) and 
Eq. (4.22).  
According to the analysis discussed above, we assume that the activity of the MDE is 
central to the ECs density. The degradation rate of ECM depends on ECM, the substrate of 
the enzyme, and the activity of the MDE. The model also expresses that the amount of 
ECM degraded depends on the duration of proteolysis, which means that the longer the 
time lasts, the more the ECM is degraded.  
Because the complexity of the constitution of the ECM, we could simply describe that the 
ECM is composed of components, some of which are easy to degrade, such as plasma 
proteins which are similar to meat, and some of which are not easy to degrade, such as 
collagen fibres which are similar to bone. The different ECM components may be subject 
to proteolysis by the different proteases secreted by the ECs during their migration. On the 
one hand, when the ECs in the tip cell phenotype move fast, they stay at the location for a 
brief time, and of course proteolysis takes place but only degrades the meat. However, 
when the ECs in the tip cell phenotype move slowly, they stay longer, and so there is 
enough time for the proteolysis to degrade both meat and bone. 
Degraded at different degrees, the compositions at the adjacent microenvironment are 
subtly different. This makes the ECM cleave and remodel, forming migration paths. The 
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ECM may also provide force released from collagen assembly or cell-ECM interactions, 
and this propels cell movement and facilitates angiogenesis in different ways.  
During the tumour invasion and induction of angiogenesis, the ECM is proteolysed and 
degraded. Abnormal changes in the amount and composition of the ECM can significantly 
affect ECM biochemical properties, enhance the tumourigenic effects, and deregulate cell 
functions during malignant transformation [186]. ECM also indirectly affects cancer cells 
by influencing the behaviour of stromal cells, including ECs and fibroblasts, which are the 
main initial factors triggering abnormal ECM production [186]. As a result, abnormal 
ECM further promotes the formation of a tumourigenic microenvironment and subsequent 
tumour metastasis [186]. 
 
4.5.2 Haptotaxis influence 
According to Shekhar, Pauley and Heppner, ‘the invasive carcinoma is often associated 
with expansion of the tumour stroma and increased deposition of ECM’ [163]. Such an 
increased deposition of ECM in tumours is known as desmoplasia and is similar to changes 
that are observed during organ fibrosis. According to Folkman, solid tumours vascularize 
more actively than the normal tissue [163]. The fibroblast is an important stromal cell type 
in cancer progression [133].  
Tumour can be initiated and developed by the interactions between malignant cells and 
cancer-associated fibroblasts (CAFs) [134, 135]. Through modulating stromal ECM, CAFs 
produce directional paths of fibronectin in order for tumour invasion [136]. Fibronectin is 
critical in many cell processes, such as cell adhesion, migration, growth and differentiation 
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[187]. Fibronectin is expressed in many different cell types and its expression is activated 
during epithelial-mesechymal transition (EMT) [137]. This is a process to facilitate cell 
motility and invasion [138-140]. 
The increased expression of fibronectin has been observed by Lundberg [130] in a 
subgroup of colorectal cancer (CRC) classified as CIMP-negative tumours. They point out 
that fibroblasts induce CIMP-negative tumour cells to produce more fibronectin. They 
indicate that the density of fibroblasts is higher at the front of the tumour than the normal 
tissue. Similar results have been reported by Derya, Yilmaz and Aytekin in Small Cell 
Lung Cancer (SCLC), an aggressive form of lung cancer. The ECM surrounding SCLC 
cells contains a great amount of fibronectin [141], and a density gradient of the fibronectin 
may exist so we express it as Eq. (4.23). 
From Figure 4.1, we can observe the gradient of TAF and the gradient of fibronectin in an 
opposite direction, which means that when chemotaxis and hapotaxis take effect 
simultaneously, the velocity of ECs offset by both chemotaxis and haptotaxis is decelerated. 
This result indicates that the ECs could not reach the tumour side, as shown in Figure 4.6. 
From Figure 4.2, we can observe that the gradient of TAF and the gradient of fibronectin 
are in the same direction, which means that when chemotaxis and hapotaxis take effect 
simultaneously, the velocity of ECs increased by both chemotaxis and haptotaxis is 
accelerated. This result indicates that the ECs reach the tumour side very fast and pass the 
domain, as presented in Figure 4.7. Here, the quick migration of ECs approaching the 
tumour means that angiogenesis occurs quickly when the invasive tumour produces high 
concentration of fibronectin in the stroma and its adjacent microenvironment. Thus, it is 
possible that the fibronectin promotes the haptotaxis and facilitates the chemotaxis to 
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accelerate the angiogenesis.  
Previous studies have suggested that fibronectin can be generated by various types of cells, 
including tumour cells [188]. Fibronectin enhances the secretion of MMPs and promotes 
the invasive migration of gallbladder cancer (GBC) cells. Stromal fibronectin is produced 
by tumour cells. Recent studies in human melanoma and ovarian cancer have revealed that 
MMPs could cleave fibronectin into shorter fragments, and facilitate fibronectin 
integrating  adhesive interactions. This process in turn reinforces the generation of MMPs, 
forming a positive feedback loop for the invasive migration of GBC cells [132]. 
Angiogenesis plays a major role in solid tumour growth, because it links the harmless 
avascular growth phase and the fatal vascular growth phase [7]. Angiogenesis supplies 
oxygen and conveys the cancer cell. In our model, we assume that fibronectin is high at the 
side of the tumour line source at the malignant phase. Our hypothesis is that during the 
tumour malignant phase, the CAFs in some kind of caner such as GBCs create higher 
fibronectin concentration for the cancer cell migration, which results in an acceleration of 
angiogenesis. Finally, the rapid growth of the vascular tumour contributes to cancer cell 
progression, known as metastasis, and the establishment of a new colony in distant organs 
[189]. We think that there may be a density gradient of fibronectin, which is expressed as 
Eq. (4.23). This generates a positive haptotatic effect and augments the velocity of ECs, as 
shown in Figure 4.7. The quick migration of ECs approaching to tumour means that 
angiogenesis occurs quickly when the invasive tumour produces a high concentration of 
fibronectin in the stroma and its adjacent microenvironment. 
According to Cao et al. [132], the overexpression of fibronectin will promote cancer 
progression. Their experimental results indicate that exogenous fibronectin significantly 
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enhances and promotes proliferation and metastasis. We think that an invasive tumour can 
generate fibronectin, and the fibronectin forms a gradient and enhances the haptotactic 
effect. The enhanced haptotaxis can cooperate with chemotaxis to accelerate angiogenesis. 
The formed vessels supply oxygen and nutrients which may boost the development of the 
tumour. Therefore, we propose a potential mechanism whereby both tumour-invasion and 
tumour-induced angiogenesis promote each other; this remains, as yet, unnoticed in cancer 
research. 
 
4.6 Summary  
In section 4.2, we first extended Anderson and Chaplain’s work on tumour-induced 
angiogenesis by creating a proliferation term and combining it into Eq. (4.3). Their 
continuous model was developed to meet the demands of making quantitative predictions 
about the dynamics in the complex process of angiogenesis. Mantzaris, Webb and Othmer 
[125] point out that the density of the capillary network increases when it approaches the 
tumour during angiogenesis, so the density of the ECs should increase first. Proliferation is 
essential for the formation of the capillary network so that the capillary network can be 
formed with a sufficient population of cells. To introduce a proliferation term of ECs is a 
reasonable way to improve the mathematical model. We improved it in this way, and our 
simulation results show that EC density increases during the angiogenesis. 
Secondly, we extended Anderson and Chaplain’s work on tumour-induced angiogenesis in 
the aspect of the degradation of ECM, because the ECM should be degraded for the 
development of the capillary network to occur when the migration and proliferation of ECs 
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approach the tumour. Our simulation results clearly show that the ECM is degraded during 
the angiogenesis. As a result, the degradation dynamics of the ECM is catalysed by the 
protease enzyme [125].  
Thirdly, we extended Anderson and Chaplain’s work on tumour-induced angiogenesis in 
the aspect of fibronectin gradient direction. They assume the highest concentration of 
fibronectin is at the side of parent vessel and the lowest concentration is at the side of the 
tumour line source, with the movement rate of the ECs slowing down under the influence 
of Eq. (4.12). We think that there is another possibility in that the invasive tumour 
generates fibronectin, which enhances haptotaxis; thus, we set Eq. (4.23). Our simulation 
results show that during angiogenesis under the influence of enhanced haptotaxis, the ECs 
move much faster than that in Anderson and Chaplain’s model due to the TAF and 
fibronectin gradient being in the same direction. The synthetic effect of both chemotaxis 
and haptotaxis accelerates the movement of the ECs. On this basis, we deduce that the 
possible mechanism of tumour-invasion and tumour-induced angiogenesis is that they 
promote each other to facilitate faster or malignant tumour development. 
Our model improves Anderson and Chaplain’s work in the continuous model in 
introducing the terms of proliferation, ECM degradation, and the concept of enhanced 
haptotaxis. Our simulation results clearly demonstrate these improvements and indicate 
that there is a possible mechanism. It is clear that the model successfully describes the 
migration of ECs guided by chemotaxis and hoptotaxis from parent vessel to the tumour; it 
suggests that angiogenesis promotes a malignant mechanism for some subgroups of 
tumour. However, there are some limitations of the mathematical model, in that the 
enzymes are simplified as the variable m. In fact, the enzymes are a large family consisting 
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of a huge number of different enzymes, such as MMPs, ADAMTS and so on. Their 
specificity is different, for example, different enzymes have their special target substrate. 
In the model, the ECM is simplified as a homogenous substrate, but in fact the ECM is a 
very complex tissue consisting of many different components, such as proteins, 
proteoglycans, and glycoproteins.     
 
4.7 Conclusion 
Endothelial cell (EC) migration is the crucial step in tumour-induced angiogenesis. EC 
migration is influenced by both chemotaxis and haptotaxis. According to recent bio-clues, 
tumour progression promotes overexpression of fibronectin. The overexpression of 
fibronectin generates a fibronectin concentration gradient which is in the same direction 
of TAF concentration gradient. We assume that some subgroups of invasive tumours 
generate fibronectin, leading to enhanced haptotaxis. Hence, we developed a mathematical 
model simulating the influence of haptotaxis. Our simulation results show that 
angiogenesis can be accelerated when the fibronectin gradient generates the positive 
haptotaxis which increases the velocity of ECs toward the invasive tumour. The invasive 
tumour enhances haptotaxis, which means angiogenesis can be synthetically and 
simultaneously promoted by both chemotaxis and heptotaxis. According to the consensus 
theory that angiogenesis supplies oxygen and nutrients to promote tumour development, by 
linking the relationship of tumour invasion and angiogenesis we propose that there is a 
possible mechanism for the cross promotion between tumour-invasion and 
tumour-induced angiogenesis, which would make the tumour develop faster, and thus 
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become more harmful for some subgroups of tumours. 
 
Although the mathematical model could not cover all complexities of angiogenesis, it can 
simulate the microenvironment where many of biological phenomena are continuous. By 
developing the PDEs model, we can simulate the parameters which change in position and 
time. These parameters will be used in the establishment of a regulatory model based on a 
VEGF and Notch signalling pathway. The regulatory model will be discussed in detail in 
Chapter Six. 
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Chapter 5. Modelling of Tumour-Induced 
Angiogenesis with Regression by Cell 
Cytotoxic Factor 
A phenomenon observed by Folkman [39, 190] is that tumour regresses when blood 
vessels approach. This is the response of immune system to the tumour cells. 
Tumour-induced angiogenesis promotes growth of blood vessels through which host 
immune factors are delivered to the tumour and kill tumour cells, making tumour regress. 
This interaction is very complex. It is important to model them mathematically. 
Mathematical models can help us to better understand these procedures. Computational 
models can help and enhance our understanding of the immune system-tumour interactions 
by allowing us to simulate complex systems and behaviours that cannot be observed 
directly. The immune system includes the innate immune system which is quickly 
mobilised and triggered when recognises tumour cells. These procedures occur spatially 
and temporally. Therefore, we develop the mathematical models in PDE to simulate the 
impact of innate immune system on tumour during tumour-induced angiogenesis. In this 
chapter, we model and simulate large tumour load in which tumour regress and recurrence. 
We also simulate small tumour load in which tumour can be eliminated by immune system, 
and simulate the syntheses effect of immune system and drugs on large tumour.   
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5.1 Introduction  
Tumour immunotherapy is a promising anticancer approach in which the patient’s immune 
system is either stimulated or mobilied to fight tumours. Recently, the understanding of the 
immune system and tumour immunology has increased. This has enabled scientists to 
develop specific immunotherapies designed to enhance the immune response of a 
particular patient against a unique tumour [191]. However, because it is complicated, the 
exact mechanism of tumour immunity still remains unclear. Tumour immunoediting is the 
process whereby immune cells protect against tumour formation by sculpting the 
immunogenicity of developing tumours. The process is hypothesized as three phases: 
elimination, equilibrium, and escape called the three Es of tumour immunoediting [192, 
193]. In the elimination phase, the tumour cells are successfully recognized and eliminated 
by the immune system, thus returning the tissues to their normal function [194]. However, 
the immune rejection of cancer is not clear and there is still much to be learned about the 
specifics of immune tumour elimination. Tumour cells that are not completely eliminated 
by the immune system are predicted to proceed into a phase of equilibrium, in which the 
immune system is hypothesized to control tumour development but not completely 
eliminate the transformed tumour cells. It was hypothesized that in the equilibrium phase, 
the constant interaction of the immune system with tumours may sculpt or edit the 
phenotype of developing tumours, resulting in tumours no longer being susceptible to 
immune attack and thus able to progress into the third phase of the immunoediting process, 
termed as escape. Numerous experimental data have shown that tumours in the escape 
phase destroy the immune system to aid growth and recurence [195]. 
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The immune system has an innate and adaptive immunity, the former responding fast and 
the latter taking time to respond. Innate immunity can manifest tumour immunoediting 
activity in the absence of adaptive immunity. This activity requires natural killer (NK) cells 
and interferon γ (IFN-γ), which mediate the induction of M1 macrophages to cancer 
immunoediting [196]. P101, p102,  
Mathematical modelling and simulation of the tumour cytotoxic influence can promote the 
development of an immunotherapy strategy. Based on the mathematical model established 
in Chapter 4, we have developed another mathematical model further by incorporating 
the formation of vessels, tumour loads, immune tumour cytotoxic factor, and a tumour 
cytotoxic drug. In this chapter, we present our mathematical models of tumour-induced 
angiogenesis with tumour regression by immune tumour cytotoxic factor, and simulate 
the influence of immune tumour cytotoxic factor on different tumour loads. Although the 
tumour cytotoxic immune factor can be delivered to the tumour by either blood vessel 
tips or by vessels, the immune factor identified by Folkman et al. (1975) is described as 
being delivered by the blood vessel tips and only to the areas within about 0.5 mm of the 
tips [37]. In our model, we assume the immune tumour cytotoxic factor is the innate 
immunity which responds immediately to the tumour cells, and the innate immune cells 
are delivered to the tumour by the blood vessel tips during tumour-induced angiogenesis. 
Hence, our model describes the delivery of tumour cytotoxic immune factor as being 
limited to the tips. The simulation results provide a possible form of tumour therapy by 
improving and enhancing the patients’ immune system. 
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5.2 Modelling of tumour-induced angiogenesis with 
regression by cell cytotoxic factor 
The immune system is a collection of cells and molecules that can respond and generate 
resistance to disease, especially infectious disease. There are many indications that 
tumours can be influenced by the immune system. Enhancing a patient’s immune system to 
augment conventional therapies has been a clinical practice for a long time. In this chapter, 
we establish a mathematical model involving the immune system and its effect on tumours. 
We consider that the immune factor generated in the host is delivered from the limbus to 
the tip position. Further, we believe the modelling of tumour-induced angiogenesis with 
regression by tumour cytotoxic immune factor delivered through formed vessel tips will 
facilitate a better understanding of tumour-induced angiogenesis. Hence, in this section, we 
develop the mathematical model established in section 4.2 with another three PDEs 
describing tumour, vessel, and cytotoxic factor, to simulate the regression, recurrence, or 
clearance of the tumour by involving tumour cytotoxic factor, including the immune 
system and drugs delivered through the vessels formed during angiogenesis. 
It should be acknowledged that tumours interacting with immune system are very complex 
and that the mathematical model established in this chapter is simplified. This 
simplification is to make it more easily and clearly to illustrate the influence of 
tumour-induced angiogenesis on tumour load. Even though there are few biological 
evidences to support the assumption,we assume that: 1) the immune factor is a kind of 
innate cells and is tumour cytotoxic factor which can recognize and interact with tumour 
cells immediately then kill the tumour cells once they meet together; 2) only the tip cells 
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can recruit the tumour cytotoxic factor and the only one immune factor is involved as the 
tumour cytotoxic factor in our model; 3) the immune factor level declines during the 
simulation.   
The interactions of tumours with the host immune system are very complex and very 
difficult to be mathematically described in detail. Hence, simplification is necessary for 
mathematical modelling. Although simplifying a model would make it not absolutely 
suitable to reflect the whole reality in vivo, mathematical models can generate visual output 
and help us to better understand the interactions, and the simulation results of the model 
could be qualified to a certain extent. 
5.2.1 Establishing the mathematical model 
Back to 1974, the tumour immune phenomenon was firstly observed by Folkman et al. 
They observed that angiogenesis commenced when the tumour was in the range of 2 mm, 
and the tumour began to regress when the front edge of the vessel was 0.5 mm from the 
tumour[190]. This implies that there is a kind of cytotoxic factor which can kill the tumour 
cells. The tumour cytotoxic factor could be delivered to the front edge of the vessel where 
the tip cells are and diffuse towards the tumour cells. When both meet together, the tumour 
cells may be killed and the tumour regresses. Once the tumour regresses, the vessel front 
regress and then tumour develops again to maintain equilibrium. This tumour cytotoxic 
factor could be part of the immune system, leading to the supposition that some tumour 
cytotoxic drugs could be delivered by the formed vessels, and that this may be a helpful 
method to assist the body as it tries to fight tumours. The kinetics of tumour cytotoxic 
factor should be investigated, and therefore simulating this kinetics is valuable. Folkman et 
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al. [37, 192], observed that after the tumour regressed, the vessel also decayed. This means 
that there is a mechanism by which these influence each other. In the aspect of tumour 
cytotoxic immune simulation, it should be mentioned that in 2010 Addison-Smith 
developed and proposed a mathematical model in a one dimensional domain, considering 
factors such as the immune system’s influence on the development of vessels and tumour 
cells [117]. Some of the parameters we have used come from her thesis. 
We take the model established in section 4.2.1.1. Eq. (4.18) as the basis of the model. For 
simplicity, in section 5.1, we ignore the influence by haptotaxis, so the term haptotaxis in 
Eq. (4.18) is excluded and the relative equation Eq. (4.20) is eliminated. The ECs described 
in Eq. (4.18) are also assumed to undergo a random motility, chemotaxis, and proliferation. 
The change rate of endothelial tip cells is described in Eq. (5.1). 
𝜕𝑛
𝜕𝑡
   =  𝐷𝛻2𝑛 − 𝛻 · (𝜒(𝑐)𝑛𝛻𝑐) + 𝜇𝑀𝑛 (1 −
𝑛
𝑛0
) (5.1) 
where n represents the concentration of ECs, 𝑛0 represents the initial concentration of ECs, 
c represents TAF concentration, M indicates ECM density. On the right of the Eq. (5.1), the 
first term represents the EC diffusive flux with the diffusion coefficient D, the second set of 
terms represent the EC flux by chemotaxis, and the third set of terms represent the 
proliferation with the proliferation coefficient 𝜇. All the meanings of the variables and 
coefficients are the same as those described in section 4.3.  
For modelling the tumour, it is assumed to develop as the tumour cells increase. The 
increasing rate of tumour 
𝜕𝑇
𝜕𝑡
 is proportional to the load of total tumour cells T. This is to 
describe its development as a simple exponential growth. The tumour cells are also subject 
to physical spread in two dimensions based on Fick’s diffusion law, called random motility. 
In addition, we assume that the formed vessel can deliver nutrients to supply the 
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development of the tumour, so the tumour growth rate is promoted by interactions with the 
blood vessels. In the model, the tumour cells are assumed to die on interaction with the 
tumour cytotoxic cells described as tumour cytotoxic factors  in modelling. Tumour 
cytotoxic factors have been found in the human immune system, such as natural killer (NK) 
and CD8+ T cells, both of which can kill tumour cells. These would eventually be able to 
defeat the tumour. Based on this assumption, once the host’s immune system responds and 
develops effectively, and the tumour is defeated or regresses to an extent, further 
tumour-induced angiogenesis will regress and no further vascularization will occur. 
According to the behaviour of the tumour and immune system, in the two dimensional 
domain, the equation of a tumour influenced by a generalized tumour cytotoxic factor 𝐼, 
delivered through the formed blood vessels b, can be described in Eq. (5.2) as follows. 
𝜕𝑇
𝜕𝑡
= 𝐷𝑇(
𝜕2𝑇
𝜕𝑥2
+
𝜕2𝑇
𝜕𝑦2
) + 𝑘1𝑇𝑏 − 𝑘2𝑇𝐼 + 𝑘3𝑇 (5.2) 
Where T represents tumour cells, I represents immune cytotoxic factor, and b is the formed 
blood vessels respectively. On the right of Eq. (5.2), the first term represents the random 
motility of tumour cells with diffusion coefficient 𝐷𝑇, the second term represents tumour 
development rate enhanced by blood vessel density b and the density of tumour cells with 
the rate constant 𝑘1, the third term indicates the killing rate of tumour cells by immune 
cytotoxic factor with the rate constant 𝑘2, the fourth term refers to the natural tumour 
growth rate with the rate constant 𝑘3. 
The capillary vessels, b, are laid down by migration of the tips. The length of capillary 
vessels is the trail of tip cell migration, so the rate of generating new vessels by tips is 
assumed to be proportional to the total tip flux at rate of 𝑘4. The term  𝑛 (
𝜕𝑐
𝜕𝑥
+
𝜕𝑐
𝜕𝑦
) means 
the total tip flux. If no new tips are produced, the capillary vessels will undergo a natural 
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decay. The decay rate is 𝑘5 and the natural decay is proportional to the length of vessels, b. 
It is described in Eq. (5.3). 
𝜕𝑏
𝜕𝑡
= 𝐷𝑏 (
𝜕𝑏
𝜕𝑥
+
𝜕𝑏
𝜕𝑦
) + 𝑘4𝑛 (
𝜕𝑐
𝜕𝑥
+
𝜕𝑐
𝜕𝑦
) − 𝑘5𝑏 (5.3) 
where b represents blood vessel density, c represents TAF respectively. On the right of Eq. 
(5.3), the first term represents the random motility of blood vessels with diffusion 
coefficient 𝐷𝑏, the second term represents blood vessels development rate enhanced by 
ECs with the rate constant 𝑘4, the third term indicates the decay rate of blood vessels with 
the rate constant 𝑘5.  
To model the tumour immune factor, we denote the immune factor as I and assume that the 
immune factor is recruited by the tip cells and delivered through the vessels formed, so the 
increasing rate 
𝜕𝐼
 𝜕𝑡
 is proportional to the density of the endothelial tip cells n at the rate of 
𝑘6. The immune factor is diffused into the two dimensional domain based on Fick’s law. 
The diffusion coefficient is 𝐷𝐼. The immune factor also decays at an exponential rate with 
the coefficient of 𝑘7. Hence, it is described in Eq. (5.4). 
𝜕𝐼
 𝜕𝑡
= 𝐷𝐼(
𝜕2𝐼
𝜕𝑥2
+
𝜕2𝐼
𝜕𝑦2
) + 𝑘6𝑛 − 𝑘7𝐼 (5.4) 
where I represents immune cytotoxic factor, and n represents ECs respectively. On the right 
of Eq. (5.4), the first term represents the random motility of immune cytotoxic factor with 
diffusion coefficient 𝐷𝐼, the second term represents immune cytotoxic factor recruited by 
tip ECs with the rate constant 𝑘6, the third term indicates the decay rate of immune 
cytotoxic factor with the rate constant 𝑘7. 
The governing equations for tip cell density is denoted as n, tumour cells load as T, immune 
factor density as I, tumour angiogenic factor TAF concentration as c, and the formed vessel 
density as b. These have been described above by the set of PDEs which are Eq. (5.1), Eq. 
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(5.2), Eq. (5.3), and Eq. (5.4), respectively. Other equation in the model is taken directly 
from Eq. (4.19). We use the solution result of Eq. (4.19) to generate a steady state 
concentration gradient profile of TAF, and use it as the initial condition of TAF 
concentration to simulate the main model.  
 
5.2.1.1 Parameters and non-dimensionalisation  
For the non-dimensionalisation of Eq. (5.1), Eq. (5.2), Eq. (5.3), and Eq. (5.4), we set a 
square domain for the model in the range of 22  𝑚𝑚2, and the tumour is at one edge 
opposite to the pre-existing limbus vessel. The distance L from the tumour to the vessel at 
the onset of angiogenesis is 2mm. The timescale is 𝜏 =
𝐿2
𝐷𝑐
, the parameters including the 
diffusion coefficient of endothelial tip cells is   𝐷𝑛 , and the chemotactic function of 
coefficient 𝜒 have been non-dimensionalised in the same way as in section 4.3.  
Scaling values for concentration of these parameters and variables of the model are 
indicated with star notation. That is ?̃? =
𝑇
𝑇∗
, 𝐼 =
𝐼
𝐼∗
, ?̃? =
𝑛
𝑛∗
, ?̃? =
𝑐
𝑐∗
 and ?̃? =
𝑏
𝑏∗
 respectively. 
We take the diffusion coefficient of TAF as the standard coefficient. The other diffusion 
coefficients are non-dimensionalised by division of TAF coefficient 𝐷𝑐
∗. Tilde notation is 
used for the non-dimensionalised variables. The definitions of the parameters in Eq. (5.5), 
Eq. (5.6), Eq. (5.7), and Eq. (5.8) for non-dimensionalisation is described as follows: 
𝜏 =
𝐿2
𝐷𝑐
∗, ?̃? =
𝑡
𝜏 
,  ?̃? =
𝑥
𝐿
, ?̃? =
𝑦
𝐿
, ?̃? =
𝑇
𝑇∗
, 𝐼 =
𝐼
𝐼∗
, ?̃? =
𝑛
𝑛∗
, ?̃? =
𝑐
𝑐∗
, ?̃? =
𝑏
𝑏∗
,  𝐷?̃? =
𝐷𝑛
𝐷𝑐
∗,   ?̃? =
𝜒∗𝑐∗
𝐷𝑐
∗ , 
𝐷𝑇 
̃ =
𝐷 𝑇
𝐷𝑐
∗ ,  𝐷𝑏  
̃ =
𝐷 𝑛𝐿
2𝑛
𝐷𝑐
∗𝑏
, 𝐷?̃? =
𝐷𝐼
𝐷𝑐
∗, ?̃?1 = 𝑘1𝜏𝑏
∗， ?̃?2 = 𝑘2𝜏𝐼
∗，?̃?3 = 𝑘3𝜏，?̃?8 =
𝑘6𝜏𝑛
∗
𝐼∗
， 
?̃?9 =
𝜒∗𝑐∗𝐿2𝑛∗
𝐷𝑐
∗𝑏∗
， ?̃?10 = 𝑘5𝜏，?̃?14 = 𝑘7𝜏 [117]. 
Where 𝜏 is the timescale and the definition of timescale is 
𝐿2
𝐷𝑐
∗. 𝐷𝑐
∗ is the diffusion 
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coefficient of TAF. 𝜒∗ is the chemotactic coefficient. L is the length of domain.      
The values of parameters for Eq. (5.6), Eq. (5.7), and Eq. (5.8) after 
non-dimensionalisation are described as follows: 
 𝐷𝑇 
̃ = 0.0005, 𝐷𝑏  
̃ = 20𝐷𝑛 , 𝐷?̃? = 0.05, ?̃?1 = 2.0, ?̃?2 = 1.0, ?̃?3 = 0.055, ?̃?8 = 40 , 
?̃?9 = 2.5, ?̃?10 = 1.0, ?̃?14 = 1.0 [117]. 
The definitions and values of parameters for Eq. (5.5), and Eq. (4.19) after 
non-dimensionalisation are described in detail in section 4.3. 
The model with five PDEs described below is in a two-dimensional domain. In the five 
equations, the Eq. (4.19) comes from the model established in section 4.3, and the other 
four equations, Eqs. (5.5)-(5.8), are developed by introducing the concept of tumour 
cytotoxic factor. After non-dimensionlisation, the set of equations can be given as follows:  
where Eq. (5.5) governs the tip cell density n, Eq. (5.6) governs the tumour cell density T, 
Eq. (5.7) governs the tumour cytotoxic immune cell density I and Eq. (5.8) governs the 
blood vessel density b respectively. 
 
 
𝜕𝑛
𝜕𝑡
   =  𝐷𝛻2𝑛 − 𝛻 · (𝜒(𝑐)𝑛𝛻𝑐) + 𝜇𝑀𝑛 (1 −
𝑛
𝑛0
) (5.5) 
 
𝜕𝑇
𝜕𝑡
= 𝐷𝑇(
𝜕2𝑇
𝜕𝑥2
+
𝜕2𝑇
𝜕𝑦2
) + 𝑘1𝑇𝑏 − 𝑘2𝑇𝐼 + 𝑘3𝑇 
(5.6) 
 
𝜕𝐼
 𝜕𝑡
= 𝐷𝐼(
𝜕2𝐼
𝜕𝑥2
+
𝜕2𝐼
𝜕𝑦2
) + 𝑘8𝑛 − 𝑘14𝐼 
(5.7) 
 
𝜕𝑏
𝜕𝑡
= 𝐷𝑏 (
𝜕𝑏
𝜕𝑥
+
𝜕𝑏
𝜕𝑦
) + 𝑘9𝑛 (
𝜕𝑐
𝜕𝑥
+
𝜕𝑐
𝜕𝑦
) − 𝑘10𝑏 
(5.8) 
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5.2.1.2 Boundary condition 
To simulate the model, we should set appropriate initial and boundary conditions for 
equations respectively. The boundary conditions at the vessel and tumour side satisfy the 
Dirichlet condition 𝑐(0, 𝑦 , 𝑡) = 0, 𝑐(1, 𝑦, 𝑡) = 1 and at the left and right side satisfy the 
Neumann condition 
∂c
∂y
= 0 for Eq. (4.19). For Eq. (5.5), Eq. (5.6), Eq. (5.7), and Eq. (5.8), 
the boundary conditions should convey the idea that the ECs are issued at 𝑥 = 0, moving 
from 𝑥 = 0 to 𝑥 = 1. The boundary conditions of the domain subject to the non-flux 
conditions satisfy the Neumann condition and can be presented as follows:  
Eq. (5.5), Eq. (5.6), Eq. (5.7), and Eq. (5.8),   
𝜕𝑐
𝜕𝑥
= 0, 
𝜕𝑐
𝜕𝑦
= 0, 
𝜕𝑛
𝜕𝑥
= 0, 
𝜕𝑛
𝜕𝑦
= 0, 
𝜕𝑏
𝜕𝑥
= 0, 
𝜕𝑐
𝜕𝑦
  
𝜕𝐼
𝜕𝑥
= 0,
𝜕𝐼
𝜕𝑦
= 0 and  
𝜕𝑇
𝜕𝑦
= 0 , 
𝜕𝑇
𝜕𝑥
= 0.  
 
5.2.1.3 Initial condition 
For the ECs, we are going to set three clusters of cells at the parent vessel by setting Eq. 
(5.9), and take three clusters of EC concentration as the initial condition for the simulation 
of the model.   
 𝑛(𝑥, 𝑦, 0) = 𝑒
−
𝑥2
𝜖3 𝑠𝑖𝑛2(10𝜋𝑦)  (5.9) 
The initial conditions for other variables are:  
 𝐼(𝑥, 𝑦, 0) = 0 (5.10) 
 𝑏(𝑥, 𝑦, 0) = 0 (5.11) 
   
Simulation and discussion 
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Before simulation, we set the tumour load adjacent to the border of the domain. The 
domain is divided into a 100×100 grid with 101 × 101 net nodes. From x=0.97 to x=1, 
y=0~1, t=0, the tumour density is set at each node as 1. We designed two tumour load 
situations. One is a relatively large tumour load which can be described as T (0.97~1, 0~1, 
0)=1, so the total large tumour load is 4 × 101 × 1 = 404. The other is a relatively small 
tumour load which can be described as T (0.97~1, 48~52, 0)=1, so the total small tumour 
load is 4 × 5 × 1 = 20. 
For the big tumour load, we assume that the tumour is large and the domain is relatively 
small so the tumour source is a line at the edge of the domain. Angiogenesis is introduced 
by a tumour line source and the regression of the tumour is triggered by the angiogenesis. 
In this assumption, the tumour is set at the opposite side of the pre-existing vessel. Because 
the tumour is large enough, it can be described as a line tumour at one edge of the domain. 
For the small tumour load, the tumour is in the middle position adjacent to the edge.  
 
5.2.1.4 Simulating large tumour load regression and 
recurrence by immune tumour cytotoxic factor  
We assume the large tumour load is a great one and forms a line TAF source. The TAF is 
secreted and diffused to the side of the vessel based on Eq. (4.19), and forms a TAF 
concentration gradient at a steady state. The distribution of TAF is shown in Figure 5.1.  
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Figure 5.1. The steady state TAF concentration gradient is generated by a line tumour. This 
figure is obtained by numerically simulating Eq. (4.19).  
We take the steady state TAF concentration gradient shown in Figure 5.1 as the initial 
condition for the simulation of Eq. (5.5), Eq. (5.6), Eq. (5.7), and Eq. (5.8). In this section, 
5.1.2.1, we set a large tumour load T=400. The simulation results are shown as follows. 
1) The tip cell density (ECs) 
  
(a) t=1                     (b) t=2                   (c) t=3 
Figure 5.2. Spatiotemporal evolution of EC density n 
The initial three clusters of EC density are moving towards the line tumour. The figure 
shows the evolution result of EC density towards the tumour line source by numerically 
simulating Eq. (5.5). 
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From Figure 5.2 shown above, we can observe that the ECs (tips), n, migrate up the 
gradient of TAF under the influence of chemotaxis. The position of the tip cell reach 
represents the position of the front edge of the vessels, through which the immune factor is 
delivered at the same time, recruited by the tip cells.  
2) The tumour cytotoxic immune factor  
 
    
(a) t=1                      (b) t=2                   (c) t=3 
Figure 5.3. Spatiotemporal evolution of an immune factor density I  
These are the same EC steps as the profile view. The three clusters of immune factor 
density are moving through the vessel or may be recruited by the ECs towards the line of 
the tumour. The figure shows the evolution result of immune factor density towards the 
tumour line source by numerically simulating Eq. (5.7). 
 
From Figure 5.3 shown above, we can observe that the tumour immune factor, I, migrates 
up the gradient of TAF in the same position of tip cells, n. The position of the tip cell reach 
represents the position of the front edge of the vessels, through which the immune factor is 
delivered at the same time, as recruited by the tip cells. The immune factor is diffused into 
the surroundings, making the immune factor reach the tumour ahead of the front edge of 
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the vessel. This is in line with Folkman’s [190] observation. He found that the tumour 
began to regress when the vessel was within 0.5mm from it. The regression is the 
consequence of the tumour cells making contact with the immune factor.  
3) The vessel density  
 
(a) t=1                     (b) t=2                    (c) t=3 
Figure 5.4. Spatiotemporal evolution of a vessel density b[8][8] 
The three clusters of vessel density are moving through the trail of tip cells towards the line 
tumour. The figure shows the evolution result of vessel density towards the tumour line 
source by numerically simulating Eq. (5.8). 
 
From Figure 5.4 above, we can observe the vessel density, b, migrates up the gradient of 
TAF under the influence of chemotaxis. The vessels are laid down on the trail of tip cells, 
through which the immune factor is delivered at the same time, as recruited by the tip cells. 
The vessel density can be dynamically observed. When the vessels approach the tumour, 
the density of the vessels becomes higher and higher, which is consistent with what is 
called the ‘brush border’ phenomenon [8]. 
4) Tumour influenced by the cytotoxic immune factor 
The change in tumour load is calculated by integrating the tumour densities at each time 
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step across the domain. The tumour load increases until the immune factor or the 
tumour-cytotoxic factor reaches the position of tumour. These make the tumour regress, 
and the rate of regression depends on the coefficient. If the 𝑘2 in Eq. (5.6) increases, the 
term 𝑘2𝑇𝐼  becomes significant and the tumour load becomes lower. Thus, we can 
consider the parameter 𝑘2 as a sensitive parameter of the tumour to the tumour cytotoxic 
factor. If the coefficient k8 in Eq. (5.7) increases, the term 𝑘8𝑛𝐼 will increase and make 
the rate of generating immune factor increase, make the total magnitude of immune factor 
increase significantly, and finally influence the tumour load. The profile of the tumour load 
changing via time steps can be observed in Figure 5.5.  
    
(a) t=1                     (b) t=3                      (c) t=5 
Figure 5.5. Spatiotemporal evolution of a line tumour T  
From the profile view of the tumour, it can be seen to regress when the vessels reach it. In 
the time step (t=5), the three clusters of vessels pass through tumour, making the tumour 
regress at the positions where the vessel passed. The figure shows the evolution result of 
the line tumour load by numerically simulating Eq. (5.6). 
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Figure 5.6. Profile of the large tumour load changing via time steps  
In this case, at t=0, the original tumour load is set to be 404. During the simulation, the 
tumour load develops from the original load of 404 to the load of 440 at time step 3, then 
after the tumour cytotoxic factor reaches the tumour position, the tumour load decreases to 
the load of 390 at time step 5. After time step 5, with no tumour cytotoxic factor again, the 
tumour load increases and recurs.  
 
Figure 5.6 shows the profile of change in the tumour load. The tumour mass develops from 
the very beginning to the time 3, each time step represents the length of timescale 𝜏. From 
time 3 when the immune cytotoxic factor reaches the tumour, it kills the tumour cells and 
makes the tumour regress, so the tumour load becomes lower and lower. After time 5, the 
tumour load increases again, which is called recurrence. This is due to the disappearance of 
the immune factor, because in the model, the immune cells is assumed only delivered by 
the tips in front of vessels when tips disappeared the immune cells disappeared. The 
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surviving tumour cells then begin to recur. This indicates that the tumour may not develop 
again. To make it easier to understand, we have plotted simulation results in the following 
sequence of images. 
5) The sequence of images extracted from animation results.  
  
(a) t=1                                       (b) t=2 
  
                  (c) t=3                                      (d) t=4 
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                    (e) t=5                                      (f) t=6 
Figure 5.7. Animation profile of large tumour load, tip, vessel and immune factor profile in 
different time steps 
 
From the sequence of images shown above, it is clear that in t=1 and t=2, the tip cells do not 
reach the tumour, so the immune factor is also far from the tumour, and the tumour is 
developing. At t=3, the immune factor reaches the tumour and begins to kill tumour cells. 
After t=4, the tip cells pass the position of the tumour, and the concentration of the immune 
factor decreases and finally disappears. After the tip cells have passed the tumour, the 
density of immune factor decreases simultaneously. Lacking the immune factor, the 
tumour begins to recur and develops again after the time t=5 shown in Figure 5.5, Figure 
5.6, and t=1                                       (b) t=2 
  
                  (c) t=3                                      (d) t=4 
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                    (e) t=5                                      (f) t=6 
Figure 5.7.  
 
5.2.1.5 Modelling of drug delivery through the vessel  
From the simulation above, we can find that when the tumour cytotoxic factor reaches the 
tumour, it will kill the tumour cells and make the tumour regress. However, after the 
tumour cytotoxic factor disappears in tumour mass, the tumour begins to develop again. 
This is the recurrence phenomenon of a tumour. Thus, we should consider how to 
continuously deliver the tumour cytotoxic factor into the tumour. We set the drug equation 
as follows:  
 
𝜕𝑑
𝜕𝑡
= 𝐷𝑑 (
𝜕2𝑑
𝜕𝑥2
+
𝜕2𝑑
𝜕𝑦2
) + 𝑘15𝑏 (
𝜕𝑐
𝜕𝑥
+
𝜕𝑐
𝜕𝑦
) (5.12) 
where d represents tumour cell cytotoxic drugs, b represents formed blood vessel density 
and c represents TAF respectively. On the right of Eq. (5.12) the first term represents 
diffusion of tumour cell cytotoxic drugs by random motility with diffusion coefficient 𝐷𝑑, 
the second term represents the tumour cell cytotoxic drugs delivered through the formed 
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vessels with the rate constant 𝑘15, in which the rate of drug delivered is proportional to the 
vessel density b.  
In Eq. (5.12) the molecular component drug may diffuse faster than the cellular component 
immune factor. The diffusion coefficient 𝐷𝑑 of the drug should be greater than that of 𝐷𝐼, 
but would be in the same scale. Considering the possibility that the drug is delivered 
following the formation of vessels and the immune factor is recruited by the tip cells, we 
assume that the drug and the immune factor reach the tumour at almost the same time, so 
the magnitude of the drug diffusion coefficient 𝐷𝑑 is taken to be the same as 𝐷𝐼 to Eq. 
(5.12). The drug is delivered through the capillary vessels, so the flux of the drug is 
proportional to the density of the vessel denoted as b. We assume the concentration of drug 
delivered is in the same scale as the immune factor, but it could be higher because the drug 
can be delivered artificially to a certain extent. Thus, we take the magnitude of the 
coefficient k15 in Eq. (5.12) as high as five times of 𝑘9 in Eq. (5.8) in our simulation.  
For the equation of the tumour, we think that the tumour cytotoxic factor consists of two 
parts. The first is the immune factor delivered from the host immune system throughthe 
vessels formed. The immune factor reaches the tumour at the same time as the tip cells. 
The second is the drug which is delivered from the vessels. The drug reaches the tumour 
along with the vessel development. Both of the cytotoxic factors have a synthetic effect on 
the tumour. The former makes the tumour cells more sensitive to the drug. The tumour 
cytotoxic drug coefficient is k16. The magnitude of 𝑘16 is taken to be the same as 𝑘2. We 
assume that the killing rate is proportional to the concentration of drug and tumour cells. It 
is described as Eq. (5.13). 
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𝜕𝑇
𝜕𝑡
= 𝐷𝑇(
𝜕2𝑇
𝜕𝑥2
+
𝜕2𝑇
𝜕𝑦2
) − 𝑘2𝑇𝐼 − 𝑘16𝑇𝑑 + 𝑘11𝑇𝑏 + 𝑘3𝑇 
(5.13) 
where T represents tumour cells, I represents immune cytotoxic factor, d represents tumour 
cell cytotoxic drugs and b is the formed blood vessels respectively. On the right of Eq. 
(5.13), the first term represents flux of tumour cells by random motility with diffusion 
coefficient 𝐷𝑇 , the second term represents the killing rate of tumour cells by immune 
cytotoxic factor with the rate constant 𝑘2, the third term indicates the killing rate of tumour 
cells by tumour cell cytotoxic drugs with the rate constant 𝑘16, the fourth term refers to the 
tumour development rate enhanced by blood vessels with the rate constant 𝑘11 the fifth 
term refers to the natural tumour growth rate with the rate constant 𝑘3. 
Based on the analysis above, we set another simulation assuming that a tumour cytotoxic 
drug is delivered through the vessels formed. In this simulation, the condition of the 
tumour and TAF are the same as discussed above, which is a line tumour and a steady state 
TAF distribution. Except for the immune factor, the different point from above is that we 
simulate the delivery of a tumour cytotoxic drug through the vessels in Eq. (5.12). The 
variables denoted as d represent the tumour cytotoxic drug. The influence of the drug on 
the tumour is described in Eq. (5.13). The result of simulation is as shown in Figure 5.8. 
The figure for the tip cells, vessel density, and the immune factor concentration is the same 
as that simulated above, so here we only present the tumour cytotoxic drug concentration 
profile and the simulated tumour profile. 
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5.2.1.6 Simulating large tumour load regression by both 
immune factor and cytotoxic drug  
We assume the large tumour load is a great one and forms a line TAF source. The TAF is 
secreted and diffused to the side of the vessel based on Eq. (4.19), and forms a TAF 
concentration gradient at a steady state. The distribution of TAF is shown in Figure 5.1. We 
take the steady state TAF concentration gradient shown in Figure 5.1 as the initial 
condition for the simulation of Eq. (5.5), Eq. (5.6), and Eq. (5.8). In addition, the two 
equations which describe the drug delivery and tumour response to the drug, Eq. (5.12) and 
Eq. (5.13), are involved in the simulation. We set the large tumour load to be the same as 
that in section 5.2.2. The simulation results are shown as follows. 
 
(a) t=1                     (b) t=4 
 
                          (c) t=5                      (d) t=6 
Figure 5.8. Spatiotemporal evolution of a line tumour T influenced by immune factor and 
drug  
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From the profile view, the tumour regresses when the vessels reach the tumour. In time step 
(t=5), the three clusters of the immune factor pass through the tumour, and the drug 
remains in range of the tumour, making the tumour regress. The figure shows the evolution 
result of line tumour load by numerically simulating Eq. (5.13). 
1) Simulation of tumour cytotoxic drug concentration.  
  
(a) t=1                     (b) t=2                     (c) t=3 
Figure 5.9 Spatiotemporal evolution of the tumour cytotoxic drug d 
The drug concentration corresponds with the density of the vessels formed. It is in the same 
step with the vessels from the view of profile. The three clusters of tumour cytotoxic drug 
are moving through the vessels towards the line tumour. The figure shows the evolution 
result of tumour cytotoxic drug delivered towards the tumour line source by numerically 
simulating Eq. (5.12). 
 
From Figure 5.9, we can observe the change of tumour cytotoxic drug, denoted as d in Eq. 
(5.12). The drug is delivered through the vessels, through which the immune factor is also 
delivered at the same time. The tumour cytotoxic drug can be observed dynamically, 
consistent with the density of vessels. 
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2) The sequence of images extracted from animation results 
  
(a) t=1                                       (b) t=2 
 
                  (c) t=3                                       (d) t=4 
  
                   (e) t=5                                      (f) t=6 
Figure 5.10 Animation profile of the tumour, tip, vessel, immune factor, and drug profile at 
different time steps 
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Figure 5.11 Profile of the large tumour load change via time steps influenced by immune 
factor and drug 
In the profile, the original tumour load of 404 developed to 440 at time step 3, then after 
both the cytotoxic factor and drug reached the position of tumour, the tumour load 
decreased significantly to the load of 100 at time step 6. Which mean that tumour 
regressed significantly When the synthetic effect of tumour immune cytotoxic factor and 
drug occurred simultaneously and the drug effect remained.  
 
In Figure 5.8, t=1                                       (b) t=2 
 
                  (c) t=3                                       (d) t=4 
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                   (e) t=5                                      (f) t=6 
Figure 5.10, and Figure 5.11, it can be observed that the tumour is reduced from the system 
significantly after the immune factor reached the tumour mass. The drug delivered through 
the vessels reaches the tumour mass later and remains for a longer time. This means that the 
killing effect of the drug is maintained longer and the tumour continuously regresses. At 
time step (t=6), the tumour mass becomes a smaller one and is still regressing. This is 
because the drug remains there. The vessels reach the tumour before significant effects 
occur. The model simulation results show that the drug reaches the tumour a little later than 
that of the immune factor. This may be because the tip cells recruit the cytotoxic immune 
factor but the drug should be delivered after the formation of the vessel. Usually, drugs are 
molecular components and they diffuse faster than cellular components, such as the 
cytotoxic immune factor. However, in the simulation, the drug reaches the tumour mass 
later. This could be due to the drug being delivered through the vessels, but the immune 
factor being carried by tip cells. 
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5.2.1.7 Simulating a small tumour load clearance by immune 
tumour cytotoxic factor  
Now, we assume that there is a tumour which is relatively small. The tumour load is set as 
4 × 5 × 1 = 20. We put the small tumour in the middle adjacent to the edge opposite to the 
vessel. For the simulation domain, no tumour line source exists, and only a small tumour is 
put in the mid-point adjacent to the side of domain opposite to the pre-existing vessel. The 
TAF is secreted by the small tumour and diffused into the microenvironment. After the 
TAF reaches a steady state, the contribution of TAF can be shown as follows in Figure 
5.12.  
 
Figure 5.12 The steady state TAF concentration gradient generated by a small tumour. This 
figure is obtained by numerically simulating Eq. (4.19)  
In the same way as shown in section 5.2.1, we take the steady state TAF concentration 
gradient shown in Figure 5.12 as the initial condition for the simulation of Eq. (5.5), Eq. 
(5.6), Eq. (5.7), and Eq. (5.8). In this section, we set a small tumour load T=20. The 
simulation results are shown as follows in Figure 5.13, Figure 5.14, Figure 5.15, Figure 
5.16, Figure 5.17, and Figure 5.18. 
Based on the assumption, we set three clusters of ECs on the side of the vessel which is the 
same as the simulation above. Under the influence of chemotaxis, the ECs migrate from the 
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side of pre-existing vessel to the tumour in the midle of the opposite side. The migration of 
tip cells and their change in density are shown in Figure 5.13. The three clusters of ECs 
migrate due to the attraction of the chemotaxis.  
 
 
(a) t=2                   (b) t=2.5                  (c) t=2.6 
Figure 5.13 Spatiotemporal evolution of ECs density n 
The initial three clusters of EC density are moving towards the line tumour. The figure 
shows the evolution result of EC density towards a small tumour source by numerically 
simulating Eq. (5.5). 
 
1) Tip cells (ECs) migration attracted by a small tumour 
From Figure 5.13, we can observe that from time step (t=1, t=2) to t=2.5, the movement 
velocity of endothelial tip cells in three clusters remains almost the same. The distance 
covered by the ECs is only two thirds of the domain. This means that the velocity of the 
move is relatively low because the gradient is low. From time step (t=2.5) to time step (t=3), 
the movement velocity of endothelial tip cells in three clusters accelerates and covers the 
rest of the domain. It takes less than half a time step to cover one third of the domain. This 
is due to the precipitous gradient of TAF concentration approaching the small tumour. We 
can observe that the three clusters of ECs get closer to the centre and move faster towards 
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the tumour. At this local range, the gradient becomes steeper and leads to a strong 
chemotactic influence. When the ECs approach the tumour, the three clusters of ECs gather 
and overlap, leading to higher local density.  
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2) The vessel density induced by a small tumour 
   
(a) t=2                     (b) t=2.5                    (c) t=2.7 
 
(d) t=2.8                     (b) t=2.9                    (c) t=3 
Figure 5.14 Spatiotemporal evolution of vessel density b. 
The three clusters of vessel density are moving towards the small tumour. The figure shows 
the evolution result of vessel density towards a small tumour source by numerically 
simulating Eq. (5.8)  
 
From Figure 5.14 shown above, we can observe that the vessel density is the highest at the 
tumour at time step (t=3). The position it reaches represents the position of the front edge 
of the vessels, through which the immune factor is delivered at the same time, which would 
be recruited by the tip cells.  
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3) Immune factor attracted by the small tumour 
   
(a) t=1                       (b) t=2                    (c) t=3 
Figure 5.15 Spatiotemporal evolution of an immune factor density I.  
The three clusters of immune factor density are moving towards the small tumour. The 
figure shows the evolution result of immune factor density towards a small tumour source 
by numerically simulating Eq. (5.7). 
 
4) A small tumour clearance by the immune factor 
     
(a) t=1                      (b) t=3                    (c) t=3.7  
   
            (d) t=3.8                    (e) t=3.9                    (f) t=4 
Figure 5.16 Spatiotemporal evolution of a small tumour load T cleared by immune factor  
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From the profile view, the tumour regresses when the vessels reach the tumour. In time step 
(t=4), the three clusters of overlapping vessels pass through tumour, making the tumour 
regress significantly at time step (t=4). The figure shows the evolution result of small 
tumour load by numerically simulating Eq. (5.6). 
 
5) Sequence images extracted from animation results 
    
  
(a) t=1                                   (b) t=2 
  
    (c) t=3                               (d) t=4 
Figure 5.17 Animation profile of a small tumour, tip, vessel, immune factor profile at 
different time steps 
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Figure 5.18 Profile of the tumour load change via time steps  
The tumour developed from the original small load of 20 to 23 at time step 3, then after the 
tumour cytotoxic factor generated by immune system reached the position of the small 
tumour, the tumour load decreases to the load of 7 at time step 5. The trend remained. This 
means that a very small tumour load could be eliminated by the immune factor if the 
tumour cytotoxic factor can be focused enhanced on it.  
 
In Figure 5.16, Figure 5.17, and Figure 5.18, it can be observed that the small tumour is 
reduced significantly after the immune factor passed the tumour mass after time step (t=3). 
At time step (t=5), the tumour mass has been eliminated. This is because the immune factor 
from three clusters of vessels gathers and enhances the tumour cytotoxic effect. The results 
imply that if the tumour is small enough, the tumour load would probably be eliminated, 
such as when the tumour cells have metastasis from a primary tumour and appear close to a 
limbus vessel, and when the immune factor generated by the limbus vessel is strong 
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enough.  
Tumours can raise the function of the immune system, as the immune system interacts with 
tumours. The immune system can kill the tumour cells and regress the tumours. At the 
same time, it can partly sculpt the cancer phenotype, making the tumour cells less 
immunogenic and ultimately aiding tumour growth [195]. The dual functions of the 
immune system hinder and facilitate tumour growth, leading to the theory of cancer 
immunoediting [193]. The tumour immunoediting process hypothesis consists of three 
phases: elimination, equilibrium, and escape, termed the three Es of tumour 
immunoediting [192, 193]. 
In the elimination phase, the tumour cells are successfully recognised and eliminated by 
the immune system, thus returning the tissues to their normal state of function. Numerous 
studies have now demonstrated this phenomenon of the immune system for such a phase 
[194, 197]. The tumour cells that are not completely eliminated by the immune system 
proceed into a phase of equilibrium, in which the immune system controls tumour cell 
growth but not completely eliminate the cells. In the phase of equilibrium, the constant 
interaction of the immune system with tumours over a long period of time may finally edit 
or sculpt the cells of developing tumours, resulting in tumour cells shaped into a 
less-immunogenic state, which leads to being less susceptible to immune attack. Thus, the 
tumour progresses into the third phase of the immunoediting process, termed escape. The 
tumours in the escape phase destroy the immune system to facilitate their growth through 
different mechanisms [194, 197]. Now, numerous experiments and intensive research work 
are being carried out to develop strategies that can target these mechanisms of escape, as 
this represents new means of cancer immunotherapy [198].  
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In our simulation, we find that when the tumour is small, the immune factor can eliminate 
the tumour completely, but when the tumour becomes large, the immune factor can only 
make the tumour regress then recur. Our model and simulation results are consistent with 
the tumour immunoediting process described in recent research [192, 193]. In our model, 
for the therapy of a large tumour, we have developed two equations described in Eq. (5.12) 
and Eq. (5.13). The two equations involve the variables I and d. The simulation results in 
Figure 5.8, t=1                                       (b) t=2 
 
                  (c) t=3                                       (d) t=4 
  
                   (e) t=5                                      (f) t=6 
Figure 5.10 and Figure 5.11 show that the large tumour regresses and does not recur by the 
influence of I and d. Here, the variable d can be a tumour cytotoxic drug or some kind of 
immune therapy substance delivered through the formed vessels. From the simulation 
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results, we can imagine that if we can mobilise, recruit the tumour cytotoxic immune 
factor, and focus it on a tumour, the immune factor will be strong enough to defeat the 
tumour. These simulation results imply that there may be possible ways progress: by 
improving the patients’ immune system; by mobilising and recruiting patients’ immune 
factor; or by superimposing immune factor and drug effects together. These are possible 
forms of early tumour therapy and in some cases the tumour might be cured completely. 
The simulation results indicate the potential for tumour therapy. 
 
5.3 Summary  
In section 5.1, we further developed the model established in section 4.2 by involving 
another three PDEs and simulating the tumour regression, recurrence, and clearance by 
cytotoxic factor delivered through the vessels formed by tumour-induced angiogenesis 
under different conditions. The model is able to simulate a sequence of tumour-induced 
angiogenesis, the delivery of a tumour cytotoxic factor, including innate tumour cytotoxic 
immune factor such as natural killer (NK) cells and macrophages, or a tumour cytotoxic 
drug through the newly formed capillary vessels, and consequently the regression of the 
tumour. In the model, we assume that based on the steady state of concentration gradient of 
a tumour angiogenesis factor (e.g. VEGF), the angiogenesis from a pre-existing limbus 
vessel commences. The main equation used to describe the density of capillary tip cells 
both spatially and temporally is a nonlinear PDE. The development of capillary tip cells 
governs the density of blood vessels and the concentration of cells of the immune system. 
The density of tumour cells is also described by using a PDE. From the simulation, we can 
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observe that the tumour regresses when the tip cells lead the approach of vessels. This is the 
reason why tip cells carry the immune factor approaching at the same time and make the 
tumour regress. Here we call it a system approaching. If the tumour cell loading is 
relatively low and the immune tumour cytotoxic factor enhanced, the system approaching 
can eliminate the tumour by itself. If the tumour cell loading is relatively high, the immune 
factor cannot eliminate the tumour by itself, so the tumour recurs. We also developed a 
PDE to describe the delivery of tumour cytotoxic drug. By simulating the model, we can 
observe that the tumour regresses significantly by introducing drugs. We can observe the 
synthesis effect of immune factor generated in the body and the tumour cytotoxic drug 
delivered through the vessels formed from the simulation. 
The computational modelling approach is of a lot of benefits in describing the interactions 
of tumours between immune factors for the results come out fast and visually, but in vivo 
experiments the results are usually very costly and can take months or years for an 
experienced team to perform. The interactions between tumours and immune factors are 
also very complex to follow since it is difﬁcult to observe them without disrupting the 
ongoing process. Therefore, in silico, computer modelling can help our understanding of 
the tumour-immune factor interactions by allowing us to simulate the behaviours that 
cannot be observed directly in vivo. Computer models can simulate experiments lasting 
years in real time in a far shorter time even days and give access to information which is 
normally hidden during in vivo studies. The precision of these simulations depends on the 
model established. 
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5.4 Conclusion 
In this chapter, we have presented and discussed our mathematical models of 
tumour-induced angiogenesis with tumour regression by cell immune tumour cytotoxic 
factor.  
We developed the model by involving cytotoxic factor under different conditions to 
describe the tumour regression, recurrence, and clearance. The simulation demonstrates 
the synthesis effect of immune factor generated in the body and the tumour cytotoxic 
drug delivered through the formed vessels. The results show that a small tumour load can 
be eliminated completely by enhancing the immune factor, and a large tumour load can be 
regressed by the immune factor but recur again. Here we would like to emphasize that it is 
oversimplified for the model that the precision of the simulation results are limited and it is 
necessary to carry out much more biological research to make this model more useful. 
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Chapter 6. Modelling of VEGF/Notch 
regulatory mechanism in angiogenesis  
Signal transduction plays a vital role in tumour-induced angiogenesis in which cells divide, 
differentiate, migrate and proliferate. The VEGF/Notch signalling pathways are the 
important regulatory mechanism for the proper formation of capillary vessel networks. 
Tumour-induced angiogenesis usually starts at the subcellular level. This subcellular level 
is marked by events that occur within and between ECs, such as transduction of chemical 
signals between VEGF ligand and VEGF receptors or Dll4 ligand and Notch receptors.  A 
large number of intracellular components regulate activities at the cellular level, such as tip 
and stalk cell differentiation. This cellular level can be referred to as the microscopic scale. 
It is a challenging task to modelling the regulatory mechanism of VEGF and Notch 
signalling pathways which make the capillary vessels formed in an appropriate network. 
Mathematical models can help us to better understand these mechanisms.  
This chapter firstly presents the VEGF signalling pathway regulatory model in 
angiogenesis, then demonstrates the Notch signalling pathway regulatory model in 
angiogenesis, and also discusses the VEGF-Notch feedback regulatory mechanism in 
angiogenesis. Finally, it analyses the developed enzymatic catalysed kinetic model in ODE 
hybrid with ABM to simulate the regulatory mechanism.  
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6.1 Introduction  
This chapter presents our innovative models involving the regulatory mechanism of a 
VEGF/Notch signalling pathway, which is crucial in the selection of tip and stalk cells 
during the angiogenesis process and influences the morphology of the capillary network. 
The mechanism of sprouting and branching is also simulated in this chapter. 
 
6.2 Establishing the VEGF signalling pathway regulatory 
model in angiogenesis 
Based on the bio-evidence described in section 2.3.4.1, when the ligand VEGF-A binds the 
receptor VEGFR-2 on the surface of ECs, they form receptor-ligand complex. The 
formation of receptor-ligand complex triggers the VEGF signalling pathway and generates 
the VEGF signals. For simplicity, we described VEGF-A as VEGF and VEGFR-2 as 
VEGFR, so the receptor-ligand complex here is described as VEGF-VEGFR. The reaction 
of forming VEGF-VEGFR complex is catalysed by tyrosine kinase. We describe the 
VEGF as substrate, denoted as S, and the VEGF-VEGFR complex formed by enzymatic 
catalysed reaction as product, denoted as P. In the triggering of VEGF signalling pathway, 
VEGFR-1 suppresses angiogenesis by trapping VEGF-A and suppressing the local 
concentration of VEGF-A near VEGFR-2 on the surface of ECs [95]. Thus, VEGFR-1 can 
act as a competitive inhibitor in the expression of VEGF signalling. We assume that 
co-receptors, VEGFR1 etc., are the competitive inhibitors in our model during the reaction, 
denoted as I, which can competitively inhibit the combination of VEGF with VEGFR-2. 
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Therefore, we assume that VEGFR-1 competitively inhibits the reaction rate of forming 
VEGF-VEGFR complex. According to the theory of enzymatic catalysis, we use the 
Michaelis-Menten enzymatic reaction kinetics model, described as follows: 
 
𝑣 = 𝑣𝑚𝑎𝑥1
[𝑆]
[𝑆] + 𝐾𝑀1 (1 +
[𝐼1]
𝐾𝐼1
)
   
(6.1) 
 ∵  𝑣 =  −
𝑑[𝑆]
𝑑𝑡
  or  𝑣 =
𝑑[𝑃]
𝑑𝑡
 (6.2) 
 
∴
𝑑[𝑆]
𝑑𝑡
=  − 𝑣𝑚𝑎𝑥1
[𝑆]
[𝑆] + 𝐾𝑀1 (1 +
[𝐼1]
𝐾𝐼1
)
 
(6.3) 
Where v is the enzymatic catalysed reaction rate, 𝑣𝑚𝑎𝑥1  is the maximum reaction rate, 
[S] is the concentration of substrate, the VEGF. KM is the Michaelis constant. KI is the 
inhibition constant and I1  is the concentration inhibitor. From the equation, if the I1 
increases or the inhibition constant KI decreases, the reaction rate will decrease. We use 
[S0]  to represent the local original VEGF concentration and [P1] to represent the 
concentration of reaction product, the VEGF-VEGFR. The relationship can be described 
as:  
 [𝑃1] = [𝑆0] − [𝑆] (6.4) 
 
 𝑑[𝑃1]
𝑑𝑡
= − 
𝑑[𝑆]
𝑑𝑡
 (6.5) 
Therefore, we obtain the equation as follows: 
 
𝑑[𝑃1]
𝑑𝑡
=   𝑣𝑚𝑎𝑥1
[𝑆0] − [𝑃1]
([𝑆0] − [𝑃1]) + 𝐾𝑀1 (1 +
[𝐼1]
𝐾𝐼1
)
 
(6.6) 
Considering the decay of P1with the time elapse, the rate of degradation is proportional to 
its concentration, with the coefficient of k1. As a result, Eq. (6.6) can be rewritten as 
follows:  
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𝑑[𝑃1]
𝑑𝑡
=   𝑣𝑚𝑎𝑥1  
[𝑆0] − [𝑃1]
([𝑆0] − [𝑃1]) + 𝐾𝑀1 (1 +
[𝐼1]
𝐾𝐼1
)
− 𝑘1[𝑃1] (6.7) 
The complex is formed based on the equations described above during the VEGF and 
VEGFR reaction under the tyrosine kinase catalysis. Once the complex is formed, the 
VEGF signalling is expressed. The increasing rate of P1 represents the expressing rate of 
VEGF signalling. The higher the magnitude of P1, the stronger the strength of VEGF 
signalling is expressed and the faster the tip cells are formed. The EC differentiation 
towards the tip cells is accelerated. VEGF signalling stimulates a series of reactions to 
generate Dll4 on its surface.  
From Eq. (6.7), where [S0]  represents the original local VEGF concentration, [P1] 
represents the VEGF signalling, and [I1] represents the inhibition of VEGFR-1 triggered 
by the Notch signalling, it is clearly shown that the increasing rate of [P1] is determined by 
[S0] (the local original VEGF concentration), and also inhibited by the expression of 
inhibition [I1]. [I1] will be described in detail later in section 6.4. 
 
6.3 Establishing Notch signalling pathway regulatory model 
in angiogenesis 
Based on the bio-evidence described above in 2.3.4.2, the Notch signalling pathway starts 
from the receptor-ligand interaction between adjacent cells. This interaction triggers a 
series of proteolytic cleavages of the Notch receptor inside the cell. There are several 
Notch receptors and ligands. As the Dll4 ligand is the most important ligand and the only 
protein in the Notch signalling pathway, we assume that Notch signalling begins with 
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receptor-ligand interactions between neighbouring cells to form a Dll4-Notch complex, 
which in turn triggers a series of proteolytic cleavages of the Notch receptor and is a very 
complicated reaction inside the cell. The Notch pathway must be tightly regulated to 
ensure proper vascular formation during angiogenesis.  
 
 
Figure 6.1. Elucidation of Notch signalling pathway  
Notch signalling begins with Notch receptor-Dll4 ligand interaction between neighbouring 
cells. This interaction triggers a series of proteolytic cleavages of the Notch receptor, 
releasing NICD from the cell membrane, promoting Notch signalling and releasing 
Jagged1 as a competitive ligand. The Dll4 ligand is also a target gene regulated by the 
Notch signalling pathway [4]. 
 
Based on Figure 6.1, we assume that the Notch signal is generated by enzyme catalysed 
interactions between ECs. They regulate adjacent cells to specify different characteristics 
during sprouting angiogenesis. The strength of the signal depends on the reaction rate.  
Since Dll4 is the principal ligand in the Dlls family and Jagged1 is the principal ligand in 
the Jagged family (see 2.3.4.2), for simplicity the Dlls ligand family is denoted as Dll4 
ligand, and the Jagged ligand family is denoted as Jagged1 ligand. To establish the model, 
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thereby, we describe the complicated system as the reaction of Dll4 ligand with the Notch 
receptor and this reaction is catalysed by on enzyme (glycosyltransferase Fringe) [4] on 
the surface of adjacent ECs.  
Once the Dll4-Notch receptor complex is formed, it triggers a series of complicated 
reactions inside the ECs and produces the Notch signal which makes the cell itself turn into 
a stalk cell without sprouting; at the same time, it sends the Notch signal to regulate the 
adjacent cells in front of it. This is a chain reaction representing the Notch signalling 
pathway. Once the reaction happens, it means the Notch signalling pathway is expressed. 
To describe the Notch signalling pathway regulation model, we assume that the reaction 
rate implemented inside the cells is faster than the reaction rate on the surface. Hence, the 
limited reaction rate depends on the reaction route shown in Eq. (6.8).  
 𝐷𝑙𝑙4 𝑙𝑖𝑔𝑎𝑛𝑑𝑠 + 𝑁𝑜𝑡𝑐ℎ 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 
𝑒𝑛𝑧𝑦𝑚𝑒
↔      𝐷𝑙𝑙4/𝑁𝑜𝑡𝑐ℎ 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 (6.8) 
Then, the expression of Notch signalling pathway depends on the reaction route shown in 
Eq. (6.9).  
 𝐷𝑙𝑙4 𝑁𝑜𝑡𝑐ℎ 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 
𝑡𝑟𝑖𝑔𝑔𝑒𝑟 𝑠𝑒𝑟𝑖𝑒𝑠 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑖𝑛𝑠𝑖𝑑𝑒 𝐸𝐶𝑠
→                             𝑁𝑜𝑡𝑐ℎ 𝑠𝑖𝑔𝑛𝑎𝑙𝑖𝑛𝑔 (6.9) 
We describe the reaction in Eq. (6.10) to represent the whole Notch signalling pathway 
kinetic. Once the Notch signalling pathway is expressed strongly, it makes the reaction 
happen inside the ECs. As a result, the ECs turn into stalk cells and trigger the enzyme 
(Fringe) to catalyse the Jagged1 ligand to combine with the Notch receptor. In this way, the 
reaction competitively inhibits the combination of Dll4 with the Notch receptor, and finally 
lowers the Notch expression strength, whereas the Notch receptor shows strong activation 
by Dll4 and competitive inhibition by Jagged1.  
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We use S2  to denote Dll4 which is the substrate of the reaction. [S2] represents the 
concentration of Dll4. I2 denotes the coreceptor Jagged1 which acts as the inhibitor during 
the reaction. [I2] represents the concentration of Jagged1. I2 can combine with enzyme 
E during the reaction. The magnitude of I2  is influenced by the Notch signal. P2 
represents the Dll4-Notch receptor complex and [P2] represents the concentration of the 
Dll4-Notch receptor complex. The increasing rate of P2 is consistently promoted by the 
strength of VEGF signal. 
When the strength of Notch signal increases, the magnitude of I2 increases and so does 
the down-regulation effect; when the Notch signal decreases, the magnitude of I2 
decreases and so does the down-regulation effect. It is a cell autonomous regulation. 
During the procedure, the balance decreases the rate of generating P2 and the activation of 
I2 depresses the expression of Notch signalling pathway by adjusting the inhibition. As a 
result, the cells can realise the regulation of the Notch signalling pathway autonomously.  
Considering Jagged1 as a competitive inhibitor, we obtained the competitive inhibition 
dynamic balance based on the concept of enzymatic catalytic kinetics. In the same way as 
described above in VEGF signalling pathway, we derived the competitive/inhibitive 
kinetic equation as follows:  
 
     
𝑑[𝑃2]
𝑑𝑡
=   𝑣𝑚𝑎𝑥2
[𝑆2]
[𝑆2] + 𝐾𝑀2 (1 +
[𝐼2]
𝐾𝐼2
)
     
(6.10) 
where Ki2 is the inhibitor constant, because Dll4 is produced by the expression of the 
VEGF signal pathway. The higher the magnitude of the VEGF expression, the higher is the 
Dll4. Hence, in magnitude we can assume that Dll4 is proportional to that of the 
VEGF-VEGFR2 complex which can be described as [S2] ∝ [P1] or [S2] = k[P1]. To 
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eliminate the symbol [S2] we used k[P1] to substitute [S2] in Eq. (6.10) and obtained Eq. 
(6.11). 
 
      
𝑑[𝑃2]
𝑑𝑡
=   𝑣𝑚𝑎𝑥2
𝑘[𝑃1]
𝑘[𝑃1] + 𝐾𝑀2 (1 +
[𝐼2]
𝐾𝐼2
)
     
(6.11) 
Considering the decay of P2 with the time elapse, the rate of degradation is proportional to 
its concentration, with the coefficient of k2 and kM = k ⋅ KM2. As a result, Eq. (6.11) can 
be rewritten as follows: 
 
     
𝑑[𝑃2]
𝑑𝑡
=   𝑣𝑚𝑎𝑥2
[𝑃1]
[𝑃1] + 𝐾𝑀 (1 +
[𝐼2]
𝐾𝐼2
)
− 𝑘2[𝑃2]    (6.12) 
We assume the Notch receptor on the surface of the cell adjacent to the tip cell reacts with 
the Dll4 which is produced in the tip cell. Dll4 is generated by the VEGF signalling 
pathway expression catalysed by enzymes. We suppose that the reaction rate depends on 
Dll4. Based on the equation described above, during the Dll4 and Notch receptor reaction 
under the enzyme catalysis, the Dll4/Notch receptor complex is formed, and thereby the 
Notch signalling pathway is expressed. With the reaction carried out, the concentration of 
the complex is accumulated and then increased; the strength of Notch signalling pathway 
expression is increased, and the ECs differentiation towards stalk cells is accelerated. 
When the stalk cell is formed, it sends a signal to stimulate a series of reactions to lower 
VEGFR. From Eq. (6.12), it is clearly shown that the increasing rate of [P2] is determined 
by [P1] (adjacent Dll4 concentration), and also inhibited by the expression of inhibition 
[I2] which is triggered by the Notch signalling pathway.  
The activation of Notch signalling promotes tip cell formation. The overexpression of 
Notch signalling inhibits the tip cell characteristics. Thus, the activation level of Notch 
signalling expression quantitatively determines the ability of individual EC differentiation 
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to tip or stalk cell during sprouting.  
Jagged1 enhances differential Notch activity by competitively interfering with the ability 
of Dll4. The Notch signalling pathway can be modulated not only by the quantity of 
individual ligands, but also by their activity profile when Dll4 or Jagged1 interacts with the 
Notch receptor. 
VEGF-A and Notch signalling pathways are key players governing tip and stalk cell 
behaviour. VEGF and Notch signalling regulate tip and stalk specification during 
pathological angiogenesis, such as cancer [17, 97]. Dll4 ligand has been observed to be 
strongly expressed in the tumour vasculature. The overexpression of Dll4 and increased 
Notch activation result in reduced tumour sprouting and angiogenesis. Notch signalling 
acts as a negative regulator of VEGF-induced angiogenesis and is essential for proper 
vascular morphogenesis.   
The VEGF and Notch signal pathways are both key regulators of the angiogenic process 
and both are involved in the specification of the tip and stalk cell phenotypes. These two 
pathways work together to achieve functional patterning during sprouting angiogenesis. 
Several lines of evidence indicate that VEGF signalling acts upstream of the Notch 
signalling pathway during physiological and pathological angiogenesis to control the 
expression of different Notch components [21, 23, 98]. In addition to VEGF-A acting as 
the upstream of Dll4, it has become clear that Notch, in turn, controls VEGF signalling. In 
general, all observations support the concept that Notch signalling via Dll4 principally acts 
as a negative feedback regulator to control VEGF-induced angiogenesis.  
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6.4 Establishing the VEGF-Notch feedback regulatory 
mechanism in angiogenesis 
6.4.1 Modelling the VEGF-Notch signalling feedback loop 
inside each cell 
Inside each EC, both VEGF and Notch signalling feedback occur simultaneously. The 
VEGF and Notch signalling pathways cooperate tightly to specify and balance the tip and 
stalk cell phenotypes between the ECs that constitute the sprouts during angiogenesis 
process. To this end, Notch signalling acts in a negative feedback loop with VEGF 
signalling during sprouting angiogenesis.  
From the VEGF signalling pathway and Notch signalling pathway described above, we 
obtained two equations, Eq. (6.7) and Eq. (6.12), both of which are regulatory mechanisms. 
For simplicity, we put both Eq. (6.7) and Eq. (6.12) together and mark them as Eq. (6.13) 
and Eq. (6.14), expressed as follows: 
 
    
𝑑[𝑃1]
𝑑𝑡
=   𝑣𝑚𝑎𝑥1  
[𝑆0] − [𝑃1]
(𝑆0 − 𝑃1) + 𝐾𝑀1  (1 +
[𝐼1]
𝐾𝐼1
)
− 𝑘1  𝑃1   (6.13) 
 
  
𝑑[𝑃2]
𝑑𝑡
=   𝑣𝑚𝑎𝑥2
[𝑃1]
[𝑃1] + 𝐾𝑀2 (1 +
[𝐼2]
𝐾𝐼2
)
− 𝑘2 𝑃2    (6.14) 
  𝐼1(𝑉𝐸𝐺𝐹𝑅1,𝑁𝑟𝑝1, 𝑒𝑡𝑐. ) = 𝑓(𝑃2)  (6.15) 
  𝐼2(𝐽𝑎𝑔𝑔𝑒𝑑1) = 𝑔(𝑃1)  (6.16) 
Considering our assumption that the inhibitors I1 and I2 play negative feedback roles and 
are triggered by the variables P2 and P1 respectively, we establish another two equations 
Eq. (6.15) and Eq. (6.16). In Eq. (6.15) and Eq. (6.16), both inhibitors I1 and I2 are 
described as function of  P2 and P1 in which both are triggered by P2 and P1 respectively, 
145 
leading to down-regulation of P1 and P2.  
Till now, we have established a pair of ODEs in Eq. (6.13) and Eq. (6.14) and two 
inhibitive regulation equations in Eq. (6.15) and Eq. (6.16), respectively. The four 
equations compose the VEGF and Notch signalling model. At each time step, the regulated 
results are obtained using the Euler method to solve the ODEs in Eq. (6.13) and Eq. (6.14) 
at each time step, and by using ABM to update data, to compare P values with C values, to 
judge how to take I1 or I2, to make decisions on cell state, and then reiterate the process. 
The down-regulation of Notch signalling to VEGF signalling is implemented by P2which 
triggers the expression of I1in Eq. (6.15), which is realised by the ABM method. In this 
way, the down-regulation of P2 to P1 is realised in our model. As a result, we established 
the VEGF-VEGFR-Dll4-Notch-VEGFR regulatory feedback loop mechanism inside each 
EC, described as Eq. (6.13), Eq. (6.14), Eq. (6.15), and Eq. (6.16).  
In Eq. (6.13), P1 represents the concentration of VEGF-VEGFR complex. We assume the 
Dll4 is proportional to the VEGF-VEGFR complex, so the formed Dll4 is logically 
represented as  P1 . In Eq. (6.14), [ P1]  represents the concentration of Dll4 which is 
generated through a series of complicated reactions triggered by the formation of 
VEGF-VEGFR complex. 
 
6.4.2 Regulation of specification of tip/stalk between 
adjacent ECs in angiogenesis 
The specification of tip and stalk is the interplay between adjacent ECs. Any EC activated 
by VEGF-A and not directly inhibited by a neighbour expressing high levels of Dll4 can be 
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developed into the tip cell phenotype, and thus initiate a new sprout. The model described 
above in Eq. (6.13) and Eq. (6.14) happens not only inside each cell, but also between 
adjacent cells. This is a competitive/inhibitive feedback regulatory mechanism in which 
VEGF is up-regulatory signal pathway and Notch is down-regulatory signal pathway 
between the tip cell and stalk cell selection during sprouting.  
 
Figure 6.2. Tip and stalk cell specification during sprouting angiogenesis under the 
VGEF/Notch regulatory mechanism [4]  
 
Figure 6.2 shows the regulatory mechanism formed from the implementation of VEGF and 
Notch signalling pathway between adjacent cells in which the tip and stalk cells are 
specified. High VEGF signalling generates high concentration of Dll4 on the surface of the 
tip cell.   
When the VEGF signalling increases, the ECs in front which are specified into tip cells 
generate Dll4. The higher the VEGF signal is, the higher Dll4 is in magnitude. Dll4 is 
up-regulated in the tip cells by the VEGF signalling. Dll4 generates high Notch signalling 
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by triggering the reaction between the Dll4 and Notch receptor on the surface of the 
adjacent cells following the tip. The Notch signalling inhibits the tip characteristic and 
makes itself turn into a stalk cell. Consequently, once Dll4 is formed, it acts as the ligand 
triggering the reaction with the Notch receptor on the surface of adjacent cells. The 
reaction is catalysed by enzymes in the stalk cells which suppresses the tip cell phenotype. 
Notch signalling activation reduces VEGFR2 expression and increases 
VEGFR1/sVEGFR1 levels which are expressed in the equation as I1 , meaning the 
inhibition of the VEGF signal.  
When the tip cell receives low Notch signalling, it allows a high expression of VEGFR2 
and Nrp1, but low expression of VEGFR1. By contrast to Dll4, at the same time Jagged1 
ligand is expressed by the stalk cells. Jagged1 antagonises Dll4-Notch signalling in the 
front of sprout when the Notch receptor is modified by the glycosyltranferase (Fringe), 
which is expressed as I2 in Eq. (6.14). It is the competitive inhibition of Dll4. Thereby, the 
competitive inhibition enhances differentiation of Notch activity between tip and stalk 
cells.  
What is described above is the computational model of the VEGF-Dll4-Notch-VEGFR 
regulatory feedback loop mechanism between ECs. Up to now, we have established the 
enzymatic catalysed kinetics computational model, based on the evidence of the VEGF 
signal and Notch signal pathways described above and the VEGF-Notch-VEGFR 
regulatory feedback loop mechanism theory. We have summarised several fundamental 
rules of the mechanism, as follows: 
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(1) The VEGF signalling pathway up-regulates sprouting. It is necessary to induce the 
tip characteristic which makes ECs appear as a tip phenotype. Blocking VEGF 
prevents tip cell formation. 
(2) VEGF signalling pathway is upstream of the Notch. It positively up-regulates to 
promote the Notch signalling pathway consistently.  
(3) Notch signalling pathway critically regulates the ratio of tip and stalk cells by 
suppressing tip cell formation in adjacent cells and turning them into stalk cells. 
Jagged1 enhances differential Notch activity by competitively interfering with 
Dll4.  
(4) Notch signalling pathway down-regulates the VEGF signalling pathway and forms 
a feedback loop regulatory mechanism during sprouting angiogenesis.  
(5) The VEGF and Notch signalling pathways cooperate to adjust the specification of 
tip cell and stalk cell instantaneously.  
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Figure 6.3 Regulation procedure of sprouting Eq. (6.13), Eq. (6.14), Eq. (6.15) and Eq. 
(6.16)  
 
Figure 6.3 describes the regulation procedure of tip/stalk cell differentiation inside and 
between adjacent ECs at the spearheading point during sprouting angiogenesis. Each 
rectangle represents a cell which includes two equations representing the VEGF and Notch 
signal respectively. The regulation takes place inside each cell by the solution of the four 
equations. The two rectangles represent two adjacent cells, and the regulation occurs by the 
established feedback mechanism between the two cells, as described above. Figure 6.3 
elucidates the relationship between VEGF and Notch signalling pathways which are 
implemented in the differentiation of tip and stalk cells in the vascular endothelium.  
In the front cell Eq. (6.13) represents the VEGF signalling pathway. It demonstrates the 
interaction between VEGF and VEGFR2 on the surface of ECs. The bind of VEGF and 
VEGFR2 triggers the VEGF signalling and generates Dll4 (P1). P1 value represents the 
VEGF signalling. The increasing P1  value promotes the increase of P2  value which 
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represents the Notch signalling. Eq. (6.14) reveals the relationship that the Notch 
signalling is up-regulated by the VEGF signalling.  
In the back cell, the mechanism of the regulation is the same as that in the tip cell. The front 
cell sends the signal back to the cell behind it to enhance Notch signalling by the high Dll4 
ligand. Notch signalling in the cell behind takes the competitive inhibitors denoted as I1. 
This is realised using the ABM method. Thus, the Notch signalling reduces VEGF 
signalling inside itself, which reduces  P1. The low VEGF signalling generates low Dll4, 
which makes the front cell lower the Notch itself. Consequently, the front cell is 
characterized as tip and the back cell as stalk. The regulation procedure of sprouting is 
shown in Figure 6.3. Here, the competitive receptors VEGFR1/sVEGFR1 are denoted as 
I1 and the Jagged1 as I2 in the cells. The solution of Eq. (6.13), Eq. (6.14), Eq. (6.15), and 
Eq. (6.16) results in the change of P1 and P2 values, both of which influence the cell 
behaviour. 
 
6.5 Establishing discrete model by Agent-based Modelling 
(ABM) 
6.5.1 ABM 
6.5.1.1 The rationale 
Agent-based modelling (ABM) is a computational modelling approach providing a 
systematic view for the simulation of action and interaction between autonomous 
individual entities [142]. A network of cellular automata (CA) is another framework for 
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defining the interacting components in a system [146]. Since CA is not capable of 
representing a large amount of data transformation between entities due to the increasing 
complexity of the input symbols and the number of states, to model tumour-induced 
angiogenesis we have applied an agent-based approach which provides a more powerful 
state machine to allow an intuitive exploration of the dynamics and complexity of 
biological systems.  
 
6.5.1.2 The implementation  
Finding and representing a realistic agent representation is the main focus of ABM. Maes 
[199] defines agent architecture as the methodology of building agents. The architecture 
encompasses techniques and algorithms to specify the agent into a set of component 
modules and define the interaction between modules. The interaction between modules 
determines the current internal state of the agent and future agent actions. In addition, agent 
architecture is famous for its particular decision making characteristics. Müller [200] 
summarised some of the main types of agent architecture as follows. 
 Reactive-based architectures  
The decision making procedure is based on a very limited amount of information 
and simple situation action rules. It focuses on producing robust behaviour rather 
than correct or optimal behaviour. This type of architecture allows its decisions 
determined by the limited input information without other information from 
environment.  
 Deliberative-based architectures 
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Different from the reactive agents, its decision making procedure is based on the 
explicit information from environment. The agent takes into account all the 
available environment information and integrates it with the internal knowledge 
before making a plan of action. The desire is to achieve the goals that an agent 
wishes to achieve. Intentions are the drives that propel agents to achieve their goals. 
The belief-desire-intention (BDI) architecture is a well-known type of deliberative 
architecture. The BDI agent takes into account the information about its 
surrounding environment and other agents.  
 Interaction-based architectures 
The decision making procedure is attained by explicitly reasoning about the 
environment via different software layers. This type of architecture originates from 
distributing artificial intelligence.  
The development process of an agent-based model involves creating agents that mimic 
the attributes and behaviours of their environment. In this study, agents represent the 
different types of ECs. Each EC has been built to have a cognitive process dictating its 
decision, while staying in the microenvironment during tumour-induced angiogenesis. 
MASON [201] is a computational modelling toolkit used in developing the agent-based 
model. There are two different kinds of interactions: cell-cell and cell-ECM. The former is 
the interaction between ECs, while the latter is the interaction between the EC and its 
environment. Agents representing ECs are the core of the MASON model, so they are the 
main decision-making components in this model. Finally, the model consists of active, 
autonomous agents (i.e. ECs), and passive entities representing the surrounding 
environment in tumour-induced angiogenesis. 
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6.5.1.3 A hybrid ABM approach 
Modelling the individual cell behaviour in the process of angiogenesis is a challenging and 
complicated task. It involves interdisciplinary processes and concepts, such as theories 
from biology, mathematics, and computer engineering. In addition, the local heterogeneity 
of important factors, such as VEGF, MDE, ECM, and EC distribution in the 
microenvironment, makes the model more challenging. We have used ordinary differential 
equations (ODEs) to simulate regulation signalling, providing a signalling system model. 
We have used partial differential equations (PDEs) to simulate the vital factors which 
dynamically and simultaneously change in spatial and temporal dimensions, providing a 
microenvironment model. Now, we have to use the agent behaviour concept to describe 
how to realise the signalling communication and make decisions, especially the signalling 
generation and communication inside and between different ECs, which should be solved 
by the use of ODEs, PDEs and ABM iteratively at every time step.  
In this sense, our research seeks to elucidate the complexity of building a cell behaviour 
model including cell interaction, specification of tip and stalk from ECs, migration of tip, 
and proliferation of stalk etc. Accordingly, this research proposes a novel agent-based 
model approach combining the microenvironment model and signalling system model. In 
comparison with the existing architecture reported in the literature, this research adapts a 
combined architecture based on a dynamic angiogenesis process. 
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6.5.2 The ODEs regulatory mechanism 
To explore the mechanism of tumour-induced angiogenesis, we have introduced the 
discrete modelling approach to capture the features of the cell behaviours which could 
represent the cell-cell interaction and cell-ECM interaction in an easy way. The ABM 
method is a discrete modelling approach capable of representing features such as cell 
behaviours, ECM remodelling, and cell signalling. We are going to present and discuss a 
hybrid multi-scale model integrating with ABM and incorporating with the ODEs and 
PDEs in this section.  
In the discrete model, each lattice point can be occupied by an agent representing the cell at 
any situation and at any time. The continuum model integrates with a VEGF layer, a MDE 
layer, and an ECM layer. We assume that every lattice site is associated with a field 
describing the concentrations of VEGF, MDE, and ECM. Agent states can be quiescent, 
proliferative, and migratory, and transitions between the states are regulated by the rules 
described later in section 6.5.3 and 6.5.4. Transitions to a state of migration or 
proliferation go through a series of regulations, the number of which depends on the result 
of VEGF/Notch regulation mechanism. The change of states is influenced by the local 
chemical environment and the agents nearby.  
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(a)                (b)                    (c) 
Figure 6.4. Illustration of the structure of sprouting [16] 
Filopodia, tip and stalk are in a queue. Filopodia extends forward from the tip cell. The 
stalk cell is behind the tip cell，in (a) the mark m is macrophage, in (b) the mark star (*) 
represents tip cell [16].  
 
The intercellular communication occurs through the field. The local and global 
concentrations change the agent state inside. The reaction diffusion equations govern the 
evolution of VEGF, MDE, and ECM. The PDEs we described above allow agents to 
determine which characters will be performed.   
Based on Figure 6.4, we designed the sprouting model. The tip extends filopodia in front 
and the stalk follows the tip. Proliferation is confined by the stalk cells, and tip cells do not 
proliferate but can migrate [16]. MDE is secreted by the agent at the tip state and this 
degrades the ECM. The generation rate of MDE and the degrading rate of ECM are based 
on the following two equations described in Chapter 4: 
 
∂m
∂t
= αn + ε∇2m− νm        (4.21)   
 
∂M
∂t
= −ωMm                (4.22)  
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where n represents the tip cell density, m represents the activity of MDE, M represents 
the density of ECM, the coefficients are described in detail in section 4.3.2.   The rate of 
MDE produced by the tip cell is proportional to the tip cell. The generated MDE is diffused 
toward its environment, based on Fick-Diffusion law. The decay of MDE also takes place. 
M represents the ECM, and the rate of degradation is proportional to the MDE generated. 
The proliferation and migration of cells require sufficient room; if there are too many cells, 
there will not be enough room for the cell to move and proliferate. By accounting for the 
empty lattices around it, the cell determines where to implement migration or proliferation. 
If there is not enough room left, the ability of proliferation and motility will be affected.  
According to Anderson and Chaplain’s work [6-8, 152] on molecular layers, the soluble 
chemical substance VEGF concentrations are solved at each time step. The agent entities 
are updated in a random order. At every time step of the simulation, each agent is updated 
according to the agent behaviour flowchart in Figure 6.5, as follows: 
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Figure 6.5 Schematic cell behaviour flowchart overview  
A cellular level basic transition of agent decisions for both tip and stalk phenotype 
selection in sprouting and branching for every time step. 
 
Our tumour-induced angiogenesis model was designed on three scales: at the tissue level 
such as branching and sprouting, at the cellular level such as the tip and stalk selection, and 
at the molecular level, including VEGF, MDE diffusion, and ECM density. The cellular 
level flow chart shown in Figure 6.5 represents agent decisions for both tip and stalk cells 
behaviours at each time step.  
We use a two-dimensional space to represent the simulation domain in a grid net of 
200×200. The location of the ECs is determined by a set of coordinates (x, y), considering 
each EC occupying every other lattice point. The MDE is secreted by each tip cell which 
takes a lattice at the front position and degrades the local ECM. The soluble VEGF secreted 
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by the tumour engages in the regulatory mechanism of tip and stalk state selection. We 
assume VEGF-A diffuses based on Fick’s law. Hence, its concentration is different at 
different positions, forming a gradient stretch from the side of the tumour to the parent 
vessel.  
Rules for behaviours were created from the literature [5, 30, 142-144, 202-206], relating 
each cell action to its local concentrations of VEGF physical properties. We systematically 
assume the way cells interact with one another. We introduce the background for how we 
approached the model and characterized cell behaviours. After identifying cell behaviours, 
we defined the rules computationally and described how the rules interact with each other, 
as shown in Figure 6.5.  
The position of tip agents at the front edge of the capillary network is consistent with the 
position of the ECs simulated from Eq. (4.18). The consistency of both is realised by the 
iteration simulation between the continuum and discrete model. At every time step of the 
simulation, each agent position is updated according to the ECs position in the simulation 
of continuum model.  
The tip cells are in front of the capillary network. They generate filopodia which probes 
into the ECM in front of it to check the gradient of VEGF-A. The filopodia generated by 
the tip determines the route of migration by sensing the VEGF gradient and local ECM 
density. Based on the filopodia role and function discussed in section 2.3.2, we set the 
agent at the filopodia state’s extending direction, depending on VEGF and ECM density at 
the microenvironment around itself. As shown in Figure 6.6 (a), the agent at the filopodia 
state makes its selection of extending destination based on the comparison of both VEGF 
and ECM density weight from the seven empty grids (white) around it.  
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6.5.3 Sprouting 
Sprouting is the most important process in angiogenesis. During sprouting, this very 
complicated procedure involves the specification of tip and stalk phenotype from ECs, the 
migration of tip cells, the proliferation of stalk cells, and the determination of the 
approaching route, which is sensed and led by filopodia. Filopodia  are generated by the 
tip and extend into the ECM. We designed a model which is schematically presented in 
Figure 5.4 to elucidate the procedure of sprouting. Here, filopodia, tip, and stalk are 
designed in the agents and marked in green, blue, and red respectively. The continuous 
development of sprouting finally forms a capillary vessel in which the only tip is at the 
spearhead point of the vessel, and following the tip, the stalks are joined to form the whole 
body of the vessel.  
 
(a)                            (b) 
Figure 6.6 Illustration of cell movements.  
Cell movements are illustrated in a 2D domain and represented by rules in the model. The 
tip cell movement is represented by a blue grid. The filopodia is represented by a green 
grid. The stalk cell is represented by a red grid. The grey grid represents the stalk cell 
activated by VEGF-A. (a) represents the migration of tip cell directed by its filopodia 
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(green). The stalk cell (red) proliferates and generates a cell (grey) in front of itself in an 
idle state. The tip cell triggers the VEGF/Notch signalling to make the cell adjacent 
behind it and turn into stalk. (b) represents the extension of the filopodia. 
 
The extending direction of the filopodia is based on VEGF and ECM density at the 
microenvironment around itself. The grid selected is by the comparing the magnitude of 
introducing factor, which is determined by both VEGF and ECM density. The magnitude 
takes both in individual weight. The procedure is shown in Figure 6.7 (a), in which the 
seven grids in white represent the possibility of choice, and the grid in green represents the 
agent in filopodia state  
The transition limitation conditions are as follows: (a) there is VEGF adjacent to it; (b) 
there is no agent at tip state adjacent to it. The agent in the tip state expresses Dll4. Dll4 
influences the adjacent grids in which the Notch becomes high in expression. Once the 
conditions described above are satisfied, the agent in the idle state turns into the tip state. 
Once an agent becomes tip, induced by its local VEGF, it generates an agent in filopodia 
state which probes into the grid nearby. After the time interval it becomes mature and turns 
into tip state (blue). The grid occupied by the agent in the tip state turns into the agent in the 
stalk state (red), as shown in Figure 6.6. The change happens based on the comparison of 
Notch signalling.  
The tip cell migration is guided and pulled by its filopodia, which extend into the ECM and 
adhesion with the astrocyte. The moving is sensed by the stalk cell right behind it, then the 
stalk triggers the proliferation and produces a new cell in front of itself, so the new cell 
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partly has some tip cell characteristics and engages in the battle for the tip [16]. 
  
6.5.4 Branching 
Branching is a special state of sprouting. When a stalk in the vessel is activated due to the 
change of VEGF and Notch signals and thereby obtains the tip characteristic, it begins to 
sprout. This procedure continuously forms a new vessel. From this point, a new branch is 
formed. We designed the agents to elucidate the procedure schematically in Figure 6.7 (b), 
in which we can observe that the branching occurs from the point where a stalk is activated. 
The grids in white around the tip represent the possible directions for the new sprouting to 
develop.  
 
(a)                   (b) 
Figure 6.7 The schematic design of the agent-based model: sprouting and branching 
 
In Figure 6.7, the sprouting and branching of angiogenesis is illustrated in a 2D grid and 
ruled by the rules set in the model. The tip cell is represented by a blue grid. The filopodia 
are represented by a green grid. The stalk cell is represented by a red grid. The grey cell 
represents the cell proliferated by the stalk behind it. The white grid represents the possible 
directions in which the filopodia could extend. (a) represents the extension of filopodia 
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(green) during the sprouting procedure. Filopodia will extend to the empty grid nearby 
(white). (b) represents the branching procedure when one of the stalk cells is in activated 
state (grey) and it proliferates and generates a cell (blue). The blue one is a tip because 
there are no cells in front of it. The tip cells extend filopodia (green), which extend into the 
empty grid nearby (white), and they begin to sprout when a new sprouting occurs and a 
new branch is formed. The process of sprouting and its special state branching iterates 
continuously, leading to the formation of a capillary network, which is the mechanism of 
angiogenesis. 
 
6.6 Simulation and discussion 
6.6.1 Solution of the ODEs using the Euler method and 
ABM 
We discretized Eq. (6.13) and Eq. (6.14) as follows and used the Euler method to solve the 
initial valued ODEs. The solution is to discretize the time scale and take the first existing 
value to calculate the second value, and then to use the second value to calculate the third 
value. This iterates, and finally a solution of ODEs can be obtained. This is the famous 
Euler method. In our model, we used two ways to solve the regulatory model. One is to use 
the Euler method to solve the ODEs in Eq. (6.13) and Eq. (6.14) and obtain the smooth 
curves which were used as the criteria values shown in Figure 5.2; the other way is to use 
the Euler method combined with the ABM to solve Eq. (6.13), Eq. (6.14), Eq. (6.15), and 
Eq. (6.16).  
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Our solution is described as follows. We firstly discretized the time scale then used the 
Euler method and ABM alternatively at every time step. By using the first set of values of 
Eq. (6.13) and Eq. (6.14) to calculate the second set of values, we then used ABM to 
compare the set of second values with the criteria values and made judgments and 
decisions. Next, we triggered the solution to Eq. (6.14) and Eq. (6.15), and triggered the 
inhibitors I1 and I2, leading to the curves P1 and P2 oscillating in the period. In this way, 
we realised the modelling of the VEGF/Notch regulatory mechanism.  
 P1
T+1 = P1
T + Δt 
(
 
  vmax1  (S0 − P1
T)
(S0 − P1
T) + KM (1 +
I1
T
ki1
) 
− k1 P1
T
)
 
 
  (6.17) 
 P2
T+1 = P2
T + Δt 
(
 
  vmax2  P1
T
P1
T + KM (1 +
I2
T
ki2
) 
− k2 P2
T
)
 
 
 (6.18) 
Here is the description of how the state of the system changes during the simulations for 
each of the variables of the model. The state at t = (T + 1)Δt is obtained from that at 
t = TΔt, where Δt is the local cell time step and T is an integer index. The superscripts T 
and T + 1 here indicate the values at t = TΔt  and t = (T + 1)Δt respectively. 
The simulation time t  is then incremented by Δt, and the cycle is repeated using the 
newly calculated P1  and P2  concentrations. I1 and I2 are then updated based on the 
regulation. The solution of Eq. (6.17) and Eq. (6.18) is shown as follows: 
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(a)                      (b)                       (c) 
Figure 6.8 The results of the solutions to Eq. (6.17) and Eq. (6.18)  
The dashed line represents the P2 curve; the solid line represents the P1 curve; (a), (b) and 
(c) represent the results of the solution at S0 = 0.2, S0 = 0.4, S0 = 0.6 respectively 
 
From Figure 6.8, the two curves are the results of the solution of Eq. (6.17) and Eq. (6.18). 
The values of P1 and P2 depend on the local VEGF concentration expression, which is 
denoted as S0. From the three figures, we can observe that both the P1 curve and P2 curve 
are based on the local S0. When S0 increases from 0.2 to 0.6, the P1  and P2values 
increase slightly.  
Eq. (6.17) is in the upstream position and Eq. (6.18) is in the downstream position. Eq. 
(6.17) positively regulates Eq. (6.18). As the two equations are not negatively feedback 
regulated, the solution results show that the two curves appear continuously and smoothly, 
and increase in the same trend. At the very beginning, the P1value increases fast, which 
promotes the P2value to increase fast spontaneously. Then, the P1 and P2values increase 
gradually. Both curves appear lower in slope with time elapse, and they dynamically 
change with time. Dynamic change criteria were created to compare with the values 
regulated instantaneously. Hence, we used the solution results of Eq. (6.17) and Eq. (6.18) 
as the local criteria which change dynamically at different positions. 
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6.6.2 Regulation of sprouting  
We used the solution of Eq. (6.13) and Eq. (6.14) which exhibit two smooth curves as 
dynamic criteria. Figure 6.9 illustrates that the solution of the model comprised of Eq. 
(6.13), Eq. (6.14), Eq. (6.15), and Eq. (6.16) exhibits two oscillating curves P1 and P2. The 
P1 and P2 curves regulated by VEGF and Notch signalling oscillate around their own 
criteria curves (C1 and C2). Both the P1 and P2 values are updated based on their state 
and the regulatory results.  
The curve represented in the solid red line is based on the result solved by Eq. (6.14). The 
curve represented in the dashed black line is based on the result solved by Eq. (6.13). Both 
curves are used as criteria in the later analysis. The solid green line with star markers 
represents the P1 curve, which denotes the VEGF signalling. The dashed blue line with 
cross markers represents the P2 curve which denotes the Notch signalling. Both curves are 
the solution to the regulatory model shown in Figure 6.9. 
From Figure 6.9, the P1 and P2 values fluctuate during the procedure. We took the critical 
C1 value and the critical C2 value as the criteria respectively, by comparison with the 
relative magnitude. There are two different compositions: 
  P1 ≥ C1   and    P2 < C2  (6.19) 
 P1 ≤ C1   and    P2 > C2 (6.20) 
We define that P1 > C1  represents high VEGF signalling and high Dll4; P1 < C1 
represents low VEGF signalling and low Dll4; P2 > C2 represents high Notch signalling; 
P2 < C2 represents low Notch signalling.  
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ECs are specified into tip at high VEGF signalling, high Dll4 and low Notch signalling. 
In our model, once ECs satisfy the condition of Eq. (6.19), they will be specified into a 
tip. In the same way, high Notch and low VEGF signalling specify as a stalk. In our 
model, once ECs satisfy the condition of Eq. (6.20), they will be specified into the stalk 
phenotype. Hence, we define that the cell satisfying Eq. (6.19) is the tip cell, and the cell 
satisfying Eq. (6.20) is the stalk cell. 
According to the theoretical analysis above, we simulated the regulatory model in Figure 
6.3, in which the adjacent cells regulate each other during sprouting angiogenesis, 
making the P1 and P2 values of the cells fluctuate. The results are shown in Figure 6.9 1, 
in which both P1 and P2  values fluctuate around their own critical standard values 
respectively. The P1 curve (the dashed blue line with cross markers) fluctuates around 
the C1 curve (the solid red line) dynamically. The P2 curve (the solid green line with 
star markers) fluctuates around the C2 curve (the dashed black line) dynamically. The 
fluctuation is influenced by the adjacent cell sending a Notch signal. Thus, we divided the 
cell cycle into three different stages. Stage I (from a  to b ) is of tip characteristics 
(hereafter called tip); stage II (from b to c) is the transition state; and stage III (after c) is 
the stalk stage.  
167 
 
Figure 6.9 1Regulation procedure of sprouting analysis  
Stage I (from a to b) is the transition state. Stage II (from b to c) is the sprouting state. 
Stage III (after c) is the stalk state. Tip cells include Stage I and II. 
 
We divided the curve into two zones (tip and stalk), as shown in Figure 6.9. The cell 
differentiation is triggered by the successful combination of VEGF and VEGFR. This 
enzyme catalysed combination generates the VEGF signalling. The VEGF signalling 
promotes the generation of Dll4 which promotes the increase of Notch signalling in the cell 
shown as Arrow1. This is an up-regulation mechanism which can be observed in the range 
from point a to b where P1 and P2 increase at the same trend. When the Notch signalling 
begins to be up-regulated by the front cell through high Dll4, it down-regulates the VEGF 
signalling by controlling the expression of I1 which makes the VEGF lower. This can be 
observed in the range from point b to c  where P2 increases but P1 decreases in the 
opposite trend shown as Arrow2 . Both of Arrow1  and Arrow2  show the 
VEGF-VEGFR-Dll4-Notch-VEGFR feedback loop regulation mechanism in the same EC.  
Between the cells, the Dll4 on the surface of the front cell reacts with the Notch receptor on 
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the surface of the back cell to promote its Notch signalling which is an up-regulation. This 
regulation is shown in Arrow3 where VEGF signalling in the front cell simultaneously 
increases the Notch signalling in the back cell in the same trend. From Figure 6.10, we can 
observe that when the front cell P1 value increases, the P2 value in the back cell increases 
simultaneously in the same trend in the range from point b to c . The lower VEGF 
signalling in the back cell regulates the Notch signalling in the front cell, shown as Arrow4, 
indicating a trend to make the Notch lower in the front cell in the range after point c. Both 
the VEGF and Notch signal regulate to promote the sprouting of the new cell. 
Through the period of tip, P1 > C1 represents a higher VEGF signalling, and a higher Dll4 
is generated. P2 < C2 means that the Notch is modulated by Jagged1 and a lower Notch 
signalling is generated. Thus, when P1 > C1  and P2 < C2 , it is in the tip cell stage. 
P1 < C1  represents a lower VEGF signalling and P2 > C2  represents a higher Notch 
generated. Accordingly, when P1 < C1 and P2 > C2, it is in the stalk cell stage. 
At the inference of VEGF signalling, when the front cell begins to migrate, it generates 
high Notch signalling back to the back cell. During the procedure, Notch signalling triggers 
the reaction of co-receptors such as VEGFR1, Nrarp etc., which are denoted as the 
competitive inhibitor I1. This is a competitive inhibition which makes the P1 curve turn 
down (at point b).  
According to the literature, the Notch receptors can be combined by either Dll4 or Jagged1, 
whereas Dll4 has a competitive relationship with Jagged1. When Dll4 wins over the 
combination with the Notch receptors, the Notch signalling is enhanced; when Jagged1 
wins over the combination with the Notch receptors, the Notch signalling is weakened [4]. 
In our model, when the P1 curve intersects with the C1 curve (at the point c), Jagged1 is 
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weakened by the feedback mechanism, leading to the enhancement of the Notch signalling. 
The reaction is catalysed by glycosyltranferase (Fringe) [4]. The magnitude of inhibition is 
denoted as I2. 
From Figure 6.10, we can observe that after point c, P2 > C2 and P1 < C1 . This means 
that the cell turns into the stalk cell state. After the tip cell receives low Notch signalling, 
the front cell expresses high VEGFR2 and Nrp1, and makes itself become a tip cell. 
From Figure 6.10, we can observe that the P1 curve turns down slightly (at b point). This 
is because the cell takes the signal from the cell in front of it and triggers their cell inhibitor 
I1. In the P1 curve, the magnitude of I1 depends on competitive coreceptors. The higher 
inhibitor I1makes the P1 curve turn down more significantly.   
 
Figure 6.10 Regulation procedure of sprouting angiogenesis based on the VEGF 
signalling pathway and Notch signalling pathway  
Stage I (from a to b) shows the up-regulation of VEGF to Notch inside the cell. Stage II 
(from b to c) shows the down-regulation of Notch to VEGF inside the cell and the 
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up-regulation of VEGF to Notch. Stage III (after c) shows the differentiation of the cell. 
 
Our model delineates a molecular pathway of tip-stalk cell selection that is controlled by 
the interplay of three ligands, VEGF, Dll4 and Jagged1. According to the description above, 
the Notch changes and promotes the differentiation of tip and stalk. This result is produced 
by the change of Notch signalling co-expressed by Jagged1, which leads to the formation 
of a tip or stalk cell.  
Being suppressed, the P1 decreases. When the P1 curve intersects with the C1 curve (at 
point c), it triggers the release of inhibitor Jagged1, which competitively binds with the 
Notch receptor and increases the Notch activity. This makes the cell move into the stalk 
stage. At the same time, the front cell is regulated by the back cell which is low in Notch 
and high in VEGF. Thereby, the regulatory mechanism enhances the differentiation 
between tip cell in front and stalk cell behind. 
Figure 6.10 shows the sprouting procedure regulated by VEGF signalling pathway and 
Notch signalling pathway. The VEGF and Notch signalling pathways cooperate tightly to 
specify and balance the tip and stalk cells between ECs that constitute the sprouts. Notch 
signalling acts in a negative feedback loop with VEGF signalling during sprouting 
angiogenesis. 
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6.6.3 Regulation of branching 
 
Figure 6.11 Regulation procedure of sprouting angiogenesis based on the VEGF 
signalling pathway and Notch signalling pathway.  
Stage I (from a to b) is the tip cell. Stage II (from b to c) is the stalk cell. Stage III (from c 
to d) is the activated cell with tip characteristic. Stage IV (after d) is the stalk cell. 
 
For the mechanism of regulation during the branching of angiogenesis, we assume that 
when a stalk cell in the vessel is activated, it obtains the characteristic of a tip cell, which 
can sprout. When a sprout is formed and a new vessel is successfully developed from the 
cell, a new branch is formed and then emerges from this point. This is the procedure of 
branching during angiogenesis.  
We assume that in a stalk cell, the binding of co-receptors (VEGFR1, Nrp1, Nrp2, etc.) 
with VEGF weakens with the time elapse. This increases the reaction of VEGF and 
VEGFR2 to enhance the VEGF signalling. It is shown in our model that when the 
competitive inhibitor I1 weakens, the VEGF signalling increases. The curve P1 rises and 
finally intersects with curve C1, this leadsto  P1 > C1, so high VEGF signalling appears at 
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point c, shown in Figure 6.11. At the same time Notch changes with the expression of 
Jagged1. This makes the Notch signalling decrease and P2 < C2, so low Notch signalling 
appears. High VEGF and low Notch signalling appear simultaneously, satisfying the 
condition of the tip cell. Thus, the stalk cell is activated and obtains the characteristic of the 
tip cell. This result is consistent with the phenomenon that tip cells are at intervals with 
stalk cells, which is called ‘salt and pepper’. From this point, the activated cell begins to 
sprout and form a new branch. The regulation procedure described above is shown in 
Figure 6.11. 
 
Figure 6.12 Regulation procedure of sprouting angiogenesis based on the VEGF 
signalling pathway and Notch signalling pathway 
Stage I (from a to b) is the tip cell. Stage II (from b to c) is the stalk cell. 
 
Based on the assumption described above, only if a stalk cell in the vessel is activated can it 
obtain the characteristic of a tip cell. The cell has the ability to sprout and develop a new 
branching. However, if there is no stalk cell activated, no cell will obtain the characteristic 
of tip cells and there will not be a new sprout formed. The angiogenesis finally develops 
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into a single vessel with no branching at all. 
In a stalk cell, the binding of co-receptors (VEGFR1, Nrp1, Nrp2, etc.) with VEGF 
weakens with the time elapse. This increases the reaction of VEGF and VEGFR2 to 
enhance the VEGF signalling. It is shown in our model that the competitive inhibitor I1 
weakens and the VEGF signalling increases near the point b. The curve P1 rises, but is 
never high enough to intersect and become higher than curve C1. The VEGF signalling 
remains low and maintains P1 < C1. Under this condition, the VEGF signalling is not high 
enough to trigger the Notch. The Notch signalling keeps high and maintains P2 > C2. This 
state continuously satisfies the condition of the stalk cell, and thus it will never be activated 
and branching (extra sprouting beside the vessel) will never appear. This procedure is 
described in Figure 6.12. 
 
6.6.4 Simulation of angiogenesis 
According to the analysis described above, in this section we are going to implement the 
simulation of angiogenesis based on the regulation of VEGF and Notch signalling 
pathways. Under the regulation, ECs are specified into tip and stalk cells, respectively. This 
procedure forms the sprouting at the spearhead of the vessel and makes the vessel grow 
forward continuously. If the condition of the tip is satisfied in a stalk, it will be activated, 
obtain the tip cell characteristic, and begin to sprout, forming a new branch. In this way, a 
capillary network is formed. 
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(a)                (b)                (c) 
 
            (d)                 (e)                (f) 
Figure 6.13 Spatiotemporal evolution of the capillary network using the agent-based 
method to discretize the continuum model under the regulation of VEGF/North signalling 
pathways  
The background formed with contour lines and colours shows the ECM density degraded 
by the MDE secreted from tip cells. 
 
Figure 6.13 shows the simulated vessels regulated by the VEGF and Notch feedback 
regulatory mechanism. The regulation process is shown in Figure 6.11, from which we can 
observe the periodic alternation of tips and stalks, governed by VEGF and Notch signalling. 
The simulation results come out under the regulation process shown in Figure 6.13. 
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Sprouting is regulated by VEGF and Notch in the specification of tip and stalk, which 
forms vessels, whereas the branching that appears at intervals is the result of the tip and 
stalk in the so called ‘salt and pepper’ pattern. New branches are formed from the tips and 
finally result in the generation of a capillary network. 
The background formed with contour lines round the tips represents ECM density 
degraded by the MDE secreted by the tip cells. The ECM density is different around the 
location of the tips. At each spearhead, we can observe three colours of grids, including 
green, blue, and red. The green ones represent filopodia tips, which are located at the front. 
Following the green grids are the blue grids representing the tip cells. The red ones follow 
the tip and represent the stalk cells. 
   
(a)                (b)                (c) 
  
               (d)                 (e)                (f) 
Figure 6.14 Spatiotemporal evolution of capillary network with agent-based method to 
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discretize the continuum model under the regulation of VEGF/North signalling pathways  
The background formed with contour lines and colours shows the ECM density degraded 
by the MDE secreted from ECs.  
 
Figure 6.14 shows the simulated vessels regulated by the VEGF and Notch feedback 
regulatory mechanism. The regulation process is shown in Figure 6.11, from which we can 
observe the periodic alternation of tips and stalks, which are governed by VEGF and Notch 
signalling. The simulation results come out under the regulation process shown in Figure 
6.11, in which VEGF and Notch cooperate throughout the simulation. Tips and stalks are at 
intervals, and are called ‘salt and pepper.’ The branches formed by tips finally result in the 
generation of a capillary network. In this simulation, we changed the magnitude of I1and 
I2  in Eq. (6.13) and Eq. (6.14), leading to the extension of regulation periods. The 
simulation results of angiogenesis appear denser in net and slower in growth. 
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(a)                 (b)                 (c) 
 
               (d)                 (e)                 (f) 
Figure 6.15 Spatiotemporal evolution of capillary network with agent-based method to 
discretize the continuum model under the regulation of VEGF/North signalling pathways 
in which Notch signalling is overexpressed 
 
Figure 6.15 shows the simulated vessels overexpressed in Notch. The simulation results 
come out under the regulation process shown in Figure 6.12  in which Notch is 
overexpressed (P2 > C2) throughout the simulation. Only a tip cell emerges at the very 
beginning, then sprouts and becomes a vessel without any branches during the 
angiogenesis procedure. Here, VEGF and Notch satisfy the condition of stalk cells. No 
more tip cells emerge and the vessels appear like snail-trailing. The simulation results show 
no branches at all.   
From the simulation results, we can see the regulatory mechanism works well. The results 
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are consistent with the bio-clues and bio-theory of regulation, as discussed in section 
2.3.4.1, section 2.3.4.2, and section 2.3.5.1. The results arise from the complicated 
bio-system angiogenesis process which involves many scales solved by the integration of 
ODE, PDE, and ABM.  
 
6.7 Conclusion 
As the VEGF and Dll4/Notch signalling regulatory mechanism determines the 
specification of tip and stalk phenotype from ECs leading to the growth of sprouting [4], in 
this chapter we presented how we integrated enzymatic catalysed competitive ODEs 
model generating VEGF and Notch signals with ABM to simulate sprouting. Our model 
successfully demonstrates this regulatory mechanism, which has rarely been simulated in 
the current computational modelling of angiogenesis. Our simulation results are similar to 
the published biological report [4]. Thus, to a certain extent, our simulation results support 
the VEGF and Notch signalling theory from the computational viewpoint. In addition, our 
simulation results reveal that branching is just a special state of sprouting; it emerges at the 
point where a stalk is activated due to the change of VEGF and Dll4/Notch signals, and 
then turns into tip to begin a new sprouting. To conclude, the model we developed may be 
a useful tool to reveal the secret of angiogenesis. We will continue our research by 
improving the model through including an artificial intelligence method, especially a neuro 
network, which will positively promote the development of the model to decipher 
tumour-induced angiogenesis. 
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Chapter 7. Conclusion 
As the final chapter, it firstly provides an overview of the research. Then it outlines the 
research’s original contribution to the computational modelling of complex biological 
systems. Reflections on the research and future studies are provided as well.  
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7.1 Overview of the research  
Tumour-induced angiogenesis is a crucial step in the development of tumours. 
Endothelial cell (ECs) migration is the vital step in tumour-induced angiogenesis. EC 
migration is influenced by both tumour angiogenic factor (TAF) and fibronectin 
concentration gradient. In Chapter 4, we began by improving Anderson and Chaplain’s 
model by introducing proliferation terms for ECs, the degradation of ECM, and 
fibronectin initial condition, thus establishing the mathematical model describing EC 
migration during angiogenesis. The simulation results clearly demonstrate the process of 
the migration of ECs, guided by chemotaxis and haptotaxis from the pre-existing vessel 
to the tumour.  
Based on bio-clues that tumour invasion may promote production of fibronectin, we 
developed a mathematical model in partial different equations (PDEs) by altering TAF and 
fibronectin. The simulation result shows that the migration of ECs can be accelerated when 
both the TAF and fibronectin concentration gradients are in the same direction. This means 
angiogenesis can be synthetically promoted by both chemotaxis and haptotaxis 
simultaneously. Consensus theory states that angiogenesis supplies oxygen and nutrients to 
promote tumour development. By linking the relationship of tumour invasion and 
angiogenesis, we propose that there is a possible mechanism by which both invasion and 
angiogenesis promote each other to make the tumour develop faster, becoming more 
harmful for some subgroups of tumours. 
In Chapter 5, based on the model developed in Chapter 4, we further developed the 
mathematical model to simulate the effect of tumour cytotoxic factor, including the 
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immune system and drugs delivered through the vessels formed during angiogenesis in 
the development of a tumour. The simulation results reveal that the influence of tumour 
cytotoxic factor can make the tumour regress or develop. We designed two kinds of 
tumour load, both large and small, in three situations. The first was the large tumour load 
regression using the immune tumour cytotoxic factor and then recurrence. The second 
was the large tumour load regression using the immune tumour cytotoxic factor and a 
tumour cytotoxic drug. The synthesis effects of both immune factor and drugs make the 
tumour regress significantly without recurrence in the simulation range. The third was a 
small tumour load clearance using the immune tumour cytotoxic factor.  
In Chapter 6, we established a hybrid ODE model describing the VEGF and Notch 
signalling pathway in regulating vessel sprouting. Sprouting is the fundamental process 
of angiogenesis. During sprouting, ECs in the nascent sprout are specified into two 
distinct cellular phenotypes, called tip and stalk cells. Both are endowed with specialized 
functions. The fate of ECs is determined by VEGF and Notch signalling. The VEGF and 
Notch signalling regulatory mechanism engage in implicated crosstalk to balance tip and 
stalk cell differentiation and to regulate directed tip cell migration and stalk cell 
proliferation. In this way, the sprouting occurs and finally develops angiogenesis, which 
is the creation of new blood vessels from the parent vasculature [38]. Hence, VEGF and 
Notch signalling regulatory mechanism is vital in angiogenesis [4]. 
Over the past decade, VEGF and Notch signalling regulatory mechanisms have become a 
research focus in biology. Its computational modelling is still rare, leaving a wide gap 
between biology and computer engineering. We focus on developing a computational 
approach to decipher the VEGF and Notch signalling regulatory mechanism in order to 
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perceive the micro procedure of angiogenesis to provide direction for researchers in the 
field of angiogenesis. 
In this thesis, we have presented a hybrid model to describe EC behaviours under the 
control of a VEGF/Notch signalling pathway. We first established a two dimensional 
spatiotemporal mathematical model describing the process of tumour-induced 
angiogenesis, and then developed the model further by involving the tumour cytotoxic 
factor to simulate the tumour regression. Based on the mathematical models, we finally 
developed the hybrid model exploring the VEGF/Notch signalling pathway regulatory 
mechanism in the endothelial cell differentiation, tip cell migration, stalk cell 
proliferation, nascent sprouting, and the emergence of branching. It is hoped that the 
results will assist researchers in both the experimental and theoretical angiogenesis 
communities in a better understanding of the complexity, and enable the identification of 
the fundamental principles of angiogenesis. 
To realise methods, we used ordinary differential equations (ODEs) to describe the 
positive regulation and negative feedback signal transduction processes, nonlinear partial 
differential equations (PDEs) to describe the continuum field, and agent-based modelling 
(ABM) to discretise the model. Hence, the study enriches knowledge of modelling and 
provides a good example of integrating complicated and innovative modelling 
approaches for computer scientists in the relevant field.   
 
7.2 Contributions  
We have summarised the major contributions of the developed models in the six points 
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below, providing evidence for the thesis’s original contribution to knowledge. 
1) We developed a mathematical model in PDEs to simulate endothelial tip cell 
migration during angiogenesis influenced by chemotactic factor (e. g. TAF) and 
by haptotactic factor (e. g. fibronectin). The simulation results show that both 
chemotaxis and haptotaxis have an influence on the migration of tip cells, and 
their influence depends on the gradient and direction of both TAF and fibronectin. 
If both gradients are in the same direction, the migration of the tip cells can be 
promoted; if both gradients are in the opposite direction, the migration of tip cells 
can be offset. The simulation results imply a possible malignant mechanism for 
some subgroups of tumour as a potential research direction, and we assume the 
invasion of tumour and angiogenesis may promote each other.  
2) Considering the phenomenon of vessel density becoming higher towards the 
tumour, described as “brush border” in the literature, we involved the term 
proliferation of tip cells in the mathematical model, which makes the model more 
reasonable. The ECM degradation by the endothelial tip cells and secreted MDE 
was also involved in the model. The simulation results show that the degradation 
degree of ECM is influenced by the migration velocity of the endothelial tip cells. 
The results indicate that the different migration velocities of tip cells can have 
different impacts on the ECM degradation and make the ECM vary in 
composition, and even in the direction of collagen fibre, according to the 
phenomenon of ECM reorganization. In this way, we have improved the 
breakthrough models of Anderson et al. in tumour-induced angiogenesis. The 
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results also indicate some research directions, such as how the ECM composition 
influences the migration of tip cells and how the tip cells influence the ECM 
reorganization during angiogenesis.   
3) Based on the PDE model, we developed the enzymatic catalysed regulating model 
in the form of hybrid ODEs to simulate the sprouting regulated by VEGF/Notch 
signalling. In the model, sprouting was realised based on the specification of tip 
and stalk from ECs, which is dependent on the conditions of tip and stalk 
phenotype states, by comparing it with the magnitude of VEGF and Notch 
signalling. With the help of ABM to discretise the model, our simulation reveals 
that branching is just a special state of sprouting. When the VEGF and Notch 
inside a stalk change and satisfy the conditions of tip, the stalk is activated, 
obtains tip characteristics, and begins to sprout and form a new branch. In this 
way, this model can simulate EC differentiation, migration, proliferation, tip/stalk 
specification, sprouting, and branching behaviours based on the VEGF/Notch 
regulatory mechanism. This innovative model offers a huge leap over previous 
studies which have only simulated morphology visually based on stochastics. The 
simulation results are similar to the biological reports published, and thereby to a 
certain extent support VEGF and Notch signalling theory [4, 22-31] from the 
computational viewpoint. 
4) We have integrated the ABM method using Java and MATLAB languages with 
the Euler method to solve the ODEs and realise the simulation of angiogenesis. 
The agents are dynamically endowed with more functions, including calculation, 
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memory, comparison, judgment, update, taking data from outside, and sending 
signals to the adjacent agents, compared with cellular automaton (CA) in similar 
research. In this way, we have successfully simulated the regulated ODEs, which 
are impossible to obtain by simply using mathematical tools. The successful 
simulation enriches the methods in the computational modelling of angiogenesis, 
providing a new perspective for computational modellers. Hence, we recommend 
that the ABM method is a desired approach in modelling cancers related to 
regulatory mechanisms, and MATLAB is a more contemporary software 
development tool for computer scientists. 
 
7.3 Reflections on the research 
The tumour’s microenvironment plays a key role in the tumour growth model. To extend 
our understanding of the tumour microenvironment, the capillary network around the 
tumour should be modelled. The research in developing models of tumour-induced 
angiogenesis is rare, compared with the large number of biological experiments and 
hypotheses. 
In this study, we enhanced and extended our understanding of the biological procedure of 
ECs in tumour-induced angiogenesis, including proliferation, migration, branching, and 
specification. We also narrowed down the focus on the modelling of VEGF/Notch 
signalling pathway regulatory mechanism during angiogenesis, and decided the 
methodological route towards the research goal and successfully established our models.  
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One major advantage of our innovative hybrid regulatory model is that it allows the 
modellers to focus on the agent and environment based on the PDEs. This is dissimilar to 
a very complicated agent-based domain model, such as the FLAME based NF-κB and IκBα 
signalling pathway model [122].  
We attempted to develop the ODE-based technique in regulating the EC type selection 
procedure during angiogenesis. This approach takes the minimal abstraction of the 
VEGF/Notch cell signalling pathway and decreases the complexity of the system. The 
simulation results rely on the interaction reflection between different agents, which is 
very different from stochastic models.  
Due to time and resource limitation, we have not conducted biological experiments to 
validate the models developed. We identified similar results in vivo and in vitro assays in 
the literature, demonstrating the validation to a large extent. In addition, we used some 
parameters for PDEs from relevant studies in the literature. Since those studies where we 
obtained parameters have their validations, our models may also be considered as 
validated models from this perspective.   
 
7.4 Future research  
The contributions of this thesis have identified a number of areas for future research.  
 To further investigate VEGF/Notch signalling pathway during angiogenesis 
 To explore how the ECM composition influences the migration of tip cells 
 To explore how the tip cells influence the ECM reorganization during angiogenesis 
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 To improve the models through including an artificial intelligence method, especially 
a neuro network 
 To develop computational models for personal treatment with tumours 
 To examine both advantages and disadvantages of using ABM to develop models of 
complicated biological systems 
 To explore alternative techniques for the computational modelling of tumour-induced 
angiogenesis, such as statistics, as a complementary approach 
 To investigate the effects of modelling paradigms (e.g. ABM versus PDEs) and 
modelling framework (e.g. Java MASON versus FLAME) on the simulation results 
of complicated biological systems.  
 Finally, future work in the next five years arising from this thesis could be focused on 
the three aspects: to extend the current VEGF/Notch signalling pathway regulation 
models developed in Chapter 6 by involving the artificial intelligence method, 
especially the neuro network, to improve the innovative models and make them more 
sophisticated; to extend the models developed in Chapter 4 by collaborating with 
biological and biomedical researchers to verify the proposed possible mechanism 
that invasive tumour and tumour-induced angiogenesis promote each other in vivo 
and in vitro for some special tumours, seeking ways of blockades to the angiogenesis 
and modelling the impact of blockaded vessels on the tumour, by adjusting the 
models with the parameters obtained from wet-lab to make the models suitable for 
application in personal treatments for some special tumours; to extend the models 
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developed in Chapter 5 by collaborating with biological and biomedical researchers 
on the tumour immune field to explore the tumour immunoediting process and to 
develop the tumour immune models in more details. 
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Appendix A - Solution of the nonlinear 
partial differential equations  
In the equations Eq.(1), Eq.(2), Eq.(3), Eq.(4) and Eq.(5), the symbols n, c, f, m and M are 
variables, representing ECs, VEGF, fibronectin, matrix degradation enzyme (MDE) and 
extra cellular matrix (ECM) respectively. The coefficients D ,  ,  , , ,  , , a , , and 
 are positive constants in the equations to represent different rate. On is also a constant. 
  is the symbol of difference operator. 
To solute the partial differential equations we should derivate them into difference quotient 
equations in order to use finite difference scheme. 
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( )c  is the function of c. Here c represents the concentration of VEGF. This function 
means that at high concentration of VEGF the chemotaxis is not as sensitive as that at low 
concentration of VEGF to 
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The partial difference of ( )c is derivative as follows： 
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Such the Eq. (6) is derivative into its partial difference forms as in Eq. (7) and Eq. (8). 
Eq. (1), Eq. (2), Eq. (3), Eq. (4) and Eq. (5) form a nonlinear PDEs which can be solved 
numerically with finite difference method. In a 2D domain Ω(x, y). 
 
 We treat Eq. (1) as follows. In the right of the Eq. (1), the first term is defined as random 
motility and expanded as:  
2 2
2
2 2
( )
n n
random D n D
x y
 
   
 
                                  (9)
 
 
In the right of Eq. (1), the second term is defined as chemotaxis and expanded as： 
( ( ) )
[ ( ) ( )]
[ ( ) ] ( ) [ ( ) ] [( )]
{[ ( ) ( ) ] [ ( )] ( )} ( ) [ ( ) ] [( )]
{[ ( ) ( ) ] [ ( )] ( )}
{[ ( ) ( ) ] [ ( )] (
x y
x y x y
x y x y x y xx yy
x y x y x
x y x y
chemotaxis c n c
c n c c
c n c c c n c c
c c n c n n c c c n c c
c c n c n n c
c c n c n n


 
   
  
  
  
  
      
         
     
     )} [ ( ) ] [( )]
[ ( ) ] ( ) {[ ( ) ( ) ] ( )
( ) )} { ( ) ( ) ( ) ( ) }
[ ( ) ] ( ) ( ) ( ) ( ) ( )
( ) ( ) ( )
y xx yy
xx yy x y x
y x x y x y y
xx yy x x y x x x y x
x y y y
c c n c c
c n c c c n c n c n
c n c c n c n c n c n c
c n c c c n c c n c c n c c n c
c n c c n c c n

   
    
    
  
   
      
       
            
     ( )
( ) ( ) ( ) [ ] ( ) [ ] ( )[ ]
( ) ( ) ( )( ) ( ) ( ) ( ) ( )
( ) (
1 1
x y y y
xx yy x x y y x y x x y x x y y y
xx yy x x y x x y y y x x y y x y
xx yy x
c c n c
c n c c c n c n c c n c n c c n c n c n c n c
c n c c c n c n c n c n c c n c n c c n c n c
n
c c n
c c

   
   
 
 
  
                  
                  
   
  2 2
) ( ) ( )
(1 ) (1 )
x y x x y y y x y x y
x y
n n
c n c n c n c c c c c
c c
 
 
         
 
Finally, the chemotaxis is expanded and difference as follows: 
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In the right of Eq. (1), the third term is defined as haptotaxis and expanded as 
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Finally, the haptotaxis is expanded and difference as follows: 
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In the right of Eq. (1), the fourth term is defined as proliferation and described as 
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Hence, the whole Eq. (1) can be expressed in the derivative form as: 
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Finite difference scheme: 
 
To solve the equations with numerical method, we should derivate Eq. (1) from derivative 
form into difference quotients form. The difference quotients form is described as follows: 
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We set the grids in Cardial Coordinate is in the same span, and the space spans x and y  
in both x and y coordinates are same in magnitude, so  
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The first order difference
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In the same way the second order difference quotient is as follows: 
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Finally, we obtained Eq. (1) in difference quotients equation which is described as follows: 
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To make it readable we may rewrite it as this: 
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In the same way for Eq. (2) the difference quotient equation is described as follows: 
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We obtained this as follows: 
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For Eq. (3) the difference quotient equation is described as follows: 
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We obtained this as follows: 
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For Eq. (4) the difference quotient equation is described as follows: 
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We obtained this as follows: 
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For Eq. (5) the difference quotient equation is described as follows: 
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We finish the derivation of Eq. (1), Eq. (2), Eq. (3), Eq. (4) and Eq. (5) from partial 
differential equations to difference quotient equations. The Eq. (24), Eq. (25), Eq. (26), Eq. 
(27) and Eq. (30) form the difference quotient equations representing partial differential 
equation Eq. (1); the difference quotient equations Eq. (32), Eq. (34), Eq. (36), and (38) 
represent the difference equations of Eq. (2),  Eq. (3), Eq. () and Eq. (5) respectively. We 
rewrite these difference quotient equations by using the codes in Java language and run in 
computer. 
 
 
